
<html lang="en"     class="pb-page"  data-request-id="58e1baa2-bf5c-49ef-a4ae-2b3790b2165c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-8;article:article:10.1021/acs.jmedchem.9b00219"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability" /></meta><meta name="dc.Creator" content="Sean P.  Henry" /></meta><meta name="dc.Creator" content="Thomas J.  Fernandez" /></meta><meta name="dc.Creator" content="Jessica P.  Anand" /></meta><meta name="dc.Creator" content="Nicholas W.  Griggs" /></meta><meta name="dc.Creator" content="John R.  Traynor" /></meta><meta name="dc.Creator" content="Henry I.  Mosberg" /></meta><meta name="dc.Description" content="We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been show..." /></meta><meta name="Description" content="We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been show..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 29, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00219" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00219" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00219" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00219" /></link>
        
    
    

<title>Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00219" /></meta><meta property="og:title" content="Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0006.jpeg" /></meta><meta property="og:description" content="We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-place preference assays in mice, and do not produce dependence. Although these attributes are promising, these analogues exhibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinoline scaffold in this series. As such, a structure–activity relationship (SAR) campaign was pursued to improve their metabolic stability. This resulted in a shift from our original bicyclic tetrahydroquinoline core to a monocyclic benzylic-core system. By eliminating one of the rings in this scaffold and exploring the SAR of this new core, two promising analogues were discovered. These analogues (5l and 5m) had potency and efficacy values at MOR better or comparable to morphine, retained their DOR-antagonist properties, and showed a 10-fold improvement in metabolic stability." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00219"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00219">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00219&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00219&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00219&amp;href=/doi/10.1021/acs.jmedchem.9b00219" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4142-4157</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00191" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00223" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sean P. Henry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sean P. Henry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sean+P.++Henry">Sean P. Henry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas J. Fernandez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas J. Fernandez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+J.++Fernandez">Thomas J. Fernandez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessica P. Anand</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessica P. Anand</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Medical School,  Edward F Domino Research Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessica+P.++Anand">Jessica P. Anand</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicholas W. Griggs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicholas W. Griggs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Medical School,  Edward F Domino Research Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+W.++Griggs">Nicholas W. Griggs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John R. Traynor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John R. Traynor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Medical School,  Edward F Domino Research Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+R.++Traynor">John R. Traynor</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Henry I. Mosberg</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Henry I. Mosberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Edward F Domino Research Center, University of Michigan, Ann Arbor, Michigan 48109, United States</div><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c8a0a1a588a5adace6bda5a1aba0e6adacbd"><span class="__cf_email__" data-cfemail="8fe7e6e2cfe2eaeba1fae2e6ece7a1eaebfa">[email protected]</span></a>. Phone: (734) 764-8117.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Henry+I.++Mosberg">Henry I. Mosberg</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4107-8870" title="Orcid link">http://orcid.org/0000-0002-4107-8870</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00219&amp;href=/doi/10.1021%2Facs.jmedchem.9b00219" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4142–4157</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 29, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 February 2019</li><li><span class="item_label"><b>Published</b> online</span>29 March 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 April 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00219" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00219</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4142%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSean%2BP.%2BHenry%252C%2BThomas%2BJ.%2BFernandez%252C%2BJessica%2BP.%2BAnand%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D8%26contentID%3Dacs.jmedchem.9b00219%26title%3DStructural%2BSimplification%2Bof%2Ba%2BTetrahydroquinoline-Core%2BPeptidomimetic%2B%25CE%25BC-Opioid%2BReceptor%2B%2528MOR%2529%2BAgonist%252F%25CE%25B4-Opioid%2BReceptor%2B%2528DOR%2529%2BAntagonist%2BProduces%2BImproved%2BMetabolic%2BStability%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4157%26publicationDate%3DApril%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00219"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1064</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00219" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;P. Henry&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;J. Fernandez&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;P. Anand&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;W. Griggs&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;R. Traynor&quot;},{&quot;first_name&quot;:&quot;Henry&quot;,&quot;last_name&quot;:&quot;I. Mosberg&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4142-4157&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00219&quot;},&quot;abstract&quot;:&quot;We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-place preference assays in mice, and do not produce dependence. Although these attributes are promising, these analogues exhibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinoline scaffold in this series. As such, a structure–activity relationship (SAR) campaign was pursued to improve their metabolic stability. This resulted in a shift from our original bicyclic tetrahydroquinoline core to a monocyclic benzylic-core system. By eliminating one of the rings in this scaffold and exploring the SAR of this new core, two promising analogues were discovered. These analogues (5l and 5m) had potency and efficacy values at MOR better or comparable to morphine, retained their DOR-antagon&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00219&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00219" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00219&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00219" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00219&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00219" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00219&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00219&amp;href=/doi/10.1021/acs.jmedchem.9b00219" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00219" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00219" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (990 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00219%26sid%3Dliteratum%253Aachs%26pmid%3D30924650%26genre%3Darticle%26aulast%3DHenry%26date%3D2019%26atitle%3DStructural%2BSimplification%2Bof%2Ba%2BTetrahydroquinoline-Core%2BPeptidomimetic%2B%25CE%25BC-Opioid%2BReceptor%2B%2528MOR%2529%2BAgonist%252F%25CE%25B4-Opioid%2BReceptor%2B%2528DOR%2529%2BAntagonist%2BProduces%2BImproved%2BMetabolic%2BStability%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D8%26spage%3D4142%26epage%3D4157%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291285" title="Ethers">Ethers</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/jmcmar.2019.62.issue-8/20190425/jmcmar.2019.62.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We have previously reported a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands to serve as potential nonaddictive opioid analgesics. These ligands have been shown to be active in vivo, do not manifest withdrawal syndromes or reward behavior in conditioned-place preference assays in mice, and do not produce dependence. Although these attributes are promising, these analogues exhibit poor metabolic stability in mouse liver microsomes, likely due to the central tetrahydroquinoline scaffold in this series. As such, a structure–activity relationship (SAR) campaign was pursued to improve their metabolic stability. This resulted in a shift from our original bicyclic tetrahydroquinoline core to a monocyclic benzylic-core system. By eliminating one of the rings in this scaffold and exploring the SAR of this new core, two promising analogues were discovered. These analogues (<b>5l</b> and <b>5m</b>) had potency and efficacy values at MOR better or comparable to morphine, retained their DOR-antagonist properties, and showed a 10-fold improvement in metabolic stability.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">μ-Opioid analgesics, such as morphine and oxycodone, are the most clinically relevant drugs used for the treatment of chronic pain. Despite their widespread use, tolerance develops to their analgesic actions and patients suffer from undesirable side effects, such as dependence, addiction, constipation, and respiratory depression. A growing body of preclinical evidence has emerged suggesting that compounds that stimulate the μ-opioid receptor (MOR) in conjunction with antagonism at the δ-opioid receptor (DOR) can produce the desired analgesic effects without producing analgesic tolerance or dependence. For instance, rats given morphine and co-treated with the DOR antagonists TIPP[Ψ]<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> or naltrindole<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> displayed antinociception with significantly diminished chronic antinociceptive tolerance and dependence as measured by reduced withdrawal symptoms. These trends are supported by experiments wherein DOR knockout mice<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> did not develop chronic tolerance to the analgesic effects of morphine. Furthermore, mice treated with antisense DOR oligodeoxynucleotide<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> did not develop acute dependence or chronic tolerance to the analgesic effects of morphine.</div><div class="NLM_p">Many ligands have been synthesized that possess this MOR-agonist/DOR-antagonist profile,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> and some small molecule bifunctional MOR agonist/DOR antagonists have been reported that show reduced side-effect profiles (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Some of these are based on the classical morphinan scaffold (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A, <b>I</b> and <b>II</b>) and show attenuated chronic tolerance and dependence.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Mitragynine pseudoindoxyl (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, <b>III</b>), derived from the kratom alkaloid mitragynine, was found to elicit reduced withdrawal and respiratory depression and does not produce conditioned-place preference.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Others still are derived from opioid peptides (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C, D). DIPP[Ψ]-NH<sub>2</sub> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C, <b>IV</b>), an endomorphin derivative, produces antinociception in murine models without acute tolerance and chronic physical dependence.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> AAH8 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C, <b>V</b>) has also been shown to produce antinociception in murine models without developing tolerance to antinociceptive effects, physical dependence, nor does it evoke conditioned-place preference, suggesting it does not have reward properties.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Although a large number of derivatives of this last compound have been reported,<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20">(14−20)</a> these ligands show poor metabolic stability in mouse liver microsomes (MLMs) (<i>T</i><sub>1/2</sub> ∼ 5 min), suggesting that they will be too short acting in vivo for clinical development. We therefore sought to improve their metabolic stability while maintaining the desired bifunctional opioid profile.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Notable structures that exhibit a MOR-agonist/DOR-antagonist profile. Some of these compounds utilize the morphinan scaffold shared by many opioids (A) or are a derivative of kratom alkaloids (B), whereas others are derived from endomorphins (C) or cyclic opioid peptides (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With this goal in mind, we sought to identify regions that would be most amenable to modifications aimed at improving metabolic stability. Here, we used our original lead peptidomimetic KSKPP1E (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, <b>A</b>)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> as a reference point on which to base our initial design choices. Tetrahydroquinolines (THQs) have been shown to aromatize upon action by CYP2A6 enzymes,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> commonly found in mouse liver microsomes. This aromatization could in part explain the metabolic instability of our peptidomimetic series, an instability that persists for almost all compounds that contain a bicyclic core akin to the THQ system. Given the role of the THQ core as a linker for the 2′,6′-dimethyltyrosine (DMT) and benzyl pharmacophores, a structure–activity relationship (SAR) campaign aimed at transforming this core into a more stable form was pursued. Initially, we sought to remove the aliphatic ring of the THQ system, producing more conformationally flexible ligands while removing the metabolically labile cycle (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). We were encouraged by other opioids that relied on similar strategies to connect these two pharmacophore elements together, such as urea,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> piperidine or piperazine,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> pyrazinone,<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25−28)</a> alkyl diamine,<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> or long alkyl chains.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Herein, we describe our initial SAR study that eliminates the bicyclic system of the THQ core to both produce our desired MOR-agonist/DOR-antagonist profile and to improve metabolic stability.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pharmacophore and linker elements of our peptidomimetic lead.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19,21)</a> The pharmacophore elements include 2′,6′-dimethyltyrosine and benzyl pendants that are sensitive to modification, and the linker consists of a tetrahydroquinoline (THQ) core. (B) New analogues lacking the THQ core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> General Chemistry</h3><div class="NLM_p">All of the described monocyclic compounds were synthesized according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Before engaging in the main route of synthesis, the ethers and the anilines were diversified at the beginning. To synthesize functionalized anilines, 2-amino-5-bromobenzaldehyde was subjected to acylation using the appropriate neat anhydride at 100 °C, producing the acetyl and propionyl anilines <b>1g</b> and <b>1i</b>, respectively. To produce aromatic ethers, 5-bromo-2-hydroxybenzaldehyde was functionalized using an alkyl bromide (Alk-Br) or iodide, producing the methyl, ethyl, <i>n</i>-propyl, cyclopropyl methyl (CPM), and benzyl ethers <b>1j</b> and <b>1l–o</b>, respectively. The exceptions here are trifluoromethoxy ether <b>1k</b>, which was purchased, and <b>1p</b>, which used 1-(5-bromo-2-hydroxyphenyl)ethan-1-one as the starting material instead of 5-bromo-2-hydroxybenzaldehyde. The functionalized aromatic bromo ketone or aldehydes <b>1a</b>–<b>e</b>, <b>1g</b>, and <b>1i</b>–<b>p</b> were then reduced through imine formation with an Ellman’s chiral sulfonamide and subsequent reduction with sodium borohydride, producing compounds <b>2a</b>–<b>e</b>, <b>2g</b>, and <b>2i–p</b>. The Ellman’s chiral sulfonamide both enables enantioselective amine formation (if applicable), as used previously,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and protects the amine during subsequent Suzuki coupling to generate compounds <b>3a</b>–<b>e</b>, <b>3g</b>, and <b>3i</b>–<b>p</b>. This was followed by Ellman deprotection using concentrated HCl and dioxane to produce <b>4a</b>–<b>e</b>, <b>4g</b>, and <b>4i–p</b>. The exception here is the synthesis of 6-phenol (<b>4f</b>), which utilized BBr<sub>3</sub> to both remove the Ellman’s chiral sulfonamide and cleave the 6-position ether <b>3l</b>. The ethyl aniline analogue <b>4h</b> was synthesized by reduction of the acetyl aniline <b>4g</b> with a borane dimethylsulfide complex (BH<sub>3</sub>*Me<sub>2</sub>S). Finally, Boc-protected DMT was coupled to the free primary amine of structures <b>4a</b>–<b>p</b> using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), followed by removal of the Boc groups using trifluoroacetic acid (TFA) to yield the final peptidomimetics <b>5a</b>–<b>p</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Monocyclic-Core Analogues <b>5a</b>–<b>p</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) 1. (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, Ti(OEt)<sub>4</sub>, tetrahydrofuran (THF), 75 °C. 2. NaBH<sub>4</sub>. (B) BnBPin, K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 3:1 acetone/water, 80–100 °C. (C) HCl conc., dioxane. (D) 1. <i>N</i>-Boc-<i>O</i>-Boc-2′,6′-dimethyl-<span class="smallcaps smallerCapital">l</span>-tyrosine (DiBocDMT), <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), PyBOP, 6-chloro-1-hydroxybenzotriazole (6-Cl-HOBt), dimethylformamide (DMF). 2. TFA, dichloromethane (DCM). (E) Neat acyl anhydride, 100 °C. (F) MeI or Alk-Br, K<sub>2</sub>CO<sub>3</sub>, DMF. (G) BBr<sub>3</sub>, DCM. (H) BH<sub>3</sub>*Me<sub>2</sub>S, THF, 75 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> SAR</h3><div class="NLM_p">Our studies began by first probing the structural components of the aliphatic ring of the THQ core. These studies focused on binding affinity, efficacy, and potency at MOR and DOR, although the κ-opioid receptor (KOR) was also examined to determine compound selectivity. The binding affinity data can be found in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, whereas the efficacy and potency data can be found in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (see footnotes of each table for how these values were measured). Initially, all substituents and functional groups comprising this aliphatic ring were removed, yielding <b>5a</b>. This conversion had a little effect on binding affinity compared to the original lead <b>A</b> but had a significant effect on efficacy. Indeed, <b>5a</b> did not stimulate any of the three classical opioid receptors. We then began to restore different portions of the original aliphatic ring to elucidate the importance of each component. The incorporation of short linear alkyl chains (<b>5b</b> and <b>5c</b>) on the benzylic position (R<sup>1</sup>) connecting the aromatic core to the DMT pharmacophore partially restored MOR agonism (41% stimulation for compound <b>5b</b>). In this case, the methyl group (<b>5b</b>) was superior to an ethyl group (<b>5c</b>); however, MOR efficacy was less than that of morphine (57% stimulation), which serves here as a benchmark for MOR activity. It should be noted that morphine’s intrinsic activity of 57% should not be interpreted as poor MOR efficacy, only that the standard agonist [<span class="smallcaps smallerCapital">d</span>-Ala2,<i>N</i>-MePhe4,Gly-ol]enkephalin (DAMGO) in this assay has exceptional efficacy. DOR affinity was found to decrease when these alkyl chains are incorporated, although these compounds still did not stimulate DOR. KOR binding improved with increasing chain size, and weak KOR agonism was observed with both alkyl groups.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Affinity of the Benzylic-Core Compounds at MOR, DOR, and KOR<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0004.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">binding affinity, <i>K</i><sub>i</sub> (nM)</th><th class="rowsep1 colsep0" align="center">selectivity</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">–R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">–R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char="±">MOR</th><th class="colsep0 rowsep0" align="center" char="±">DOR</th><th class="colsep0 rowsep0" align="center" char="±">KOR</th><th class="colsep0 rowsep0" align="center">MOR/DOR/KOR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A</b></td><td class="colsep0 rowsep0" colspan="2" align="left">–CH<sub>2</sub>CH<sub>2</sub>NH–</td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.02<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">9.4 ± 0.8<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">68 ± 2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1:43:309</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">morphine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 2.5<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">171 ± 19<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">61 ± 17<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1:27:9.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">14.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">410 ± 47</td><td class="colsep0 rowsep0" align="left">1:15:410</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">46 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">201 ± 36</td><td class="colsep0 rowsep0" align="left">1:42:180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">61 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">49.5 ± 1.7</td><td class="colsep0 rowsep0" align="left">1:19:15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">33.9 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">360 ± 60</td><td class="colsep0 rowsep0" align="left">1:6.5:69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">38.1 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">528 ± 49</td><td class="colsep0 rowsep0" align="left">1:6.8:94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="char" char="±">9.48 ± 0.50</td><td class="colsep0 rowsep0" align="char" char="±">175 ± 26</td><td class="colsep0 rowsep0" align="char" char="±">307 ± 34</td><td class="colsep0 rowsep0" align="left">1:18:32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHAc</td><td class="colsep0 rowsep0" align="char" char="±">7.9 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">387 ± 31</td><td class="colsep0 rowsep0" align="char" char="±">1550 ± 130</td><td class="colsep0 rowsep0" align="left">1:49:200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHEt</td><td class="colsep0 rowsep0" align="char" char="±">23.5 ± 6.5</td><td class="colsep0 rowsep0" align="char" char="±">63.8 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">408 ± 54</td><td class="colsep0 rowsep0" align="left">1:2.7:17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5i</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHCOEt</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">108 ± 27</td><td class="colsep0 rowsep0" align="char" char="±">1090 ± 290</td><td class="colsep0 rowsep0" align="left">1:26:260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char="±">3.58 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">21.5 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">610 ± 100</td><td class="colsep0 rowsep0" align="left">1:6.0:170</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">370 ± 83</td><td class="colsep0 rowsep0" align="left">1:5.2:260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OEt</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">23.8 ± 3.3</td><td class="colsep0 rowsep0" align="char" char="±">1180 ± 120</td><td class="colsep0 rowsep0" align="left">1:8.5:420</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OnPr</td><td class="colsep0 rowsep0" align="char" char="±">0.91 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">390 ± 150</td><td class="colsep0 rowsep0" align="left">1:5.8:430</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCPM</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">13.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">319 ± 51</td><td class="colsep0 rowsep0" align="left">1:5.1:120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OBn</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">70.4 ± 5.4</td><td class="colsep0 rowsep0" align="char" char="±">575 ± 80</td><td class="colsep0 rowsep0" align="left">1:8.8:71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">330 ± 150</td><td class="colsep0 rowsep0" align="left">1:0.85:41</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Binding affinities (<i>K</i><sub>i</sub>) were obtained by competitive displacement of radiolabeled [<sup>3</sup>H]-diprenorphine in membrane preparations. Included are morphine and the original lead peptidomimetic (<b>A</b>) for comparison. All data were from three separate experiments, performed in duplicate. These data are reported as the average ± standard error of the mean (SEM). Selectivity was calculated by dividing the <i>K</i><sub>i</sub> of each receptor by the <i>K</i><sub>i</sub> at MOR for a given compound. DNS = does not stimulate.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Efficacy and Potency of the Benzylic-Core Compounds at MOR, DOR, and KOR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0005.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">potency, EC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="3" align="center">efficacy (% stimulation)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">–R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">–R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">MOR</th><th class="colsep0 rowsep0" align="center">DOR</th><th class="colsep0 rowsep0" align="center">KOR</th><th class="colsep0 rowsep0" align="center">MOR</th><th class="colsep0 rowsep0" align="center">DOR</th><th class="colsep0 rowsep0" align="center">KOR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A</b></td><td class="colsep0 rowsep0" colspan="2" align="left">–CH<sub>2</sub>CH<sub>2</sub>NH–</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.3<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">110 ± 6<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">540 ± 72<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">81 ± 2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">16 ± 2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">22 ± 2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">morphine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">194 ± 21<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">57 ± 5<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">44.4 ± 7.5</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">>1700</td><td class="colsep0 rowsep0" align="left">41 ± 12</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">158 ± 17</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">2200 ± 500</td><td class="colsep0 rowsep0" align="left">15.0 ± 2.6</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">26.6 ± 3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">111 ± 29</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">21.9 ± 5.3</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">250 ± 24</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">39.2 ± 1.0</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">552 ± 90</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">17.0 ± 1.1</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHAc</td><td class="colsep0 rowsep0" align="left">117 ± 13</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">32.5 ± 2.6</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHEt</td><td class="colsep0 rowsep0" align="left">156 ± 20</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">>2440</td><td class="colsep0 rowsep0" align="left">25.9 ± 5.8</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5i</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHCOEt</td><td class="colsep0 rowsep0" align="left">84 ± 26</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">>4000</td><td class="colsep0 rowsep0" align="left">28.7 ± 7.1</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">>35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">264 ± 21</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">37.2 ± 1.7</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">342 ± 80</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">45.0 ± 6.1</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OEt</td><td class="colsep0 rowsep0" align="left">77 ± 10</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">65.9 ± 5.2</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OnPr</td><td class="colsep0 rowsep0" align="left">68 ± 10</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">54.9 ± 4.0</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCPM</td><td class="colsep0 rowsep0" align="left">71 ± 13</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">37.5 ± 1.3</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OBn</td><td class="colsep0 rowsep0" align="left">107 ± 19</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">34.7 ± 3.8</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">296 ± 69</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">20.2 ± 1.4</td><td class="colsep0 rowsep0" align="left">DNS</td><td class="colsep0 rowsep0" align="left">DNS</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Efficacy and potency data were obtained using agonist-induced stimulation of [<sup>35</sup>S]-guanosine 5′-<i>O</i>-[γ-thio]triphosphate ([<sup>35</sup>S]-GTPγS) binding. Potency is represented as EC<sub>50</sub> (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), <span class="smallcaps smallerCapital">d</span>-Pen2,5-enkephalin (DPDPE) (DOR), or U69,593 (KOR) at 10 μM. Included are morphine and the original lead peptidomimetic (<b>A</b>) for comparison. All data were from three separate experiments, performed in duplicate. These data are reported as the average ± standard error of the mean (SEM). DNS = does not stimulate. ND = not determined.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>.</p></div></div></div><div class="NLM_p">In parallel with the analogues described above, an assortment of compounds was made with functional groups at the 6-position, corresponding to that of the THQ nitrogen. Initially, a few simple substituents were incorporated at this position. These included methyl, chloro, and hydroxy groups (<b>5d</b>–<b>f</b>). Each of these managed to restore MOR agonism to between 17 and 39% but much less than that seen with the parent compound. None of these ligands produced agonism at DOR, although the hydroxy (<b>5f</b>) significantly reduced the binding at DOR compared to <b>5a</b>.</div><div class="NLM_p">A small number of nitrogen-containing substituents were also incorporated at the 6-position, resulting in ethyl, acetyl, and propionyl anilines (<b>5g</b>–<b>i</b>). These were made to mimic the substituents of the original THQ core without ring cyclization or to mimic some <i>N</i>-acyl compounds that had utility in our previously reported THQ series.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These ligands were all weak partial MOR agonists and had reduced binding affinity at DOR compared to <b>5a</b>. The ethyl aniline also displayed reduced affinity at MOR.</div><div class="NLM_p">Several ethers were examined due to their synthetic accessibility, their ability to be rapidly diversified, and to probe the effect of hydrogen-bond acceptors at the 6-position. The alkyl ethers included methyl, trifluoromethyl, ethyl, <i>n</i>-propyl, cyclopropyl methyl (CPM), and benzyl (<b>5j</b>–<b>o</b>). Here, an activity maximum was observed between the ethyl ether (<b>5l</b>) and the <i>n</i>-propyl ether (<b>5m</b>). Both ethers proved to be more potent than morphine and displayed levels of efficacy similar to those of morphine at MOR. This, in combination with the high DOR affinity and the lack of DOR efficacy of these two compounds, demonstrates that these monocyclic-core compounds can retain our desired in vitro profile.</div><div class="NLM_p">A final compound was synthesized to determine whether a combination of R<sup>1</sup> and R<sup>2</sup> substituents could yield additive effects. To this end, <b>5p</b> was synthesized, in which R<sup>1</sup> = −Me and R<sup>2</sup> = −OMe. These substituents were selected as they have the same number of large atoms as the original THQ core while also utilizing the more desirable ethers. When compared to <b>5b</b>, this compound appears to have reduced binding affinity, efficacy, and potency at MOR. DOR binding, however, shows a modest improvement over <b>5b</b> and retains an antagonist profile at DOR.</div><div class="NLM_p last">With regards to KOR, most of the ligands express reduced binding affinity at this receptor compared to <b>A</b>, with the exception of <b>5c</b>. Similarly, only <b>5c</b>, <b>5h</b>, and <b>5i</b> were shown to have weak, partial efficacy at KOR; the rest have no efficacy at this receptor. Since we were interested in balancing the binding affinity between MOR and DOR, and since we were screening KOR for selectivity, we calculated binding ratios between MOR, DOR, and KOR normalized to MOR. Most of these ligands show an improved balance between MOR and DOR compared to the lead compound <b>A</b>, except <b>5g</b>. The greatest balance can be found with various functional groups at the R<sup>2</sup>-position, namely, the methyl (<b>5d</b>), chloro (<b>5e</b>), ethyl aniline (<b>5h</b>), and all of the ethers (<b>5j</b>–<b>p</b>). When comparing MOR and KOR for selectivity, only the unfunctionalized compound <b>5a</b> and the ethyl (<b>5l</b>) and <i>n</i>-propyl (<b>5m</b>) ethers contained greater selectivity than <b>A</b>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Antagonist Potency of Representative Analogues</h3><div class="NLM_p last">Finally, although analogues displaying reasonably high DOR affinity (∼20 nM or less) and no DOR efficacy are presumptive DOR antagonists, this was tested explicitly for <b>5</b>l–<b>n</b>. DOR antagonism was confirmed for all three analogues, which effected rightward shifts in the EC<sub>50</sub> of the standard DOR agonist DPDPE that equated to <i>K</i><sub>e</sub> values of 20.2, 7.4, and 20.5 nM, respectively (calculated as described in <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Metabolic Stability</h3><div class="NLM_p">In tandem with the SAR described above, the metabolic stability of these monocyclic-core compounds was characterized in mouse liver microsomes (MLMs) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) using verapamil as the positive control. Because of the variability between the measures of metabolic half-life for verapamil (from 13.8 to 22.6 min) in the different assay preparations, the ratio of <i>T</i><sub>1/2</sub> for the compound and verapamil was calculated as a stability ratio. This was to ensure consistent comparisons between different analogues.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Metabolic Stability of Monocyclic Compounds in MLM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char="±">verapamil <i>T</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char="±">stability ratio</th><th class="colsep0 rowsep0" align="center" char="."><i>c</i> Log <i>P</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A</b></td><td class="colsep0 rowsep0" colspan="2" align="left">CH<sub>2</sub>CH<sub>2</sub>NH</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">14.7 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.03</td><td class="colsep0 rowsep0" align="char" char=".">3.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">13.0 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0.89 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">4.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">8.5 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.38 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">4.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">13.8 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">0.29 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">5.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">12.2 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.54 ± 0.03</td><td class="colsep0 rowsep0" align="char" char=".">4.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char="±">16.3 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.72 ± 0.12</td><td class="colsep0 rowsep0" align="char" char=".">5.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="char" char="±">15.4 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">14.4 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">3.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHAc</td><td class="colsep0 rowsep0" align="char" char="±">10.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">14.4 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0.71 ± 0.06</td><td class="colsep0 rowsep0" align="char" char=".">2.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NHEt</td><td class="colsep0 rowsep0" align="char" char="±">12.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.54 ± 0.07</td><td class="colsep0 rowsep0" align="char" char=".">4.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char="±">19.7 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">13.8 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=".">4.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0.39 ± 0.03</td><td class="colsep0 rowsep0" align="char" char=".">5.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OEt</td><td class="colsep0 rowsep0" align="char" char="±">23.7 ± 5.9</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">4.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OnPr</td><td class="colsep0 rowsep0" align="char" char="±">33.1 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">19.6 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=".">5.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCPM</td><td class="colsep0 rowsep0" align="char" char="±">56.3 ± 10.1</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">5.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OBn</td><td class="colsep0 rowsep0" align="char" char="±">15.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">22.6 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">0.69 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">5.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5p</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">0.30 ± 0.02</td><td class="colsep0 rowsep0" align="char" char=".">4.53</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Included are the compound half-life (<i>T</i><sub>1/2</sub>), the half-life of the positive control verapamil, and the stability ratio between the compound and the positive control. The stability ratio was calculated by dividing the half-life of the analogue of interest by the half-life of the positive control in that assay. Individual compounds were tested once, with errors representing the SE in the decay curve regressed onto the data collected in 15 min intervals. Finally, the <i>c</i> Log <i>P</i> values of these analogues are included and were calculated using PerkinElmer’s ChemDraw Professional Software.</p></div></div></div><div class="NLM_p">To evaluate the improvement in the stability of these compounds, the original lead compound <b>A</b> is included in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. This compound displays the poorest metabolic stability, with a ratio of 0.21 compared to verapamil, and is characteristic of the other THQ-containing analogues in our previously reported series. Stripping away all of the substituents that make up the aliphatic portion of the tetrahydroquinoline ring (<b>5a</b>) improves the ratio 4-fold to 0.89. However, introducing alkyl chains off this benzylic position (R<sup>1</sup>, <b>5b</b> and <b>5c</b>) reduces the stability of these compounds back to that of <b>A</b>.</div><div class="NLM_p">Next, we examined our analogues at the 6-position (R<sup>2</sup>). The small substituents at this position (<b>5d</b>–<b>f</b>) did not improve the stability of these compounds, even though some of these modifications are polar (which would reduce <i>c</i> Log <i>P</i><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a>) or are electron-withdrawing groups (which would inhibit free radical formation during the CYP catalytic cycle). This also extends to the acetyl and ethyl anilines (<b>5g</b> and <b>5h</b>), in which no improvements were observed.</div><div class="NLM_p last">The ethers (<b>5j</b>–<b>o</b>) generally produced significant improvements in metabolic stability. This is particularly true for cyclopropyl methyl ether (<b>5n</b>), which was 2.5-fold more stable than verapamil, reflecting a half-life of 56 min. This was not true for all of the ethers however, as the trifluoromethyl ether (<b>5k</b>) showed lower stability levels than <b>5a</b>. Finally, the hybrid analogue <b>5p</b> had low stability, similar to compound <b>5b</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> SAR</h3><div class="NLM_p">Using <b>A</b> as a baseline, it appears that moving to <b>5a</b> causes a loss in MOR agonism and affinity. This may in part be explained by increased conformational flexibility that occurs upon elimination of the aliphatic portion of the tetrahydroquinoline ring. This activity can be partially regained through the introduction of small alkyl chains at the benzylic position (<b>5b</b> and <b>5c</b>), likely due to restoring interactions that favor  the active state of the receptor.</div><div class="NLM_p">Introducing the methyl, chloro, or hydroxy group to the 6-position of the benzylic core (<b>5d</b>–<b>f</b>) produced partial MOR agonism compared to <b>5a</b>. The hydroxyl group (<b>5f</b>) was the least potent and efficacious of the three, suggesting that either an electron-donating group on the benzylic core or a hydrogen-bond donor at the 6-position interferes with the ability of substituents at this position to activate MOR. This trend is also seen with binding affinity at DOR, as the hydroxy substituent possesses the lowest affinity. The chloro substituent (<b>5e</b>) is similar to the methyl (<b>5d</b>) substituent in its activity at the three receptors and differed only from <b>5d</b> in that it had twice the efficacy at MOR. This reinforces the electronics argument, as the chloro group is more electron withdrawing than the methyl group due to induction.</div><div class="NLM_p">The 6-position ethers produced some of the most promising ligands in this series. These ligands generally had high MOR and DOR affinity, except for the benzyl ether at DOR (<b>5o</b>). However, the potency and efficacy of these compounds at MOR vary greatly. The optimum here appears to be with the ethyl (<b>5l</b>) and <i>n</i>-propyl (<b>5m</b>) ethers, which proved comparable to morphine in efficacy and potency. This is particularly interesting when these data are compared to the 6-anilines (<b>5g</b>–<b>i</b>) and the 6-hydroxyl (<b>5f</b>), as they suggest that the hydrogen-bond donor present in these latter compounds is detrimental for MOR efficacy, rather than the presence of electron-donating groups. The orientation of the hydrogen-bond donor may be important, as the lead compound <b>A</b> displays high MOR efficacy. From the data illustrated in compounds <b>5g</b>–<b>i</b>, it appears that orientating the hydrogen-bond donor toward the DMT pendant is detrimental to MOR agonism. Since these ethers also antagonize DPDPE, these data suggest that the small-chain ethers are best for producing our desired MOR-agonist/DOR-antagonist profile.</div><div class="NLM_p">It should be noted that the ethers <b>5l</b> and <b>5m</b> do not possess the potency or efficacy at MOR of the original lead compound <b>A</b>. Since we are ultimately interested in determining whether MOR-agonist/DOR-antagonist ligands are suitable for use as opioid analgesics without abuse liabilities, the stability improvements of <b>5l</b> and <b>5m</b> represent a necessary developmental step toward this end. This is particularly true considering the instability of the THQ-core compounds such as <b>A</b>. However, <b>5l</b> and <b>5m</b> have improved potency and similar efficacy at MOR compared to morphine, which is the classic opioid analgesic. As such, sacrificing some potency and efficacy at MOR to improve pharmacokinetic parameters is worthwhile, especially if they still perform better than morphine in vitro.</div><div class="NLM_p">The hybrid compound <b>5p</b> is also notable due to its poor MOR efficacy and potency. Although the potency of this compound was akin to the simple 6-OMe precursor (<b>5j</b>), the efficacy here was less than either precursor analogues <b>5b</b> and <b>5j</b>. This suggests that steric effects within the ligand may be detrimental to activation of MOR, a problem that vanishes when these two groups are tied together in the bicyclic ring of the original THQ core.</div><div class="NLM_p last">With regard to selectivity, two notable trends can be observed. Selectivity for MOR over KOR can be reduced compared to our original lead <b>A</b> through two different means. Extending alkyl chains off the benzylic position (R<sup>1</sup>, <b>5b</b>, <b>5c</b>) do this largely through improving KOR binding, which peaks with the ethyl group (<b>5c</b>) in this series, whereas some substituents containing a hydrogen-bond donor off the 6-position (R<sup>2</sup>), namely, the hydroxyl (<b>5f</b>) and ethyl aniline (<b>5h</b>), do this through reduced MOR binding. Conversely, the ethyl and <i>n</i>-propyl ethers (<b>5l</b> and <b>5m</b>) show the best selectivity over KOR, largely due to reduced KOR binding compared to <b>A</b>. Although almost all of the compounds show improved MOR/DOR affinity balance, possibly due to elimination of the bicyclic ring system, all of the ethers (<b>5j</b>–<b>p</b>) have the best balance. Overall, the ethers <b>5l</b> and <b>5m</b> show the best selectivity over KOR and are among the compounds that best balance MOR and DOR affinities.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Metabolic Stability</h3><div class="NLM_p">Stripping away all of the components of the THQ core (<b>5a</b>) produced a 4-fold improvement in metabolic stability over <b>A</b>. When incorporating alkyl chains onto the benzylic position (<b>5b</b>, <b>5c</b>, and <b>5p</b>), this improvement is lost, suggesting that this benzylic position in both this series and in the original THQ series is a metabolic hot spot. This is consistent with the mechanism of CYP metabolism, namely, that the benzylic methyne present in compounds <b>5b</b>, <b>5c</b>, and <b>5p</b> can greater stabilize the radical formed upon interaction with the enzyme than can the methylene alone. Simple chloro (<b>5e</b>) and hydroxyl (<b>5f</b>) functional groups at the 6-position were no different than the unfunctionalized system (<b>5a</b>). The ethers (<b>5j</b>–<b>o</b>), apart from the trifluoro (<b>5k</b>) and benzyl (<b>5o</b>) ethers, displayed the greatest levels of stability, reaching stability ratios of 2.5 and half-lives of nearly an hour, as determined for <b>5n</b>.</div><div class="NLM_p">Interestingly, these ethers were more stable than the functionalized anilines, despite their greater <i>c</i> Log <i>P</i>, which is commonly associated with reduced stability.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Amines are better electron-donating substituents than ethers. As such, they may further stabilize metabolism at the adjacent benzylic positions on the aromatic ring. Notably, the most stable ether contained a cyclopropyl moiety. This can likely be attributed to a combination of steric effects and ring strain, as the cyclopropyl group can both block metabolism at adjacent positions and the ring strain destabilizes free radical formation on the cyclopropyl group itself.</div><div class="NLM_p last">Fortunately, the SAR regarding the restoration of our MOR-agonist/DOR-antagonist profile overlapped with the SAR aimed at improving metabolic stability. This suggests that these 6-position ethers are a promising new direction for the development of these peptidomimetics. As such, our future derivatization of these analogues will follow the lead provided by these promising ethers.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Conclusions</h3><div class="NLM_p last">Addiction to prescription opioids remains a major challenge for millions of Americans. This problem is driven largely by the widespread use of opioids to treat chronic pain. Consequently, there is a growing need for potent analgesics that lack these abuse liabilities. To this end, agonism at MOR with simultaneous antagonism at DOR may be able to produce analgesia without these side effects. Our previously reported peptidomimetics and their bicyclic analogues display such a profile; however, their metabolic instability represents a major hurdle in their development. The results presented here show that the metabolically labile THQ core can be changed to a monocyclic core to improve metabolic stability. Initial modification of the simplified benzyl core yielded analogues (<b>5l</b> and <b>5m</b>) that display similar potency and efficacy as morphine at MOR, are antagonists at DOR, possess a more balanced affinity between MOR and DOR, are more selective over KOR, and show improved metabolic stability in mouse liver microsome assays compared to our original THQ-core ligands. These monocyclic compounds represent an attractive new direction through which more stable MOR-agonist/DOR-antagonist ligands may be developed.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> General Methods</h4><div class="NLM_p last">All reagents and solvents were obtained commercially and were used without further purification. Intermediates were purified by flash chromatography using a Biotage Isolera One instrument. Most purification methods utilized a hexanes/ethyl acetate solvent system in a Biotage SNAP KP-Sil column, with a linear gradient between 0 and 100% ethyl acetate. Reverse-phase column chromatography using a linear gradient of 0–100% solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) using a Biotage SNAP Ultra C18 column was utilized for some intermediate amine salts. Purification of final compounds was performed using a Waters semipreparative high-performance liquid chromatography (HPLC) with a Vydac protein and peptide C18 reverse-phase column, using a linear gradient of 0–00% solvent B in solvent A at a rate 1%/min, monitoring UV absorbance at 230 nm. The purity of final compounds was assessed using a Waters Alliance 2690 analytical HPLC instrument with a Vydac protein and peptide C18 reverse-phase column. A linear gradient (gradient A) of 0–70% solvent B in solvent A in 70 min, measuring UV absorbance at 230 nm, was used to determine purity. All final compounds used for testing were ≥95% pure, as determined by analytical HPLC. <sup>1</sup>H NMR and <sup>13</sup>C NMR data were obtained on a 500 or 400 MHz Varian spectrometer using CDCl<sub>3</sub> or CD<sub>3</sub>OD solvents. The identities of final compounds were verified by mass spectrometry (MC) using an Agilent 6130 liquid chromatography (LC)–MS mass spectrometer in the positive ion mode or an Agilent 6230 time-of-flight HPLC–MS in the positive ion mode. Suzuki couplings using microwave irradiation were performed on a Discover S-class (CEM) microwave in a closed vessel with a maximum power input of 300 W and temperature set to 100 °C for 30 min under the standard method using their Synergy software.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Procedure for Ellman Reductions (Procedure A)</h4><div class="NLM_p last">A flamed-dried round-bottom flask containing 1 equiv of aldehyde or ketone and 3 equiv of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide was attached to a reflux condenser and flushed with argon. THF (4 mL) was added and cooled to 0 °C. Titanium(IV) ethoxide (6 or 7.5 equiv) was added, followed by an additional 4 mL of THF. The solution was stirred and heated to 75 °C overnight with thin-layer chromatography monitoring until all ketone or aldehyde was consumed. A separate flame-dried flask containing 6 equiv of sodium borohydride was flushed with argon. THF (4 mL) was added, at which point the solution was cooled to −78 °C. The solution containing Ellman adduct was cooled to room temperature and slowly transferred to the sodium borohydride solution via a syringe. This final solution was then allowed to warm to room temperature and stirred for 2 h, at which point the reaction mixture was quenched with methanol to consume the sodium borohydride, followed by deionized water to precipitate the titanium. The solution was vacuum-filtered, and the precipitate was washed with ethyl acetate. The filtrate was then concentrated in vacuo and purified via column chromatography (0–100% EtOAc in hexanes).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure for Suzuki Couplings Using Microwave Irradiation (Procedure Ba)</h4><div class="NLM_p last">To a microwave vessel containing the protected amine were added 2 equiv of benzylboronic acid pinacol ester, 3 equiv of potassium carbonate, and 0.1 equiv of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium. The vessel was purged with argon, and 2.5 mL of degassed 3:1 acetone/water was added. The vessel was then subjected to microwave irradiation to a temperature of 100 °C for 30 min. The solution was cooled, partitioned between brine and ethyl acetate, and extracted with ethyl acetate. The organic layer was then dried with magnesium sulfate, filtered, and concentrated in vacuo. Column chromatography was then performed (0–100% ethyl acetate in hexanes), yielding the desired Suzuki coupled derivatives.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General Procedure for Suzuki Couplings without Microwave Irradiation (Procedure Bb)</h4><div class="NLM_p last">To a round-bottom flask containing the protected amine, 2 equiv of potassium carbonate, and 0.1 equiv of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium were added 2.5 equiv of benzylboronic acid pinacol ester. The flask was equipped with a reflux condenser and purged with argon, and 5 mL of degassed 3:1 acetone/water was added. The vessel was then heated to a temperature of 80 °C overnight. The solution was cooled, partitioned between brine and ethyl acetate, and extracted with ethyl acetate. The organic layer was then dried with magnesium sulfate, filtered, and concentrated in vacuo. Column chromatography was then performed (0–100% ethyl acetate in hexanes), yielding the desired Suzuki coupled derivatives.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure for Removal of Ellman’s Chiral Sulfonamide (Procedure C)</h4><div class="NLM_p last">To a flask containing the Ellman protected amine were added 2 mL of dioxane and 0.2 mL of concentrated HCl. The solution was stirred at room temperature for 1 min and concentrated in vacuo. The ensuing salt was then purified via one of two methods. If the product was insoluble in diethyl ether, it was triturated with diethyl ether, and the precipitate was concentrated in vacuo to dryness, yielding the product as an HCl salt. If the product was soluble in diethyl ether, it was purified using reverse-phase chromatography (0–100% B in A), yielding the product as a TFA salt.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure for the Coupling of 2′,6′-Dimethyltyrosine to Functionalized Amine Salt (Procedure D)</h4><div class="NLM_p last">To a dried flask containing the amine salt under argon were added 3 mL of DMF and 10 equiv of Hunig’s base. This was followed by the addition of 1 equiv of PyBOP and 1 equiv of 6-Cl-HOBt, and finally  by 1 equiv of <i>N</i>-Boc-<i>O</i>-Boc-2′,6′-dimethyl-<span class="smallcaps smallerCapital">l</span>-tyrosine in 1.5 mL of DMF. The solution was stirred overnight at room temperature and concentrated in vacuo. TFA (2 mL) and 2 mL of DCM were then added, and the solution was stirred for an additional hour. The reaction mixture was concentrated in vacuo and purified via semipreparative reverse-phase HPLC (0.1% TFA in water/0.1% TFA in acetonitrile). The product was concentrated in vacuo and lyophilized overnight to yield the final peptidomimetic.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure for the Acylation of 2-Amino-5-bromobenzaldehyde (Procedure E)</h4><div class="NLM_p last">To a dried flask containing 2-amino-5-bromobenzaldehyde under argon was added neat acyl anhydride. The reaction mixture was stirred overnight at 100 °C and concentrated in vacuo. The product was then partitioned between sat. NaHCO<sub>3</sub> and DCM. The compound was extracted with DCM, filtered, and concentrated in vacuo, yielding the desired acylated compound.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure for the Synthesis of 6-Position Ethers (Procedure F)</h4><div class="NLM_p last">To a flame-dried flask containing phenolic aldehyde or ketone was added 3 equiv of potassium carbonate. The flask was purged with argon, and 4 mL of DMF was added. An alkyl iodide or bromide (3 equiv) was then added, and the solution was stirred at room temperature overnight. The solution was then concentrated in vacuo, partitioned between ethyl acetate and saturated sodium bicarbonate, and extracted with ethyl acetate. The organic layers were combined, dried with magnesium sulfate, filtered, and concentrated in vacuo, yielding the desired ether.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure for the Cleavage of Phenolic Ethers (Procedure G)</h4><div class="NLM_p last">To a flame-dried flask containing 1 equiv of phenolic ether under argon was added 5 mL of DCM, and 3.02 equiv of 1 M BBr<sub>3</sub> in DCM was added dropwise. The solution was stirred at room temperature for 4 h and quenched with methanol. The solution was concentrated in vacuo, suspended in diethyl ether, and filtered. The precipitate was then dissolved in methanol and filtered. The product in methanol was then concentrated in vacuo, yielding the desired phenol.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure for the Reduction of Acyl Anilines (Procedure H)</h4><div class="NLM_p">To a dried flask containing the desired acyl aniline under argon were added 2 M BH<sub>3</sub>*Me<sub>2</sub>S in THF and additional THF. The solution was heated to 75 °C for 3 h, at which point the solution was quenched with methanol and stirred for an additional 15 min at 75 °C. The solution was cooled and concentrated in vacuo, yielding the reduced alkyl aniline.</div><div id="sec4_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> <i>N</i>-(4-Bromo-2-formylphenyl)acetamide (<b>1g</b>)</h5><div class="NLM_p last">See procedure E: 74 mg (0.37 mmol) of 2-amino-5-bromobenzaldehyde and 3 mL of acetic anhydride. The compound was purified after aqueous workup via column chromatography (0–10% ethyl acetate in hexanes) to produce compound <b>1g</b> (59 mg, 65.9% yield), which was isolated as an orange solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 11.00 (br s, 1H), 9.84 (s, 1H), 8.65 (d, <i>J</i> = 8.9 Hz, 1H), 7.76 (d, <i>J</i> = 2.4 Hz, 1H), 7.67 (dd, <i>J</i> = 9.0, 2.4 Hz, 1H), 2.24 (s, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 194.22, 169.53, 139.84, 138.80, 137.98, 122.78, 121.70, 114.91, 25.38.</div></div><div id="sec4_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> <i>N</i>-(4-Bromo-2-formylphenyl)propionamide (<b>1i</b>)</h5><div class="NLM_p last">See procedure E: 98 mg (0.49 mmol) of 2-amino-5-bromobenzaldehyde and 3 mL of propionic anhydride. Compound <b>1i</b> (113 mg, 90.1% yield) was isolated as an orange solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 11.00 (s, 1H), 9.81 (s, 1H), 8.65 (d, <i>J</i> = 9.0 Hz, 1H), 7.72 (d, <i>J</i> = 2.5 Hz, 1H), 7.64 (dd, <i>J</i> = 9.0, 2.4 Hz, 1H), 2.46 (q, <i>J</i> = 7.6 Hz, 2H), 1.24 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 194.21, 173.28, 139.94, 138.75, 137.95, 122.83, 121.70, 114.71, 31.48, 9.33.</div></div><div id="sec4_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 5-Bromo-2-methoxybenzaldehyde (<b>1j</b>)</h5><div class="NLM_p last">See procedure F: 157 mg (0.78 mmol) of 5-bromosalicylaldehyde, 320 mg (2.3 mmol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, 150 μL (342 mg, 2.4 mmol, 3.1 equiv) of MeI, and 3 mL of DMF. Compound <b>1j</b> (170 mg, quantitative yield) was isolated as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.34 (s, 1H), 7.86 (d, <i>J</i> = 2.3 Hz, 1H), 7.58 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.86 (d, <i>J</i> = 8.9 Hz, 1H) 3.89 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 183.3, 169.7, 138.3, 130.9, 126.0, 113.7, 113.4, 56.0.</div></div><div id="sec4_1_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 5-Bromo-2-ethoxybenzaldehyde (<b>1l</b>)</h5><div class="NLM_p last">See procedure F: 451 mg (1.5 mmol) of 5-bromosalicylaldehyde, 608 mg (4.4 mmol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, 330 μL (482 mg, 4.4 mmol, 3.0 equiv) of EtBr, and 4 mL of DMF. Compound <b>1l</b> (495 mg, 96.3% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 10.36 (s, 1H), 7.85 (d, <i>J</i> = 2.6 Hz, 1H), 7.55 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.83 (d, <i>J</i> = 8.9 Hz, 1H), 4.10 (q, <i>J</i> = 7.0 Hz, 2H), 1.44 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 188.4, 160.2, 138.2, 130.7, 126.0, 114.5, 113.2, 64.6, 14.5.</div></div><div id="sec4_1_10_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 5-Bromo-2-propoxybenzaldehyde (<b>1m</b>)</h5><div class="NLM_p last">See procedure F: 123 mg (0.61 mmol) of 5-bromosalicylaldehyde, 251 mg (1.8 mmol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, 160 μL (217 mg, 1.8 mmol, 2.9 equiv) of <i>n</i>PrBr, and 4 mL of DMF. Compound <b>1m</b> (155 mg, quantitative yield) was isolated as a white waxy solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 10.41 (s, 1H), 7.89 (d, <i>J</i> = 2.6 Hz, 1H), 7.58 (dd, <i>J</i> = 8.9, 2.6 Hz, 1H), 6.86 (d, <i>J</i> = 8.9 Hz, 1H), 4.01 (t, <i>J</i> = 6.4 Hz, 2H), 1.86 (h, <i>J</i> = 7.3 Hz, 2H), 1.06 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 188.4, 160.4, 138.2, 130.7, 126.1, 114.5, 113.2, 70.4, 22.4, 10.5.</div></div><div id="sec4_1_10_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 5-Bromo-2-(cyclopropylmethoxy)benzaldehyde (<b>1n</b>)</h5><div class="NLM_p last">See procedure F: 99 mg (0.49 mmol) of 5-bromosalicylaldehyde, 204 mg (1.5 mmol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, 140 μL (195 mg, 1.4 mmol, 2.9 equiv) of (bromomethyl)cyclopropane, and 3 mL of DMF. Compound <b>1n</b> (128 mg, quantitative yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 10.42 (s, 1H), 7.87 (s, 1H), 7.55 (d, <i>J</i> = 8.9 Hz, 1H), 6.82 (d, <i>J</i> = 8.7 Hz, 1H), 3.89 (d, <i>J</i> = 6.6 Hz, 2H), 1.27 (m, 1H), 0.65 (m, 2H), 0.36 (m, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 188.5, 160.3, 138.2, 130.7, 126.3, 114.9, 113.3, 73.7, 10.0, 3.2.</div></div><div id="sec4_1_10_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 2-(Benzyloxy)-5-bromobenzaldehyde (<b>1o</b>)</h5><div class="NLM_p last">See procedure F: 401 mg (2.0 mmol) of 5-bromosalicylaldehyde, 828 mg (6.0 mmol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, 710 μL (1021 mg, 6.0 mmol, 3.0 equiv) of BnBr, and 5 mL of DMF. Compound <b>1m</b> (569 mg, 97.9% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 10.46 (s, 1H), 7.94 (d, <i>J</i> = 2.6 Hz, 1H), 7.60 (dd, <i>J</i> = 8.9, 2.6 Hz, 1H), 7.45–7.33 (m, 5H), 6.95 (d, <i>J</i> = 8.9 Hz, 1H), 5.18 (s, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 188.2, 159.9, 138.2, 135.5, 131.0, 128.8, 128.5, 127.3, 126.5, 115.2, 113.8, 70.9.</div></div><div id="sec4_1_10_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(5-Bromo-2-methoxyphenyl)ethan-1-one (<b>1p</b>)</h5><div class="NLM_p last">See procedure F: 198 mg (0.92 mmol) of 1-(5-bromo-2-hydroxyphenyl)ethan-1-one, 380 mg (2.8 mmol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, 0.170 mL (388 mg, 2.7 mmol, 3.0 equiv) of MeI, and 3 mL of DMF. Compound <b>1p</b> (205 mg, 97.2% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.77 (d, <i>J</i> = 2.7 Hz, 1H), 7.48 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.81 (d, <i>J</i> = 8.9 Hz, 1H), 3.86 (s, 3H), 2.55 (s, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 198.1, 157.9, 136.0, 132.8, 129.5, 113.6, 113.0, 55.8, 31.7.</div></div><div id="sec4_1_10_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> (<i>R</i>)-<i>N</i>-(3-Bromobenzyl)-2-methylpropane-2-sulfinamide (<b>2a</b>)</h5><div class="NLM_p last">See procedure A: 90 mg (0.49 mmol) of 3-bromobenzaldehyde, 179 mg (1.5 mmol, 3.0 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 600 μL (653 mg, 2.9 mmol, 5.9 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [115 mg (3.0 mmol, 6.3 equiv)] in 4 mL of THF. Compound <b>2a</b> (111 mg, 78.6% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.47 (s, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 7.1 Hz, 1H), 7.19 (t, <i>J</i> = 7.7 Hz, 1H), 4.30 (dd, <i>J</i> = 14.2, 5.1 Hz, 1H), 4.22 (dd, <i>J</i> = 14.2, 7.5 Hz, 1H), 3.56 (t, <i>J</i> = 6.3 Hz, 1H), 1.23 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 140.8, 131.1, 130.7, 130.2, 126.6, 122.6, 56.0, 48.7, 22.7.</div></div><div id="sec4_1_10_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(3-Bromophenyl)ethyl)-2-methylpropane-2-sulfinamide (<b>2b</b>)</h5><div class="NLM_p last">See procedure A: 155 mg (0.78 mmol) of 3′-bromoacetophenone, 261 mg (2.2 mmol, 2.8 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 1.00 mL (1.09 g, 4.8 mmol, 6.1 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [179 mg (4.7 mmol, 6.1 equiv)] in 4 mL of THF. Compound <b>2b</b> (125 mg, 62.5% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.46 (t, <i>J</i> = 1.8 Hz, 1H), 7.39 (ddd, <i>J</i> = 7.8, 2.0, 1.2 Hz, 1H), 7.26 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.19 (t, <i>J</i> = 7.7 Hz, 1H), 4.48 (qd, <i>J</i> = 6.6, 3.1 Hz, 1H), 3.41 (d, <i>J</i> = 3.2 Hz, 1H), 1.48 (d, <i>J</i> = 6.6 Hz, 3H), 1.21 (s, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 146.3, 130.9, 130.4, 129.6, 125.4, 122.7, 55.6, 53.6, 22.8, 22.6.</div></div><div id="sec4_1_10_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(3-Bromophenyl)propyl)-2-methylpropane-2-sulfinamide (<b>2c</b>)</h5><div class="NLM_p last">See procedure A: 106 mg (0.50 mmol) of 1-(3-bromophenyl)propan-1-one, 185 mg (1.5 mmol, 3.1 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 800 μL (870 mg, 3.8 mmol, 7.7 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [111 mg (2.9 mmol, 5.9 equiv)] in 4 mL of THF. Compound <b>2c</b> (125 mg, 78.9% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.43 (t, <i>J</i> = 1.8 Hz, 1H), 7.39 (dt, <i>J</i> = 7.6, 1.7 Hz, 1H), 7.25–7.16 (m, 2H), 4.21 (ddd, <i>J</i> = 8.9, 5.4, 4.1 Hz, 1H), 3.40 (d, <i>J</i> = 4.0 Hz, 1H), 2.01 (dtd, <i>J</i> = 14.7, 7.4, 5.5 Hz, 1H), 1.77–1.65 (m, 1H), 1.21 (s, 9H), 0.79 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 144.7, 130.9, 130.20, 130.15, 126.1, 122.7, 60.1, 55.8, 29.4, 22.6, 10.0.</div></div><div id="sec4_1_10_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-methylbenzyl)-2-methylpropane-2-sulfinamide (<b>2d</b>)</h5><div class="NLM_p last">See procedure A: 77 mg (0.39 mmol) of 5-bromo-2-methylbenzaldehyde, 143 mg (1.2 mmol, 3.1 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 490 μL (533 mg, 2.3 mmol, 6.0 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [89 mg (2.4 mmol, 6.1 equiv)] in 4 mL of THF. Compound <b>2d</b> (108 mg, 91.8% yield) was isolated as a colorless oil that solidified on standing. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.43 (s, 1H), 7.30 (d, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 8.0 Hz, 1H), 4.27 (dd, <i>J</i> = 13.9, 3.7 Hz, 1H), 4.16 (dd, <i>J</i> = 13.7, 8.4 Hz, 1H), 3.43 (dt, <i>J</i> = 8.4, 3.7 Hz, 1H), 2.26 (s, 3H), 1.22 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 138.4, 135.5, 132.1, 131.4, 130.7, 119.5, 56.0, 46.7, 22.7, 18.6.</div></div><div id="sec4_1_10_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-chlorobenzyl)-2-methylpropane-2-sulfinamide (<b>2e</b>)</h5><div class="NLM_p last">See procedure A: 104 mg (0.47 mmol) of 5-bromo-2-chlorobenzaldehyde, 162 mg (1.3 mmol, 2.8 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 600 μL (653 mg, 2.9 mmol, 6.0 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [107 mg (2.8 mmol, 6.0 equiv)] in 4 mL of THF. Compound <b>2e</b> (134 mg, 87.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.54 (d, <i>J</i> = 2.3 Hz, 1H), 7.33 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.21 (d, <i>J</i> = 8.5 Hz, 1H), 4.40 (dd, <i>J</i> = 15.0, 5.8 Hz, 1H), 4.28 (dd, <i>J</i> = 15.0, 7.5 Hz, 1H), 3.68 (t, <i>J</i> = 6.7 Hz, 1H), 1.22 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 138.3, 132.7, 132.6, 131.9, 131.0, 120.6, 56.2, 46.9, 22.6.</div></div><div id="sec4_1_10_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (<i>R</i>)-<i>N</i>-(4-Bromo-2-(((<i>tert</i>-butylsulfinyl)amino)methyl)phenyl)acetamide (<b>2g</b>)</h5><div class="NLM_p last">See procedure A: 93 (0.38 mmol) of <b>1g</b>, 144 mg (1.2 mmol, 3.1 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 600 μL (653 mg, 2.9 mmol, 7.5 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [87 mg (2.3 mmol, 6.0 equiv)] in 3 mL of THF. This compound was purified using 0–10% methanol in DCM as the mobile phase during column chromatography. Compound <b>2g</b> (130 mg, 97.5% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.89 (s, 1H), 7.80 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 7.37 (d, <i>J</i> = 2.4 Hz, 1H), 4.22 (dd, <i>J</i> = 13.5, 5.8 Hz, 1H), 4.11 (dd, <i>J</i> = 13.5, 4.5 Hz, 1H), 3.72 (t, <i>J</i> = 5.1 Hz, 1H), 2.19 (s, 3H), 1.23 (s, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 169.53, 135.72, 133.03, 132.03, 130.51, 126.03, 117.34, 56.50, 44.54, 24.08, 22.85.</div></div><div id="sec4_1_10_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (<i>R</i>)-<i>N</i>-(4-Bromo-2-(((<i>tert</i>-butylsulfinyl)amino)methyl)phenyl)propionamide (<b>2i</b>)</h5><div class="NLM_p last">See procedure A: 84 (0.33 mmol) of <b>1i</b>, 123 mg (1.0 mmol, 3.1 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 410 μL (446 mg, 2.0 mmol, 6.0 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [87 mg (2.3 mmol, 6.0 equiv)] in 4 mL of THF. Compound <b>2i</b> (78 mg, 65.8% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.70 (s, 1H), 7.83 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.36 (d, <i>J</i> = 2.4 Hz, 1H), 4.20 (dd, <i>J</i> = 13.4, 5.9 Hz, 1H), 4.08 (dd, <i>J</i> = 13.1, 4.5 Hz, 1H), 3.67 (t, <i>J</i> = 5.1 Hz, 1H), 2.44 (q, <i>J</i> = 7.6 Hz, 2H), 1.22 (m, 12H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 173.14, 135.81, 133.02, 132.07, 130.19, 125.87, 117.15, 56.47, 44.52, 30.22, 22.82, 9.69.</div></div><div id="sec4_1_10_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-methoxybenzyl)-2-methylpropane-2-sulfinamide (<b>2j</b>)</h5><div class="NLM_p last">See procedure A: 142 mg (0.66 mmol) of <b>1j</b>, 240 mg (2.0 mmol, 3.0 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 1.00 mL (1.09 g, 4.8 mmol, 7.2 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [152 mg (4.0 mmol, 6.1 equiv)] in 4 mL of THF. Compound <b>2j</b> (159 mg, 75.2% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.36 (d, <i>J</i> = 2.5 Hz, 1H), 7.33 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.72 (d, <i>J</i> = 8.6 Hz, 1H), 4.34 (dd, <i>J</i> = 14.4, 5.6 Hz, 1H), 4.11 (dd, <i>J</i> = 14.5, 7.6 Hz, 1H), 3.80 (s, 3H), 3.66 (t, <i>J</i> = 6.9 Hz, 1H), 1.19 (s, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 156.4, 131.9, 131.4, 129.3, 112.6, 112.0, 55.9, 44.8, 22.6.</div></div><div id="sec4_1_10_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-(trifluoromethoxy)benzyl)-2-methylpropane-2-sulfinamide (<b>2k</b>)</h5><div class="NLM_p last">See procedure A: 70 μL (119 mg, 0.44 mmol) of 5-bromo-2-(trifluoromethoxy)benzaldehyde, 163 mg (1.3 mmol, 3.0 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 700 μL (762 mg, 3.3 mmol, 7.5 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [103 mg (2.7 mmol, 6.1 equiv)] in 4 mL of THF. Compound <b>2k</b> (128 mg, 77.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.61 (d, <i>J</i> = 2.4 Hz, 1H), 7.43 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.11 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 4.38 (dd, <i>J</i> = 15.1, 5.8 Hz, 1H), 4.27 (dd, <i>J</i> = 15.1, 7.4 Hz, 1H), 3.61 (t, <i>J</i> = 6.6 Hz, 1H), 1.22 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 146.2 (q, <i>J</i> = 1.7 Hz), 133.5, 133.0, 132.0, 122.2 (q, <i>J</i> = 1.7 Hz), 121.4, 120.2, 119.3, 56.2, 43.7, 22.6.</div></div><div id="sec4_1_10_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-ethoxybenzyl)-2-methylpropane-2-sulfinamide (<b>2l</b>)</h5><div class="NLM_p last">See procedure A: 73 mg (0.32 mmol) of <b>1l</b>, 116 mg (0.96 mmol, 3.0 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 500 μL (544 mg, 2.4 mmol, 7.5 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [74 mg (2.0 mmol, 6.1 equiv)] in 3 mL of THF. Compound <b>2l</b> (97 mg, 91.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.36 (d, <i>J</i> = 2.5 Hz, 1H), 7.30 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.70 (d, <i>J</i> = 8.7 Hz, 1H), 4.35 (dd, <i>J</i> = 14.3, 5.6 Hz, 1H), 4.12 (dd, <i>J</i> = 14.4, 7.9 Hz, 1H), 4.00 (q, <i>J</i> = 7.0 Hz, 2H), 3.72 (t, <i>J</i> = 6.8 Hz, 1H,), 1.40 (t, <i>J</i> = 7.0 Hz, 3H), 1.20 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.8, 131.8, 131.3, 129.4, 112.8, 112.5, 63.9, 55.9, 45.0, 22.6, 14.8.</div></div><div id="sec4_1_10_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-propoxybenzyl)-2-methylpropane-2-sulfinamide (<b>2m</b>)</h5><div class="NLM_p last">See procedure A: 133 mg (0.55 mmol) of <b>1m</b>, 98 mg (0.81 mmol, 1.5 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 420 μL (457 mg, 2.0 mmol, 3.7 equiv) of Ti(OEt)<sub>4</sub>, and 3 + 3 mL of THF. Sodium borohydride [121 mg (3.2 mmol, 5.9 equiv)] in 3 mL of THF. Compound <b>2m</b> (169 mg, 88.7% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.35 (d, <i>J</i> = 2.5 Hz, 1H), 7.28 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.68 (d, <i>J</i> = 8.7 Hz, 1H), 4.33 (dd, <i>J</i> = 14.4, 5.6 Hz, 1H), 4.11 (dd, <i>J</i> = 14.4, 7.8 Hz, 1H), 3.88 (t, <i>J</i> = 6.5 Hz, 2H), 3.72 (dd, <i>J</i> = 7.8, 5.6 Hz, 1H), 1.78 (h, <i>J</i> = 7.4 Hz, 2H), 1.18 (s, 9H), 1.01 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.8, 131.8, 131.3, 129.4, 112.8, 112.4, 69.8, 55.9, 44.9, 22.6, 22.5, 10.6.</div></div><div id="sec4_1_10_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (<i>R</i>)-<i>N</i>-(5-Bromo-2-(cyclopropylmethoxy)benzyl)-2-methylpropane-2-sulfinamide (<b>2n</b>)</h5><div class="NLM_p last">See procedure A: 135 mg (0.53 mmol) of <b>1n</b>, 197 mg (1.6 mmol, 3.1 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 840 μL (914 mg, 4.0 mmol, 7.6 equiv) of Ti(OEt)<sub>4</sub>, and 4 + 4 mL of THF. Sodium borohydride [115 mg (3.0 mmol, 5.8 equiv)] in 3 mL of THF. Compound <b>2n</b> (165 mg, 86.5% yield) was isolated as a colorless oil that solidifies to a white solid on standing. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.36 (d, <i>J</i> = 2.5 Hz, 1H), 7.30 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.67 (d, <i>J</i> = 8.7 Hz, 1H), 4.39 (dd, <i>J</i> = 14.4, 5.7 Hz, 1H), 4.14 (dd, <i>J</i> = 14.4, 7.9 Hz, 1H), 3.88–3.75 (m, 3H), 1.21 (s, 9H), 0.62 (dt, <i>J</i> = 8.9, 3.2 Hz, 2H), 0.32 (dd, <i>J</i> = 4.7, 2.1 Hz, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.9, 131.8, 131.3, 129.6, 113.0, 112.5, 73.1, 55.9, 45.3, 22.6, 10.2, 3.24, 3.18.</div></div><div id="sec4_1_10_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>R</i>)-<i>N</i>-(2-(Benzyloxy)-5-bromobenzyl)-2-methylpropane-2-sulfinamide (<b>2o</b>)</h5><div class="NLM_p last">See procedure A: 440 mg (1.5 mmol) of <b>1o</b>, 558 mg (4.6 mmol, 3.1 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 2.4 mL (2.6 g, 11.4 mmol, 7.6 equiv) of Ti(OEt)<sub>4</sub>, and 5 + 5 mL of THF. Sodium borohydride [341 mg (9.0 mmol, 6.0 equiv)] in 4 mL of THF. Compound <b>2o</b> (582 mg, 97.2% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.29 (d, <i>J</i> = 2.5 Hz, 1H), 7.27–7.18 (m, 4H), 7.18–7.11 (m, 2H), 6.62 (d, <i>J</i> = 8.7 Hz, 1H), 4.98 (s, 2H), 4.32 (dd, <i>J</i> = 14.6, 5.7 Hz, 1H), 4.18 (dd, <i>J</i> = 14.6, 7.2 Hz, 1H), 4.12 (dd, <i>J</i> = 7.2, 5.8 Hz, 1H), 1.14 (s, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 155.3, 136.2, 131.7, 131.0, 129.9, 128.5, 128.1, 128.0, 127.2, 126.7, 113.3, 112.8, 70.0, 55.7, 44.5, 22.5.</div></div><div id="sec4_1_10_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(5-Bromo-2-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide (<b>2p</b>)</h5><div class="NLM_p last">See procedure A: 129 mg (0.59 mmol) of <b>1p</b>, 193 mg (1.6 mmol, 2.7 equiv) of (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, 720 μL (783 mg, 3.4 mmol, 5.8 equiv) of Ti(OEt)<sub>4</sub>, 4 + 4 mL of THF. Sodium borohydride [137 mg (3.6 mmol, 6.1 equiv)] in 4 mL of THF. Compound <b>2p</b> (173 mg, 91.9% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.33 (d, <i>J</i> = 2.5 Hz, 1H), 7.26 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.69 (d, <i>J</i> = 8.7 Hz, 1H), 4.69 (p, <i>J</i> = 6.5 Hz, 1H), 3.77 (s, 3H), 3.75 (d, <i>J</i> = 5.8 Hz, 1H), 1.40 (d, <i>J</i> = 6.7 Hz, 3H), 1.16 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.6, 134.5, 131.1, 129.7, 113.0, 112.6, 55.6, 49.6, 23.6, 22.6, 21.0.</div></div><div id="sec4_1_10_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>R</i>)-<i>N</i>-(3-Benzylbenzyl)-2-methylpropane-2-sulfinamide (<b>3a</b>)</h5><div class="NLM_p last">See procedure Bb: 55 mg (0.19 mmol) of <b>2a</b>, 120 μL (118 mg, 0.54 mmol, 2.8 equiv) of benzylboronic acid pinacol ester, 54 mg (0.39 mmol, 2.1 equiv) of potassium carbonate, 17 mg (0.023 mmol, 0.12 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 4 mL of 3:1 acetone/water. Compound <b>3a</b> (38 mg, 66.5% yield) was isolated as a colorless oil that solidified to a white solid on standing. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.32–7.24 (m, 3H), 7.23–7.10 (m, 6H), 4.31 (dd, <i>J</i> = 13.8, 4.6 Hz, 1H), 4.21 (dd, <i>J</i> = 13.8, 7.8 Hz, 1H), 3.98 (s, 2H), 3.45 (dd, <i>J</i> = 7.6, 4.6 Hz, 1H), 1.22 (s, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 141.6, 140.8, 138.7, 128.9, 128.7, 128.6, 128.5, 128.3, 126.2, 125.8, 55.9, 49.3, 41.8, 22.7.</div></div><div id="sec4_1_10_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(3-Benzylphenyl)ethyl)-2-methylpropane-2-sulfinamide (<b>3b</b>)</h5><div class="NLM_p last">See procedure Bb: 98 mg (0.32 mmol) of <b>2b</b>, 180 μL (176 mg, 0.81 mmol, 2.5 equiv) of benzylboronic acid pinacol ester, 86 mg (0.62 mmol, 1.9 equiv) of potassium carbonate, 21 mg (0.029 mmol, 0.089 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 5 mL of 3:1 acetone/water. Compound <b>3b</b> (58 mg, 57.1% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.33–7.23 (m, 3H), 7.24–7.14 (m, 5H), 7.11 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 4.51 (qd, <i>J</i> = 6.5, 2.6 Hz, 1H), 3.99 (s, 2H), 3.39 (d, <i>J</i> = 2.6 Hz, 1H), 1.49 (d, <i>J</i> = 6.5 Hz, 3H), 1.22 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 144.3, 141.7, 140.8, 128.91, 128.87, 128.5, 128.3, 127.2, 126.1, 124.2, 55.4, 53.8, 41.9, 22.8, 22.6.</div></div><div id="sec4_1_10_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(3-Benzylphenyl)propyl)-2-methylpropane-2-sulfinamide (<b>3c</b>)</h5><div class="NLM_p last">See procedure Ba: 83 mg (0.28 mmol) of <b>2c</b>, 130 μL (127 mg, 0.58 mmol, 2.1 equiv) of benzylboronic acid pinacol ester, 116 mg (0.84 mmol, 3.0 equiv) of potassium carbonate, 20 mg (0.027 mmol, 0.098 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, 2.5 mL of 3:1 acetone/water. Compound <b>3c</b> (81 mg, 94.3% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.30–7.23 (m, 3H), 7.21–7.07 (m, 6H), 4.23 (dt, <i>J</i> = 8.5, 4.6 Hz, 1H), 3.98 (s, 2H), 2.02 (dp, <i>J</i> = 13.2, 7.4 Hz, 1H), 1.73 (dq, <i>J</i> = 21.7, 7.3 Hz, 1H), 1.20 (s, 9H), 0.77 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 142.4, 141.4, 140.9, 128.9, 128.7, 128.5, 128.4, 127.9, 126.1, 124.9, 60.2, 55.7, 41.8, 29.3, 22.6, 10.0.</div></div><div id="sec4_1_10_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-methylbenzyl)-2-methylpropane-2-sulfinamide (<b>3d</b>)</h5><div class="NLM_p last">See procedure Bb: 89 mg (0.29 mmol) of <b>2d</b>, 200 μL (196 mg, 0.90 mmol, 3.1 equiv) of benzylboronic acid pinacol ester, 82 mg (0.59 mmol, 2.0 equiv) of potassium carbonate, 22 mg (0.030 mmol, 0.10 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 4 mL of 3:1 acetone/water. Compound <b>3d</b> (65 mg, 70.4% yield) was isolated as a tan solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.30–7.26 (m, 2H), 7.19 (t, <i>J</i> = 8.7 Hz, 3H), 7.12–7.07 (m, 2H), 7.05 (dd, <i>J</i> = 7.8, 1.9 Hz, 1H), 4.30 (dd, <i>J</i> = 13.3, 3.9 Hz, 1H), 4.18 (dd, <i>J</i> = 13.3, 8.8 Hz, 1H), 3.94 (s, 2H), 3.27 (dd, <i>J</i> = 9.1, 3.9 Hz, 1H), 2.31 (s, 3H), 1.20 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 141.0, 139.0, 136.2, 134.4, 130.6, 129.4, 128.9, 128.5, 128.3, 126.1, 55.9, 47.4, 41.5, 22.7, 18.6.</div></div><div id="sec4_1_10_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-chlorobenzyl)-2-methylpropane-2-sulfinamide (<b>3e</b>)</h5><div class="NLM_p last">See procedure Bb: 59 mg (0.18 mmol) of <b>2e</b>, 100 μL (98 mg, 0.45 mmol, 2.5 equiv) of benzylboronic acid pinacol ester, 47 mg (0.34 mmol, 1.9 equiv) of potassium carbonate, 13 mg (0.018 mmol, 0.098 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 4 mL of 3:1 acetone/water. Compound <b>3e</b> (45 mg, 73.7% yield) was isolated as a colorless oil that solidifies to a white solid on standing. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.30–7.24 (m, 3H), 7.21–7.18 (m, 2H), 7.15 (d, <i>J</i> = 7.5 Hz, 2H), 7.05 (d, <i>J</i> = 8.1 Hz, 1H), 4.40 (dd, <i>J</i> = 14.4, 5.1 Hz, 1H), 4.27 (dd, <i>J</i> = 14.3, 7.8 Hz, 1H), 3.93 (s, 2H), 3.60 (t, <i>J</i> = 6.8 Hz, 1H), 1.18 (d, <i>J</i> = 1.4 Hz, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 140.3, 136.0, 131.4, 130.5, 129.6, 129.5, 128.9, 128.6, 126.3, 56.1, 47.3, 41.2, 22.6.</div></div><div id="sec4_1_10_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (<i>R</i>)-<i>N</i>-(4-Benzyl-2-(((<i>tert</i>-butylsulfinyl)amino)methyl)phenyl)acetamide (<b>3g</b>)</h5><div class="NLM_p last">See procedure Ba: 125 mg (0.36 mmol) of <b>2g</b>, 140 μL (137 mg, 0.63 mmol, 1.8 equiv) of benzylboronic acid pinacol ester, 136 mg (0.98 mmol, 2.7 equiv) of potassium carbonate, 29 mg (0.040 mmol, 0.11 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 3.2 mL of 3:1 acetone/water. Compound <b>3g</b> (94 mg, 72.8% yield) was isolated as a yellow oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.72 (s, 1H), 7.79 (d, <i>J</i> = 8.3 Hz, 1H), 7.29–7.22 (m, 2H), 7.20–7.12 (m, 4H), 7.04 (d, <i>J</i> = 2.1 Hz, 1H), 4.20 (dd, <i>J</i> = 13.2, 6.0 Hz, 1H), 4.12 (dd, <i>J</i> = 13.3, 4.4 Hz, 1H), 3.90 (s, 2H), 3.65 (t, <i>J</i> = 5.3 Hz, 1H), 2.18 (s, 3H), 1.21 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 169.48, 140.67, 137.91, 134.64, 130.73, 129.71, 128.89, 128.74, 128.51, 126.19, 124.72, 56.34, 45.48, 41.28, 24.05, 22.84.</div></div><div id="sec4_1_10_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>R</i>)-<i>N</i>-(4-Benzyl-2-(((<i>tert</i>-butylsulfinyl)amino)methyl)phenyl)propionamide (<b>3i</b>)</h5><div class="NLM_p last">See procedure Bb: 76 mg (0.21 mmol) of <b>2i</b>, 120 μL (118 mg, 0.54 mmol, 2.6 equiv) of benzylboronic acid pinacol ester, 59 mg (0.43 mmol, 2.0 equiv) of potassium carbonate, 15 mg (0.020 mmol, 0.098 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 5 mL of 3:1 acetone/water. Compound <b>3i</b> (68 mg, 86.8% yield) was isolated as a yellow oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.56 (s, 1H), 7.84 (d, <i>J</i> = 8.3 Hz, 1H), 7.27 (t, <i>J</i> = 7.3 Hz, 2H), 7.23–7.11 (m, 4H), 7.05 (s, 1H), 4.19 (dd, <i>J</i> = 13.1, 6.2 Hz, 1H), 4.11 (dd, <i>J</i> = 13.1, 4.3 Hz, 1H), 3.92 (s, 2H), 3.55 (t, <i>J</i> = 5.2 Hz, 1H), 2.44 (q, <i>J</i> = 7.6 Hz, 2H), 1.25–1.21 (m, 12H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 173.06, 140.73, 137.67, 134.78, 130.73, 129.71, 128.88, 128.50, 128.46, 126.18, 124.49, 56.27, 45.47, 41.28, 30.28, 22.83, 9.87.</div></div><div id="sec4_1_10_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-methoxybenzyl)-2-methylpropane-2-sulfinamide (<b>3j</b>)</h5><div class="NLM_p last">See procedure Bb: 149 mg (0.47 mmol) of <b>2j</b>, 200 μL (196 mg, 0.90 mmol, 1.9 equiv) of benzylboronic acid pinacol ester, 193 mg (1.4 mmol, 3.0 equiv) of potassium carbonate, 33 mg (0.045 mmol, 0.096 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 3 mL of 3:1 acetone/water. Compound <b>3j</b> (98 mg, 63.5% yield) was isolated. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.26 (ddd, <i>J</i> = 7.6, 6.3, 1.3 Hz, 2H), 7.20–7.13 (m, 3H), 7.09–7.04 (m, 2H), 6.77 (d, <i>J</i> = 9.0 Hz, 1H), 4.36 (dd, <i>J</i> = 13.8, 5.1 Hz, 1H), 4.10 (dd, <i>J</i> = 13.8, 8.0 Hz, 1H), 3.90 (s, 2H), 3.79 (s, 3H), 3.76 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 1.17 (s, 9H). <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>) δ 155.8, 141.3, 133.2, 129.9, 129.0, 128.8, 128.4, 126.9, 126.0, 110.4, 55.9, 55.4, 45.5, 41.0, 22.6.</div></div><div id="sec4_1_10_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-(trifluoromethoxy)benzyl)-2-methylpropane-2-sulfinamide (<b>3k</b>)</h5><div class="NLM_p last">See procedure Bb: 141 mg (0.38 mmol) of <b>2k</b>, 110 μL (108 mg, 0.49 mmol, 1.3 equiv) of benzylboronic acid pinacol ester, 94 mg (0.68 mmol, 1.8 equiv) of potassium carbonate, 28 mg (0.038 mmol, 0.10 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 5 mL of 3:1 acetone/water. Compound <b>3k</b> (105 mg, 72.3% yield) was isolated as a tan solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.33–7.27 (m, 2H), 7.26 (s, 1H), 7.25–7.11 (m, 5H), 4.39 (dd, <i>J</i> = 14.5, 5.4 Hz, 1H), 4.26 (dd, <i>J</i> = 14.5, 7.7 Hz, 1H), 3.97 (s, 2H), 3.53 (dd, <i>J</i> = 7.7, 5.4 Hz, 1H), 1.19 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 145.6 (q, <i>J</i> = 1.5 Hz), 140.2, 140.1, 131.1, 130.5, 129.3, 128.9, 128.6, 126.4, 121.6, 120.6 (q, <i>J</i> = 1.4 Hz), 119.5, 56.03, 44.1, 41.2, 22.5.</div></div><div id="sec4_1_10_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-ethoxybenzyl)-2-methylpropane-2-sulfinamide (<b>3l</b>)</h5><div class="NLM_p last">See procedure Ba: 119 mg (0.36 mmol) of <b>2l</b>, 160 μL (157 mg, 0.72 mmol, 2.0 equiv) of benzylboronic acid pinacol ester, 151 mg (1.1 mmol, 3.1 equiv) of potassium carbonate, 29 mg (0.040 mmol, 0.11 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 2.5 mL of 3:1 acetone/water. Compound <b>3l</b> (87 mg, 70.7% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.29–7.24 (m, 2H), 7.20–7.15 (m, 3H), 7.07 (d, <i>J</i> = 2.3 Hz, 1H), 7.05 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.76 (d, <i>J</i> = 8.3 Hz, 1H), 4.39 (dd, <i>J</i> = 13.8, 5.1 Hz, 1H), 4.11 (dd, <i>J</i> = 13.8, 8.1 Hz, 1H), 4.02 (qd, <i>J</i> = 7.0, 1.1 Hz, 2H), 3.91 (s, 2H), 3.76 (dd, <i>J</i> = 8.3, 5.2 Hz, 1H), 1.40 (t, <i>J</i> = 7.0 Hz, 3H), 1.18 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.2, 141.4, 133.0, 129.9, 129.0, 128.8, 128.4, 127.1, 126.0, 111.2, 63.6, 55.8, 45.6, 41.0, 22.6, 15.0.</div></div><div id="sec4_1_10_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-propoxybenzyl)-2-methylpropane-2-sulfinamide (<b>3m</b>)</h5><div class="NLM_p last">See procedure Ba: 122 mg (0.35 mmol) of <b>2m</b>, 130 μL (127 mg, 0.58 mmol, 1.7 equiv) of benzylboronic acid pinacol ester, 135 mg (0.98 mmol, 2.8 equiv) of potassium carbonate, 25 mg (0.034 mmol, 0.098 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 2.5 mL of 3:1 acetone/water. Compound <b>3m</b> (92 mg, 73.1% yield) was isolated as a yellow oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.26 (dd, <i>J</i> = 8.1, 6.9 Hz, 2H), 7.20–7.14 (m, 3H), 7.08 (d, <i>J</i> = 2.3 Hz, 1H), 7.05 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.76 (d, <i>J</i> = 8.3 Hz, 1H), 4.39 (dd, <i>J</i> = 13.8, 5.2 Hz, 1H), 4.12 (dd, <i>J</i> = 13.8, 8.2 Hz, 1H), 3.91 (t, <i>J</i> = 6.5 Hz, 2H), 3.90 (s, 2H) 3.76 (dd, <i>J</i> = 8.2, 5.2 Hz, 1H), 1.80 (h, <i>J</i> = 7.2 Hz, 2H), 1.17 (s, 9H), 1.04 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.3, 141.4, 133.0, 129.9, 129.0, 128.8, 128.4, 127.1, 126.0, 111.2, 69.6, 55.8, 45.6, 41.0, 22.7, 22.6, 10.7.</div></div><div id="sec4_1_10_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-(cyclopropylmethoxy)benzyl)-2-methylpropane-2-sulfinamide (<b>3n</b>)</h5><div class="NLM_p last">See procedure Ba: 48 mg (0.13 mmol) of <b>2n</b>, 60 μL (59 mg, 0.27 mmol, 2.0 equiv) of benzylboronic acid pinacol ester, 56 mg (0.41 mmol, 3.1 equiv) of potassium carbonate, 10 mg (0.014 mmol, 0.10 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 3.25 mL of 3:1 acetone/water. Compound <b>3n</b> (41 mg, 82.8% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.30–7.25 (m, 2H), 7.22–7.15 (m, 3H), 7.08 (d, <i>J</i> = 2.3 Hz, 1H), 7.04 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 6.74 (d, <i>J</i> = 8.3 Hz, 1H), 4.43 (dd, <i>J</i> = 13.8, 5.1 Hz, 1H), 4.13 (dd, <i>J</i> = 13.8, 8.1 Hz, 1H), 3.91 (s, 2H), 3.86 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 3.80 (qd, <i>J</i> = 9.9, 6.9 Hz, 2H), 1.28–1.22 (m, 1H), 1.20 (s, 9H), 0.68–0.58 (m, 2H), 0.33 (tdd, <i>J</i> = 4.8, 3.3, 2.2 Hz, 2H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 155.3, 141.4, 133.1, 129.9, 128.9, 128.8, 128.4, 127.3, 126.0, 111.4, 72.8, 55.7, 45.9, 41.0, 22.6, 10.4, 3.2, 3.1.</div></div><div id="sec4_1_10_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (<i>R</i>)-<i>N</i>-(5-Benzyl-2-(benzyloxy)benzyl)-2-methylpropane-2-sulfinamide (<b>3o</b>)</h5><div class="NLM_p last">See procedure Ba: 500 mg (1.3 mmol) of <b>2o</b>, 590 μL (578 mg, 2.7 mmol, 2.0 equiv) of benzylboronic acid pinacol ester, 564 mg (4.1 mmol, 3.1 equiv) of potassium carbonate, 98 mg (0.13 mmol, 0.10 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 2.5 mL of 3:1 acetone/water. Compound <b>3o</b> (363 mg, 70.6% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.43–7.35 (m, 4H), 7.34–7.25 (m, 3H), 7.21–7.15 (m, 3H), 7.12 (d, <i>J</i> = 2.2 Hz, 1H), 7.06 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.85 (d, <i>J</i> = 8.3 Hz, 1H), 5.06 (s, 2H), 4.41 (dd, <i>J</i> = 14.0, 5.4 Hz, 1H), 4.20 (dd, <i>J</i> = 14.0, 7.8 Hz, 1H), 3.92 (s, 2H), 3.81 (dd, <i>J</i> = 7.8, 5.4 Hz, 1H), 1.13 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 154.9, 141.3, 136.9, 133.6, 130.0, 129.0, 128.9, 128.6, 128.5, 128.0, 127.32, 127.29, 126.1, 111.7, 70.1, 55.9, 45.6, 41.1, 22.6.</div></div><div id="sec4_1_10_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (<i>R</i>)-<i>N</i>-((<i>R</i>)-1-(5-Benzyl-2-methoxyphenyl)ethyl)-2-methylpropane-2-sulfinamide (<b>3p</b>)</h5><div class="NLM_p last">See procedure Bb: 134 mg (0.40 mmol) of <b>2p</b>, 240 μL (235 mg, 1.1 mmol, 2.7 equiv) of benzylboronic acid pinacol ester, 101 mg (0.73 mmol, 1.8 equiv) of potassium carbonate, 28 mg (0.038 mmol, 0.096 equiv) of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, and 4 mL of 3:1 acetone/water. Compound <b>3p</b> (75 mg, 54.2% yield) was isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.30–7.23 (m, 2H), 7.21–7.13 (m, 3H), 7.09 (d, <i>J</i> = 2.2 Hz, 1H), 7.02 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.78 (d, <i>J</i> = 8.4 Hz, 1H), 4.75 (p, <i>J</i> = 6.5 Hz, 1H), 3.92 (s, 2H), 3.80 (s, 3H), 3.77 (d, <i>J</i> = 5.0 Hz, 1H), 1.44 (d, <i>J</i> = 6.7 Hz, 3H), 1.17 (s, 9H). <sup>13</sup>C NMR (126 MHz, chloroform-<i>d</i>) δ 154.9, 141.4, 133.3, 132.2, 128.9, 128.6, 128.4, 127.4, 126.0, 110.9, 55.40, 55.37, 49.9, 41.1, 22.6, 21.9.</div></div><div id="sec4_1_10_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (3-Benzylphenyl)methanaminium Chloride (<b>4a</b>)</h5><div class="NLM_p last">See procedure C: 123 mg (0.41 mmol) of <b>3a</b>, 0.4 mL of HCl conc., and 2 mL of dioxane. Compound <b>4a</b> (85 mg, 89.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.38–7.32 (m, 2H), 7.32–7.23 (m, 4H), 7.23–7.19 (m, 2H), 7.19–7.12 (m, 1H), 4.07 (s, 2H), 4.00 (s, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 142.6, 140.8, 133.2, 129.4, 129.1, 128.9, 128.5, 128.1, 126.3, 125.8, 42.9, 41.2.</div></div><div id="sec4_1_10_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> (<i>R</i>)-1-(3-Benzylphenyl)ethan-1-aminium Chloride (<b>4b</b>)</h5><div class="NLM_p last">See procedure C: 43 mg (0.14 mmol) of <b>3b</b>, 0.2 mL of HCl conc., and 2 mL of dioxane. Compound <b>4b</b> (35 mg, quantitative yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.39–7.33 (m, 2H), 7.31 (dt, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.29–7.23 (m, 3H), 7.23–7.19 (m, 2H), 7.19–7.14 (m, 1H), 4.41 (q, <i>J</i> = 6.9 Hz, 1H), 4.01 (s, 2H), 1.61 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 142.6, 140.8, 138.4, 129.3, 129.0, 128.5, 128.1, 126.8, 125.8, 123.9, 51.0, 41.3, 19.4.</div></div><div id="sec4_1_10_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (<i>R</i>)-1-(3-Benzylphenyl)propan-1-aminium Chloride (<b>4c</b>)</h5><div class="NLM_p last">See procedure C: 81 mg (0.25 mmol) of <b>3c</b>, 0.4 mL of HCl conc., and 2 mL of dioxane. Compound <b>4c</b> (26 mg, 40.4% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.38 (dd, <i>J</i> = 8.2, 6.9 Hz, 1H), 7.31 (t, <i>J</i> = 1.7 Hz, 1H), 7.29–7.23 (m, 4H), 7.23–7.14 (m, 3H), 4.11 (dd, <i>J</i> = 9.3, 5.9 Hz, 1H), 4.01 (s, 2H), 2.09–1.85 (m, 2H), 0.86 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 142.7, 140.8, 136.9, 129.4, 129.0, 128.5, 128.1, 127.5, 125.8, 124.5, 56.9, 41.3, 27.3, 9.1.</div></div><div id="sec4_1_10_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (5-Benzyl-2-methylphenyl)methanaminium Chloride (<b>4d</b>)</h5><div class="NLM_p last">See procedure C: 65 mg (0.21 mmol) of <b>3d</b>, 0.3 mL of HCl conc., and 3 mL of dioxane. Compound <b>4d</b> (42 mg, 82.3% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.29 (d, <i>J</i> = 1.7 Hz, 1H), 7.26–7.22 (m, 2H), 7.21–7.10 (m, 5H), 4.11 (s, 2H), 3.94 (s, 2H), 2.36 (s, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 141.0, 139.9, 134.3, 131.3, 130.7, 129.5, 129.4, 128.5, 128.1, 125.7, 40.9, 40.2, 17.2.</div></div><div id="sec4_1_10_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (5-Benzyl-2-chlorophenyl)methanaminium Chloride (<b>4e</b>)</h5><div class="NLM_p last">See procedure C: 45 mg (0.30 mmol) of <b>3e</b>, 0.2 mL of HCl conc., and 2 mL of dioxane. Compound <b>4e</b> (33 mg, 91.8% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.45–7.40 (m, 2H), 7.30–7.25 (m, 3H), 7.24–7.16 (m, 3H), 4.22 (s, 2H), 4.00 (s, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 141.7, 140.3, 131.4, 131.1, 130.6, 129.6, 128.5, 128.3, 126.0, 40.6, 40.3.</div></div><div id="sec4_1_10_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (5-Benzyl-2-hydroxyphenyl)methanaminium Bromide (<b>4f</b>)</h5><div class="NLM_p last">See procedure G: 103 mg (0.298 mmol) of <b>3l</b>, 900 μL of 1 M BBr<sub>3</sub> in DCM (0.90 mmol, 3.02 equiv), and 5 mL of DCM. Compound <b>4f</b> (64 mg, 73.0% yield) was isolated as a yellow solid as the bromide salt. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.27–7.21 (m, 2H), 7.20–7.11 (m, 4H), 7.09 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 6.83 (d, <i>J</i> = 8.2 Hz, 1H), 4.04 (s, 2H), 3.88 (s, 2H). <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 154.1, 141.5, 132.8, 130.8, 130.6, 128.4, 128.0, 125.6, 119.1, 114.8, 40.4, 39.4.</div></div><div id="sec4_1_10_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (2-Acetamido-5-benzylphenyl)methanaminium Chloride (<b>4g</b>)</h5><div class="NLM_p last">See procedure C: 94 mg (0.26 mmol) of <b>3g</b>, 0.4 mL of HCl conc., and 2 mL of dioxane. Compound <b>4g</b> (69 mg, 90.6% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.43 (s, 1H), 7.30–7.24 (m, 3H), 7.24–7.20 (m, 2H), 7.20–7.15 (m, 2H), 4.00 (s, 2H), 3.99 (s, 2H), 2.20 (s, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 173.9, 142.6, 142.1, 135.3, 132.2, 131.7, 130.2, 130.0, 129.7, 127.9, 127.4, 42.2, 40.9, 23.2.</div></div><div id="sec4_1_10_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (5-Benzyl-2-(ethylamino)phenyl)methanaminium Chloride (<b>4h</b>)</h5><div class="NLM_p last">See procedure H: 21 mg (0.072 mmol) of <b>4g</b>, 260 μL (0.52 mmol, 7.2 equiv) of 2 M BH<sub>3</sub>*Me<sub>2</sub>S in THF, and 4 mL of THF. Compound <b>4h</b> was continued to the next step without further purification.</div></div><div id="sec4_1_10_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (5-Benzyl-2-propionamidophenyl)methanaminium Chloride (<b>4i</b>)</h5><div class="NLM_p last">See procedure C: 68 mg (0.18 mmol) of <b>3i</b>, 0.2 mL of HCl conc., and 2 mL of dioxane. Compound <b>4i</b> (50 mg, 89.9% yield) was isolated as a yellow oil. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.38 (s, 1H), 7.31–7.12 (m, 7H), 3.99 (s, 2H), 3.94 (s, 2H), 2.46 (q, <i>J</i> = 7.0 Hz, 2H), 1.22 (t, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 176.1, 141.0, 140.5, 133.9, 130.8, 130.4, 128.7, 128.6, 128.2, 126.4, 126.0, 40.9, 40.0, 29.1, 9.0.</div></div><div id="sec4_1_10_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (5-Benzyl-2-methoxyphenyl)methanaminium Chloride (<b>4j</b>)</h5><div class="NLM_p last">See procedure C: 98 mg (0.30 mmol) of <b>3j</b>, 0.3 mL of HCl conc., and 1 mL of dioxane. Compound <b>4j</b> (44 mg, 56.4% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.27–7.23 (m, 3H), 7.21–7.12 (m, 4H), 6.99 (d, <i>J</i> = 8.3 Hz, 1H), 4.05 (s, 2H), 3.92 (s, 2H), 3.89 (s, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 156.2, 141.3, 133.9, 131.0, 130.9, 128.4, 128.1, 125.7, 120.7, 110.5, 54.8, 40.4, 39.2.</div></div><div id="sec4_1_10_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> (5-Benzyl-2-(trifluoromethoxy)phenyl)methanaminium Chloride (<b>4k</b>)</h5><div class="NLM_p last">See procedure C: 105 mg (0.27 mmol) of <b>3k</b>, 0.2 mL of HCl conc., and 2 mL of dioxane. Compound <b>4k</b> (76 mg, 87.8% yield) was isolated as a yellow-white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.50 (d, <i>J</i> = 2.0 Hz, 1H), 7.39 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 7.33 (dq, <i>J</i> = 8.5, 1.8 Hz, 1H), 7.31–7.14 (m, 5H), 4.18 (s, 2H), 4.04 (s, 2H). <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 145.6, 141.6, 140.2, 131.1, 130.9, 128.6, 128.3, 126.1, 125.4, 121.8, 120.5, 119.2, 40.5, 37.2.</div></div><div id="sec4_1_10_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> (5-Benzyl-2-ethoxyphenyl)methanaminium Chloride (<b>4l</b>)</h5><div class="NLM_p last">See procedure C: 70 mg (0.20 mmol) of <b>3l</b>, 0.4 mL of HCl conc., and 2 mL of dioxane. Compound <b>4l</b> (37 mg, 65.7% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.24 (d, <i>J</i> = 7.0 Hz, 3H), 7.21–7.12 (m, 4H), 6.98 (d, <i>J</i> = 8.3 Hz, 1H), 4.13 (q, <i>J</i> = 6.6 Hz, 2H), 4.06 (s, 2H), 3.92 (s, 2H), 1.44 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 155.4, 141.3, 133.8, 130.9, 130.7, 128.4, 128.1, 125.7, 120.8, 111.4, 63.7, 40.4, 39.0, 13.6.</div></div><div id="sec4_1_10_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> (5-Benzyl-2-propoxyphenyl)methanaminium Chloride (<b>4m</b>)</h5><div class="NLM_p last">See procedure C: 37 mg (0.10 mmol) of <b>3m</b>, 0.4 mL of HCl conc., and 2 mL of dioxane. Compound <b>4m</b> (27 mg, 71.0% yield) was purified via reverse-phase chromatography and isolated as a colorless oil. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.27–7.22 (m, 3H), 7.20–7.13 (m, 4H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 4.06 (s, 2H), 4.03 (t, <i>J</i> = 6.6 Hz, 2H), 3.92 (s, 2H), 1.86 (h, <i>J</i> = 7.2 Hz, 2H), 1.06 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 155.4, 141.3, 133.8, 130.9, 130.6, 128.4, 128.1, 125.7, 120.8, 111.4, 69.6, 40.4, 38.8, 22.0, 9.4.</div></div><div id="sec4_1_10_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> (5-Benzyl-2-(cyclopropylmethoxy)phenyl)methanaminium Chloride (<b>4n</b>)</h5><div class="NLM_p last">See procedure D: 43 mg (0.12 mmol) of <b>3n</b>, 0.2 mL of HCl conc., and 2 mL of dioxane. Compound <b>4n</b> (20 mg, 56.9% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.27–7.21 (m, 3H), 7.21–7.13 (m, 4H), 6.97 (d, <i>J</i> = 8.4 Hz, 1H), 4.09 (s, 2H), 3.94–3.90 (m, 4H), 1.36–1.27 (m, 1H), 0.66–0.60 (m, 2H), 0.38 (dt, <i>J</i> = 6.1, 4.5 Hz, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 155.5, 141.3, 133.9, 130.9, 130.6, 128.4, 128.1, 125.7, 120.9, 111.8, 73.0, 40.4, 38.9, 9.7, 2.2.</div></div><div id="sec4_1_10_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> (5-Benzyl-2-(benzyloxy)phenyl)methanaminium Chloride (<b>4o</b>)</h5><div class="NLM_p last">See procedure D: 57 mg (0.14 mmol) of <b>3o</b>, 0.3 mL of HCl conc., and 2 mL of dioxane. Compound <b>4o</b> (31 mg, 65.3% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.50–7.45 (m, 2H), 7.41–7.36 (m, 2H), 7.35–7.30 (m, 1H), 7.28–7.21 (m, 4H), 7.21–7.14 (m, 3H), 7.07–7.01 (m, 1H), 5.19 (s, 2H), 4.10 (s, 2H), 3.92 (s, 2H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 155.1, 141.2, 136.8, 134.3, 130.9, 130.7, 128.4, 128.3, 128.1, 127.7, 127.3, 125.7, 121.1, 112.2, 70.0, 40.4, 38.8.</div></div><div id="sec4_1_10_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> (<i>R</i>)-1-(5-Benzyl-2-methoxyphenyl)ethan-1-aminium Chloride (<b>4p</b>)</h5><div class="NLM_p last">See procedure D: 29 mg (0.084 mmol) of <b>3p</b>, 0.4 mL of HCl conc., and 2 mL dioxane. Compound <b>4p</b> (20 mg, 85.8% yield) was isolated as an off-yellow colorless oil (insoluble in diethyl ether). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.27–7.22 (m, 3H), 7.21–7.13 (m, 4H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 4.59 (q, <i>J</i> = 6.6 Hz, 1H), 3.93 (s, 2H), 3.89 (s, 3H), 1.59 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (126 MHz, methanol-<i>d</i><sub>4</sub>) δ 155.3, 141.3, 134.1, 130.4, 128.4, 128.1, 127.5, 125.7, 125.3, 111.0, 54.8, 40.5, 17.6.</div></div><div id="sec4_1_10_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> (<i>S</i>)-1-((3-Benzylbenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5a</b>)</h5><div class="NLM_p last">See procedure D: Step 1: 16 mg (0.068 mmol) of <b>4a</b>, 120 μL (89 mg, 0.69 mmol, 10.1 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 39 mg (0.075 mmol, 1.1 equiv) of PyBOP, 12 mg (0.071 mmol, 1.0 equiv) of 6-Cl-HOBt, 28 mg (0.068 mmol, 1.0 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5a</b> (10 mg, 29.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.25–7.21 (m, 2H), 7.18–7.12 (m, 4H), 7.06 (d, <i>J</i> = 7.7 Hz, 1H), 6.93 (s, 1H), 6.78 (d, <i>J</i> = 7.8 Hz, 1H), 6.46 (s, 2H), 4.30 (d, <i>J</i> = 14.7 Hz, 1H), 4.11 (d, <i>J</i> = 14.7 Hz, 1H), 3.92 (s, 2H), 3.83 (dd, <i>J</i> = 11.3, 4.8 Hz, 1H), 3.19 (dd, <i>J</i> = 13.6, 11.5 Hz, 1H), 2.96 (dd, <i>J</i> = 13.8, 4.8 Hz, 1H), 2.18 (s, 6H). No <sup>13</sup>C data was acquired. Electrospray ionization mass spectrometry (ESI-MS): 389.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 36.25 min.</div></div><div id="sec4_1_10_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> (<i>S</i>)-1-(((<i>R</i>)-1-(3-Benzylphenyl)ethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5b</b>)</h5><div class="NLM_p last">See procedure D: Step 1: 14 mg (0.057 mmol) of <b>4b</b>, 100 μL (74 mg, 0.57 mmol, 10.2 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 31 mg (0.060 mmol, 1.1 equiv) of PyBOP, 11 mg (0.065 mmol, 1.2 equiv) of 6-Cl-HOBt, 26 mg (0.063 mmol, 1.1 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5b</b> (14.4 mg, 49.3% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.27–7.20 (m, 2H), 7.21–7.11 (m, 4H), 7.11 (s, 1H), 7.07 (d, <i>J</i> = 7.8 Hz, 1H), 7.03 (d, <i>J</i> = 7.5 Hz, 1H), 6.54 (s, 2H), 4.79 (q, <i>J</i> = 6.7 Hz, 1H), 3.91 (s, 2H), 3.79 (dd, <i>J</i> = 11.5, 4.6 Hz, 1H), 3.21 (dd, <i>J</i> = 13.7, 11.6 Hz, 1H), 3.01 (dd, <i>J</i> = 13.8, 4.7 Hz, 1H), 2.28 (s, 6H), 1.10 (d, <i>J</i> = 7.0 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 403.2 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 38.26 min.</div></div><div id="sec4_1_10_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> (<i>S</i>)-1-(((<i>R</i>)-1-(3-Benzylphenyl)propyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5c</b>)</h5><div class="NLM_p last">See procedure D: Step 1: 18 mg (0.069 mmol) of <b>4c</b>, 140 μL (103 mg, 0.80 mmol, 11.7 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 45 mg (0.086 mmol, 1.3 equiv) of PyBOP, 14 mg (0.083 mmol, 1.2 equiv) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.1 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5c</b> (10 mg, 27.4% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.12 (d, <i>J</i> = 8.0 Hz, 1H), 7.25–7.11 (m, 6H), 7.10 (s, 1H), 7.09–7.00 (m, 2H), 6.52 (s, 2H), 4.51 (dd, <i>J</i> = 8.8, 6.5 Hz, 1H), 3.92 (s, 2H), 3.83 (dd, <i>J</i> = 11.5, 4.6 Hz, 1H), 3.23 (dd, <i>J</i> = 13.8, 11.5 Hz, 1H), 2.98 (dd, <i>J</i> = 13.8, 4.6 Hz, 1H), 2.29 (s, 6H), 1.47 (tt, <i>J</i> = 9.2, 4.6 Hz, 2H), 0.56 (t, <i>J</i> = 7.4 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 417.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 40.94 min.</div></div><div id="sec4_1_10_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> (<i>S</i>)-1-((5-Benzyl-2-methylbenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5d</b>)</h5><div class="NLM_p last">See procedure D: 20 mg (0.081 mmol) of <b>4d</b>, 170 μL (126 mg, 0.98 mmol, 12.1 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 54 mg (0.10 mmol, 1.3 equiv) of PyBOP, 20 mg (0.12 mmol, 1.5 equiv) of 6-Cl-HOBt, 39 mg (0.095 mmol, 1.3 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5d</b> (6 mg, 14.4% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.99 (s, 1H), 7.23 (t, <i>J</i> = 7.5 Hz, 2H), 7.14 (dd, <i>J</i> = 15.9, 7.6 Hz, 3H), 7.03 (d, <i>J</i> = 7.8 Hz, 1H), 6.99 (d, <i>J</i> = 7.6 Hz, 1H), 6.94 (s, 1H), 6.41 (s, 2H), 4.25 (dd, <i>J</i> = 14.7, 4.7 Hz, 1H), 4.16 (dd, <i>J</i> = 14.5, 5.0 Hz, 1H), 3.88 (s, 2H), 3.82 (dd, <i>J</i> = 11.3, 4.7 Hz, 1H), 3.15 (dd, <i>J</i> = 13.5, 11.5 Hz, 1H), 2.93 (dd, <i>J</i> = 13.7, 4.7 Hz, 1H), 2.10 (s, 6H), 2.03 (s, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 403.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 38.13 min.</div></div><div id="sec4_1_10_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> (<i>S</i>)-1-((5-Benzyl-2-chlorobenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5e</b>)</h5><div class="NLM_p last">See procedure D: 20 mg (0.075 mmol) of <b>4e</b>, 150 μL (111 mg, 0.86 mmol, 11.5 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 47 mg (0.090 mmol, 1.2 equiv) of PyBOP, 16 mg (0.094 mmol, 1.3 equiv) of 6-Cl-HOBt, 39 mg (0.095 mmol, 1.3 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5e</b> (18 mg, 44.9% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.69–7.66 (m, 3H), 7.61–7.58 (m, 3H), 7.53–7.44 (m, 2H), 6.81 (s, 2H), 4.82 (d, <i>J</i> = 14.9 Hz, 1H), 4.67 (d, <i>J</i> = 14.8 Hz, 1H), 4.35 (s, 2H), 4.30 (dd, <i>J</i> = 11.4, 4.8 Hz, 1H), 3.57 (dd, <i>J</i> = 13.4, 11.6 Hz, 1H), 3.36 (dd, <i>J</i> = 13.9, 5.0 Hz, 1H), 2.53 (s, 6H). No <sup>13</sup>C data was acquired. ESI-MS: 423.2 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 38.05 min.</div></div><div id="sec4_1_10_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (<i>S</i>)-1-((5-Benzyl-2-hydroxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5f</b>)</h5><div class="NLM_p last">See procedure D: 12 mg (0.041 mmol) of <b>4f</b>, 90 μL (67 mg, 0.52 mmol, 12.7 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 26 mg (0.050 mmol, 1.2 equiv) of PyBOP, 9 mg (0.053 mmol, 1.3 equiv) of 6-Cl-HOBt, 20 mg (0.049 mmol, 1.2 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5f</b> (7 mg, 28.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.88 (t, <i>J</i> = 5.7 Hz, 1H), 7.23 (t, <i>J</i> = 7.5 Hz, 2H), 7.18–7.07 (m, 3H), 6.92 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 6.80 (d, <i>J</i> = 2.2 Hz, 1H), 6.66 (d, <i>J</i> = 8.2 Hz, 1H), 6.39 (s, 2H), 4.20 (d, <i>J</i> = 3.8 Hz, 2H), 3.89–3.81 (m, 3H), 3.14 (dd, <i>J</i> = 14.0, 11.2 Hz, 1H), 2.94 (dd, <i>J</i> = 13.9, 4.8 Hz, 1H), 2.12 (s, 6H). No <sup>13</sup>C data was acquired. ESI-MS: 405.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 33.69 min.</div></div><div id="sec4_1_10_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> (<i>S</i>)-1-((2-Acetamido-5-benzylbenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5g</b>)</h5><div class="NLM_p last">See procedure D: 31 mg (0.11 mmol) of <b>4g</b>, 190 μL (141 mg, 1.1 mmol, 10.2 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 58 mg (0.11 mmol, 1.0 equiv) of PyBOP, 19 mg (0.11 mmol, 1.1 equiv) of 6-Cl-HOBt, 44 mg (0.11 mmol, 1.0 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5g</b> (12 mg, 20.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.42 (d, <i>J</i> = 8.2 Hz, 1H), 7.27–7.20 (m, 2H), 7.20–7.09 (m, 4H), 6.89 (d, <i>J</i> = 2.0 Hz, 1H), 6.42 (s, 2H), 4.14 (d, <i>J</i> = 2.8 Hz, 2H), 3.93 (d, <i>J</i> = 2.9 Hz, 2H), 3.80 (dd, <i>J</i> = 11.2, 4.9 Hz, 1H), 3.15 (dd, <i>J</i> = 13.9, 11.2 Hz, 1H), 2.96 (dd, <i>J</i> = 13.9, 5.0 Hz, 1H), 2.16 (s, 3H), 2.13 (s, 6H). No <sup>13</sup>C data was acquired. ESI-MS: 446.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 31.27 min.</div></div><div id="sec4_1_10_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> (<i>S</i>)-1-((5-Benzyl-2-(ethylamino)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5h</b>)</h5><div class="NLM_p last">See procedure D: Step 1: 0.072 mmol of <b>4h</b>, 130 μL (96 mg, 0.75 mmol, 10.3 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 40 mg (0.077 mmol, 1.1 equiv) of PyBOP, 14 mg (0.083 mmol, 1.1 equiv) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.0 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5h</b> (15.9 mg, 40.4% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.42–7.32 (m, 2H), 7.31–7.22 (m, 2H), 7.23–7.14 (m, 3H), 7.00 (d, <i>J</i> = 1.8 Hz, 1H), 6.35 (s, 2H), 4.22 (d, <i>J</i> = 15.0 Hz, 1H), 4.12 (d, <i>J</i> = 15.0 Hz, 1H), 4.03 (d, <i>J</i> = 3.4 Hz, 2H), 3.88 (dd, <i>J</i> = 11.4, 4.9 Hz, 1H), 3.48 (qd, <i>J</i> = 7.2, 1.7 Hz, 2H), 3.12 (dd, <i>J</i> = 13.9, 11.5 Hz, 1H), 2.99 (dd, <i>J</i> = 13.9, 5.0 Hz, 1H), 2.03 (s, 6H), 1.45 (t, <i>J</i> = 7.2 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 432.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 28.11 min.</div></div><div id="sec4_1_10_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> (<i>S</i>)-1-((5-Benzyl-2-propionamidobenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5i</b>)</h5><div class="NLM_p last">See procedure D: Step 1: 6 mg (0.020 mmol) of <b>4i</b>, 40 μL (30 mg, 0.23 mmol, 11.3 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 12 mg (0.023 mmol, 1.1 equiv) of PyBOP, 11 mg (0.065 mmol, 3.2 equiv) of 6-Cl-HOBt, 11 mg (0.027 mmol, 1.3 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5i</b> (6.4 mg, 56.7% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.20 (t, <i>J</i> = 6.1 Hz, 1H), 7.42 (d, <i>J</i> = 8.2 Hz, 1H), 7.24 (t, <i>J</i> = 7.6 Hz, 2H), 7.18–7.11 (m, 4H), 6.87 (d, <i>J</i> = 2.0 Hz, 1H), 6.41 (s, 2H), 4.12 (d, <i>J</i> = 3.1 Hz, 2H), 3.93 (d, <i>J</i> = 3.1 Hz, 2H), 3.80 (dd, <i>J</i> = 11.2, 4.9 Hz, 1H), 3.15 (dd, <i>J</i> = 13.9, 11.3 Hz, 1H), 2.96 (dd, <i>J</i> = 13.9, 4.9 Hz, 1H), 2.44 (q, <i>J</i> = 7.6 Hz, 2H), 2.11 (s, 6H), 1.23 (t, <i>J</i> = 7.6 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 460.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 32.89 min.</div></div><div id="sec4_1_10_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> (<i>S</i>)-1-((5-Benzyl-2-methoxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5j</b>)</h5><div class="NLM_p last">See procedure D: 22 mg (0.083 mmol) of <b>4j</b>, 170 μL (126 mg, 0.98 mmol, 11.8 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 51 mg (0.098 mmol, 1.2 equiv) of PyBOP, 19 mg (0.11 mmol, 1.4 equiv) of 6-Cl-HOBt, 43 mg (0.11 mmol, 1.3 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5j</b> (18 mg, 40.5% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.63 (t, <i>J</i> = 5.9 Hz, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 2H), 7.21–7.17 (m, 2H), 7.15 (tt, <i>J</i> = 7.2, 1.3 Hz, 1H), 7.10 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 6.96 (d, <i>J</i> = 2.2 Hz, 1H), 6.81 (d, <i>J</i> = 8.4 Hz, 1H), 6.31 (s, 2H), 4.37–4.26 (m, 1H), 4.12 (dd, <i>J</i> = 14.2, 4.6 Hz, 1H), 3.89–3.83 (m, 3H), 3.67 (s, 3H), 3.10 (dd, <i>J</i> = 13.8, 11.6 Hz, 1H), 2.92 (dd, <i>J</i> = 13.8, 4.5 Hz, 1H), 2.03 (s, 6H). No <sup>13</sup>C data was acquired. ESI-MS: 419.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 37.07 min.</div></div><div id="sec4_1_10_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (<i>S</i>)-1-((5-Benzyl-2-(trifluoromethoxy)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5k</b>)</h5><div class="NLM_p last">See procedure D: 19 mg (0.060 mmol) of <b>4k</b>, 110 μL (82 mg, 0.63 mmol, 10.5 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 32 mg (0.061 mmol, 1.0 equiv) of PyBOP, 11 mg (0.065 mmol, 1.1 equiv) of 6-Cl-HOBt, 29 mg (0.071 mmol, 1.2 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5k</b> (19 mg, 54.2% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.10 (t, <i>J</i> = 5.7 Hz, 1H), 7.29–7.22 (m, 2H), 7.20–7.12 (m, 5H), 7.01 (s, 1H), 6.43 (s, 2H), 4.39 (dd, <i>J</i> = 15.1, 6.4 Hz, 1H), 4.23 (dd, <i>J</i> = 15.2, 4.7 Hz, 1H), 3.95 (d, <i>J</i> = 3.7 Hz, 2H), 3.89 (dd, <i>J</i> = 11.1, 5.0 Hz, 1H), 3.16 (dd, <i>J</i> = 13.9, 11.1 Hz, 1H), 2.97 (dd, <i>J</i> = 13.9, 5.0 Hz, 1H), 2.15 (s, 6H). No <sup>13</sup>C data was acquired. ESI-MS: 473.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 42.11 min.</div></div><div id="sec4_1_10_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (<i>S</i>)-1-((5-Benzyl-2-ethoxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5l</b>)</h5><div class="NLM_p last">See procedure D: 18 mg (0.065 mmol) of <b>4l</b>, 120 μL (89 mg, 0.69 mmol, 10.6 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 38 mg (0.073 mmol, 1.1 equiv) of PyBOP, 13 mg (0.077 mmol, 1.2 equiv) of 6-Cl-HOBt, 26 mg (0.063 mmol, 0.98 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5l</b> (15 mg, 42.4% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.35 (t, <i>J</i> = 5.7 Hz, 1H), 7.23 (t, <i>J</i> = 7.5 Hz, 2H), 7.21–7.16 (m, 2H), 7.13 (t, <i>J</i> = 7.2 Hz, 1H), 7.07 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 6.93 (d, <i>J</i> = 2.2 Hz, 1H), 6.78 (d, <i>J</i> = 8.4 Hz, 1H), 6.30 (s, 2H), 4.33 (dd, <i>J</i> = 14.3, 7.0 Hz, 1H), 4.14 (dd, <i>J</i> = 14.3, 4.6 Hz, 1H), 3.93–3.84 (m, 5H), 3.08 (dd, <i>J</i> = 13.8, 11.6 Hz, 1H), 2.91 (dd, <i>J</i> = 13.8, 4.6 Hz, 1H), 2.01 (s, 6H), 1.27 (t, <i>J</i> = 7.0 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 433.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 39.20 min.</div></div><div id="sec4_1_10_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> (<i>S</i>)-1-((5-Benzyl-2-propoxybenzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5m</b>)</h5><div class="NLM_p last">See procedure D: 24 mg (0.065 mmol) of <b>4m</b>, 110 μL (82 mg, 0.63 mmol, 9.7 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 37 mg (0.071 mmol, 1.1 equiv) of PyBOP, 14 mg (0.083 mmol, 1.3 equiv) of 6-Cl-HOBt, 30 mg (0.073 mmol, 1.1 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5m</b> (17 mg, 46.7% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.31 (t, <i>J</i> = 5.8 Hz, 1H), 7.25–7.22 (m, 2H), 7.20–7.16 (m, 2H), 7.13 (t, <i>J</i> = 7.1 Hz, 1H), 7.06 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.92 (d, <i>J</i> = 2.2 Hz, 1H), 6.78 (d, <i>J</i> = 8.3 Hz, 1H), 6.30 (s, 2H), 4.36 (dd, <i>J</i> = 14.4, 7.0 Hz, 1H), 4.15 (dd, <i>J</i> = 14.4, 4.4 Hz, 1H), 3.89–3.85 (m, 3H), 3.80 (td, <i>J</i> = 6.6, 4.5 Hz, 2H), 3.08 (dd, <i>J</i> = 13.8, 11.6 Hz, 1H), 2.92 (dd, <i>J</i> = 13.8, 4.6 Hz, 1H), 2.02 (s, 6H), 1.67 (h, <i>J</i> = 7.1 Hz, 2H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 447.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 42.13 min.</div></div><div id="sec4_1_10_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> (<i>S</i>)-1-((5-Benzyl-2-(cyclopropylmethoxy)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5n</b>)</h5><div class="NLM_p last">See procedure D: 17 mg (0.045 mmol) of <b>4n</b>, 140 μL (104 mg, 0.80 mmol, 18.0 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 35 mg (0.067 mmol, 1.5 equiv) of PyBOP, 13 mg (0.077 mmol, 1.7 equiv) of 6-Cl-HOBt, 28 mg (0.068 mmol, 1.5 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5n</b> (4 mg, 12.5% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.23 (t, <i>J</i> = 7.6 Hz, 2H), 7.20–7.16 (m, 2H), 7.13 (t, <i>J</i> = 7.3 Hz, 1H), 7.06 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 6.92 (d, <i>J</i> = 2.2 Hz, 1H), 6.76 (d, <i>J</i> = 8.4 Hz, 1H), 6.29 (s, 2H), 4.37 (d, <i>J</i> = 14.4 Hz, 1H), 4.18 (d, <i>J</i> = 14.4 Hz, 1H), 3.87 (s, 2H), 3.84 (dd, <i>J</i> = 11.7, 4.8 Hz, 1H), 3.74–3.61 (m, 2H), 3.08 (dd, <i>J</i> = 13.8, 11.5 Hz, 1H), 2.90 (dd, <i>J</i> = 13.8, 4.6 Hz, 1H), 2.03 (s, 6H), 1.12 (ddd, <i>J</i> = 12.7, 8.0, 5.6 Hz, 1H), 0.56 (d, <i>J</i> = 7.5 Hz, 2H), 0.27 (dd, <i>J</i> = 7.1, 5.0 Hz, 2H). No <sup>13</sup>C data was acquired. ESI-MS: 459.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 42.68 min.</div></div><div id="sec4_1_10_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> (<i>S</i>)-1-((5-Benzyl-2-(benzyloxy)benzyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5o</b>)</h5><div class="NLM_p last">See procedure D: 17 mg (0.050 mmol) of <b>4o</b>, 100 μL (74 mg, 0.57 mmol, 11.5 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 31 mg (0.060 mmol, 1.2 equiv) of PyBOP, 10 mg (0.059 mmol, 1.2 equiv) of 6-Cl-HOBt, 24 mg (0.059 mmol, 1.2 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5o</b> (11 mg, 36.1% yield) was isolated as a white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.44–7.38 (m, 1H), 7.36 (d, <i>J</i> = 4.4 Hz, 4H), 7.32–7.27 (m, 1H), 7.26–7.21 (m, 2H), 7.21–7.16 (m, 2H), 7.13 (t, <i>J</i> = 7.2 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.95 (d, <i>J</i> = 2.2 Hz, 1H), 6.87 (d, <i>J</i> = 8.4 Hz, 1H), 6.29 (s, 2H), 4.95 (d, <i>J</i> = 4.3 Hz, 2H), 4.40 (dd, <i>J</i> = 14.4, 7.0 Hz, 1H), 4.17 (dd, <i>J</i> = 14.4, 4.3 Hz, 1H), 3.88 (s, 2H), 3.80 (dd, <i>J</i> = 11.4, 4.6 Hz, 1H), 3.06 (dd, <i>J</i> = 13.4, 11.8 Hz, 1H), 2.89 (dd, <i>J</i> = 13.8, 4.7 Hz, 1H), 1.98 (s, 6H). No <sup>13</sup>C data was acquired. ESI-MS: 495.3 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 44.98 min.</div></div><div id="sec4_1_10_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> (<i>S</i>)-1-(((<i>R</i>)-1-(5-Benzyl-2-methoxyphenyl)ethyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-aminium Trifluoroacetate (<b>5p</b>)</h5><div class="NLM_p last">See procedure D: 12 mg (0.043 mmol) of <b>4p</b>, 76 μL (56 mg, 0.44 mmol, 10.1 equiv) of <i>N</i>,<i>N</i>-diisopropylethylamine, 24 mg (0.046 mmol, 1.1 equiv) of PyBOP, 8 mg (0.047 mmol, 1.1 equiv) of 6-Cl-HOBt, 19 mg (0.046 mmol, 1.1 equiv) of Boc-<i>O</i>-Boc-<span class="smallcaps smallerCapital">l</span>-2′,6′-dimethyltyrosine, and 3 + 1.5 mL of DMF. Step 2: 2 mL of TFA and 2 mL of DCM. Compound <b>5p</b> (7 mg, 29.6% yield) was isolated as a white solid. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.22 (dd, <i>J</i> = 8.2, 7.0 Hz, 2H), 7.16–7.09 (m, 3H), 7.02–6.94 (m, 2H), 6.82 (d, <i>J</i> = 8.3 Hz, 1H), 6.55 (s, 2H), 5.08 (p, <i>J</i> = 6.9 Hz, 1H), 3.87 (dd, <i>J</i> = 11.6, 4.7 Hz, 1H), 3.84 (s, 2H), 3.76 (s, 3H), 3.20 (dd, <i>J</i> = 13.7, 11.7 Hz, 1H), 3.02 (dd, <i>J</i> = 13.8, 4.8 Hz, 1H), 2.29 (s, 6H), 1.06 (d, <i>J</i> = 6.9 Hz, 3H). No <sup>13</sup>C data was acquired. ESI-MS: 433.4 [M + H]<sup>+</sup>, HPLC (gradient A): retention time: 40.43 min.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> In Vitro Pharmacology</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Cell Lines and Membrane Preparations</h4><div class="NLM_p last">All tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, NY) unless otherwise noted. C6-rat glioma cells stably expressing rat MOR (C6-MOR) or rat DOR (C6-DOR) and Chinese hamster ovary (CHO) cells stably expressing human KOR (CHO-KOR) were used for all in vitro assays. Cells were grown to confluence at 37 °C in 5% CO<sub>2</sub> in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 5% penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with ice-cold phosphate buffered saline (0.9% NaCl, 0.61 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.38 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4). Cells were detached from the plates by incubation in warm harvesting buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 150 mM NaCl, 0.68 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell pellet was suspended in ice-cold 50 mM Tris–HCl buffer, pH 7.4, and homogenized with a Tissue-Tearor (BioSpec Products, Inc., Bartlesville, OK) for 20 s. The homogenate was centrifuged at 15 000 rpm for 20 min at 4 °C. The pellet was rehomogenized in 50 mM Tris–HCl with a Tissue-Tearor for 10 s, followed by recentrifugation. The final pellet was resuspended in 50 mM Tris–HCl and frozen in aliquots at −80 °C. Protein concentration was determined via a bicinchoninic acid protein assay (Thermo Scientific Pierce, Waltham, MA) using bovine serum albumin as the standard.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Radioligand Competition Binding Assays</h4><div class="NLM_p last">Radiolabeled compounds were purchased from PerkinElmer (Waltham, MA). Opioid ligand binding assays were performed by competitive displacement of 0.2 nM [<sup>3</sup>H]-diprenorphine (250 μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations containing opioid receptors as described above. The assay mixture, containing membranes (20 μg protein/tube) in 50 mM Tris–HCl buffer (pH 7.4), 0.2 nM [<sup>3</sup>H]-diprenorphine, and various concentrations of test peptidomimetic, was incubated at room temperature on a shaker for 1 h to allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C filters using a Brandel harvester (Brandel, Gaithersburg, MD) and washed three times with 50 mM Tris–HCl buffer, pH 7.4. Bound radioactivity on dried filters was determined by liquid scintillation counting, after saturation with EcoLume liquid scintillation cocktail, in a Wallac 1450 MicroBeta (PerkinElmer, Waltham, MA). Nonspecific binding was determined using 10 μM naloxone. The results presented are the mean ± standard error (SE) from at least three separate assays performed in duplicate. <i>K</i><sub>i</sub> (nM) values were calculated using nonlinear regression analysis to fit a logistic equation to the competition data using GraphPad Prism, version 6.0c, (GraphPad Software Inc., La Jolla, CA).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> [<sup>35</sup>S]-GTPγS Binding Assays</h4><div class="NLM_p last">Agonist stimulation of [<sup>35</sup>S]-guanosine 5′-<i>O</i>-[γ-thio]triphosphate ([<sup>35</sup>S]-GTPγS, 1250 Ci, 46.2 TBq/mmol) binding to G protein was measured as described previously.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Briefly, membranes (10 μg of protein/well) were incubated for 1 h at 25 °C in GTPγS buffer (50 mM Tris–HCl, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, 1 mM EDTA, pH 7.4) containing 0.1 nM [<sup>35</sup>S]-GTPγS, 30 μM guanosine diphosphate, and varying concentrations of the test peptidomimetic. G protein activation following receptor activation by peptidomimetic was compared with 10 μM of the standard compounds [<span class="smallcaps smallerCapital">d</span>-Ala2,<i>N</i>-MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, <span class="smallcaps smallerCapital">d</span>-Pen2,5-enkephalin (DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by vacuum filtration through GF/C filters that were washed five times with GTPγS buffer. Bound radioactivity was measured as described above. The results are presented as the mean ± standard error (SE) from at least three separate assays performed in duplicate; potency [EC<sub>50</sub> (nM)] and percent stimulation were determined using nonlinear regression analysis with GraphPad Prism 6, as above.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>K</i><sub>e</sub> Determination</h4><div class="NLM_p last">Agonist stimulation of [<sup>35</sup>S]-GTPγS binding by the known standard agonist DPDPE at the delta opioid receptor was measured as described above. This was then compared to [<sup>35</sup>S]-GTPγS binding stimulated by DPDPE in the presence of the test compound. Both conditions produced 100% stimulation relative to DPDPE. The fold difference between the EC<sub>50</sub> of DPDPE alone and in the presence of the test compound is defined as the shift in dose response. The <i>K</i><sub>e</sub> was then calculated as <i>K</i><sub>e</sub> = (concentration of test compound)/(dose response shift – 1). The results presented are the mean ± SEM from three individual assays performed in duplicate and then averaged. The data were fitted to a nonlinear regression curve (sigmoidal dose response curve for agonist stimulation) using GraphPad Prism v8.01.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Mouse Liver Microsome Stability Assays</h4><div class="NLM_p last">All liver microsome assays were performed by Quintara Biosciences. The metabolic stability of testing compounds was evaluated using mouse liver microsomes to predict intrinsic clearance. Mouse liver microsome tissue fractions were obtained from Corning or BioreclamationIVT. The assay was carried out in 96-well microtiter plates at 37 °C. Reaction mixtures (25 μL) contained a final concentration of 1 μM test compound, 0.1 mg/mL liver microsome protein, and 1 mM reduced nicotinamide adenine dinucleotide phosphate in 100 mM potassium phosphate, pH 7.4 buffer with 3 mM MgCl<sub>2</sub>. At each of the time points (0, 15, 30, and 60 min), 150 μL of quench solution (acetonitrile with 0.1% formic acid) with internal standard (bucetin) was transferred to each well. Verapamil was included as a positive control to verify assay performance. Plates were sealed, vortexed, and centrifuged at 4 °C for 15 min at 4000 rpm. The supernatant was transferred to fresh plates for LC/tandem mass spectrometry (MS/MS) analysis. All samples were analyzed on LC/MS/MS using an AB Sciex API 4000 instrument, coupled to a Shimadzu LC-20AD LC Pump system. Analytical samples were separated using a Waters Atlantis T3 dC18 reverse-phase HPLC column (20 mm × 2.1 mm) at a flow rate of 0.5 mL/min. The mobile phase consists of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). The extent of metabolism was calculated as the disappearance of the test compound, compared to the 0 min time incubation. Initial rates were calculated for the compound concentration and used to determine <i>T</i><sub>1/2</sub> values and subsequently the intrinsic clearance.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00219" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00219" class="ext-link">10.1021/acs.jmedchem.9b00219</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00219/suppl_file/jm9b00219_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00219/suppl_file/jm9b00219_si_001.csv">jm9b00219_si_001.csv (3.34 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00219" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Henry I. Mosberg</span> - <span class="hlFld-Affiliation affiliation">Edward F Domino Research Center, 
     and , University
of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4107-8870" title="Orcid link">http://orcid.org/0000-0002-4107-8870</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#87efeeeac7eae2e3a9f2eaeee4efa9e2e3f2"><span class="__cf_email__" data-cfemail="7911101439141c1d570c14101a11571c1d0c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean P. Henry</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas J. Fernandez</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, Medical
School and , University
of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica P. Anand</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, Medical
School, 
    Edward F Domino Research Center, 
     and , University
of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas W. Griggs</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, Medical
School, 
    Edward F Domino Research Center, 
     and , University
of Michigan, Ann Arbor, Michigan 48109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John R. Traynor</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacology, Medical
School, 
    Edward F Domino Research Center, 
     and , University
of Michigan, Ann Arbor, Michigan 48109, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109, United
States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Synthesis was carried out by S.P.H. The research project was designed by S.P.H., J.R.T, and H.I.M. In vitro assays were carried out by T.J.F., J.P.A., and N.W.G.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6325-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by the NIH grant DA003910 (H.I.M, and J.R.T). S.P.H. was supported by the Substance Abuse Interdisciplinary Training Program administered by NIDA (T32 DA007281). J.P.A. was supported by the grant G020292 (Domino Center). N.W.G. was supported by the Pharmacological Sciences Training Program administered by NIGMS (T32 GM007767). Tyler Trask and Jack James Twarozinski are thanked for additional in vitro studies.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Alk-Br</td><td class="NLM_def"><p class="first last">alkyl bromide</p></td></tr><tr><td class="NLM_term">BH<sub>3</sub>*Me<sub>2</sub>S</td><td class="NLM_def"><p class="first last">borane dimethylsulfide complex</p></td></tr><tr><td class="NLM_term">BnBPin</td><td class="NLM_def"><p class="first last">benzylboronic acid pinacol ester</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CPM</td><td class="NLM_def"><p class="first last">cyclopropyl methyl</p></td></tr><tr><td class="NLM_term">DAMGO</td><td class="NLM_def"><p class="first last">[<span class="smallcaps smallerCapital">d</span>-Ala2,<i>N</i>-MePhe4,Gly-ol]enkephalin</p></td></tr><tr><td class="NLM_term">DiBocDMT</td><td class="NLM_def"><p class="first last"><i>N</i>-Boc-<i>O</i>-Boc-2′,6′-dimethyl-<span class="smallcaps smallerCapital">l</span>-tyrosine</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DPDPE</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">d</span>-Pen2,5-enkephalin</p></td></tr><tr><td class="NLM_term">DMT</td><td class="NLM_def"><p class="first last">2′,6′-dimethyl-<span class="smallcaps smallerCapital">l</span>-tyrosine</p></td></tr><tr><td class="NLM_term">DNS</td><td class="NLM_def"><p class="first last">does not stimulate</p></td></tr><tr><td class="NLM_term">DOR</td><td class="NLM_def"><p class="first last">δ-opioid receptor</p></td></tr><tr><td class="NLM_term">GTPγS</td><td class="NLM_def"><p class="first last">guanosine 5′-<i>O</i>-[γ-thio]triphosphate</p></td></tr><tr><td class="NLM_term">6-Cl-HOBt</td><td class="NLM_def"><p class="first last">6-chloro-1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">KOR</td><td class="NLM_def"><p class="first last">κ-opioid receptor</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">μ-opioid receptor</p></td></tr><tr><td class="NLM_term">Pd(dppf)Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride</p></td></tr><tr><td class="NLM_term">PyBOP</td><td class="NLM_def"><p class="first last">benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">THQ</td><td class="NLM_def"><p class="first last">1,2,3,4-tetrahydroquinoline</p></td></tr><tr><td class="NLM_term">DIPP[Ψ]-NH<sub>2</sub></td><td class="NLM_def"><p class="first last">H-Dmt-TicΨ[CH<sub>2</sub>NH]Phe-Phe-NH<sub>2</sub></p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i106">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fundytus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weltrowska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, T. J.</span></span> <span> </span><span class="NLM_article-title">Attenuation of Morphine Tolerance and Dependence with the Highly Selective δ-Opioid Receptor Antagonist TIPP[Ψ]</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00554-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2F0014-2999%2895%2900554-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=8566146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK2MXpt1alu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1995&pages=105-108&author=M.+E.+Fundytusauthor=P.+W.+Schillerauthor=M.+Shapiroauthor=G.+Weltrowskaauthor=T.+J.+Coderre&title=Attenuation+of+Morphine+Tolerance+and+Dependence+with+the+Highly+Selective+%CE%B4-Opioid+Receptor+Antagonist+TIPP%5B%CE%A8%5D&doi=10.1016%2F0014-2999%2895%2900554-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ]</span></div><div class="casAuthors">Fundytus, Marian E.; Schiller, Peter W.; Shapiro, Michelle; Weltrowska, Grazyna; Coderre, Terence J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-8</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We examd. the effects of i.c.v. treatment with naltrindole, and the two highly selective peptide δ-opioid receptor antagonists H-Tyr-Tic-Phe-Phe-OH (TIPP) and H-Tyr-Ticψ[CH2-NH]-Phe-Phe-OH (TIPP[ψ]), on the development of morphine tolerance and dependence.  Each treatment significantly decreased naloxone-pptd. withdrawal, with TIPP[ψ] reducing the most symptoms.  TIPP[ψ], but neither naltrindole nor TIPP, attenuated the development of analgesic tolerance in the tail-flick test.  These results suggest that δ-opioid receptors are critically involved in the development of morphine tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDvwID-eMcdrVg90H21EOLACvtfcHk0lgUZ9QlYrnTTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpt1alu7s%253D&md5=22ac2008dc965f1d08828e737ef4f9fd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900554-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900554-x%26sid%3Dliteratum%253Aachs%26aulast%3DFundytus%26aufirst%3DM.%2BE.%26aulast%3DSchiller%26aufirst%3DP.%2BW.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DWeltrowska%26aufirst%3DG.%26aulast%3DCoderre%26aufirst%3DT.%2BJ.%26atitle%3DAttenuation%2520of%2520Morphine%2520Tolerance%2520and%2520Dependence%2520with%2520the%2520Highly%2520Selective%2520%25CE%25B4-Opioid%2520Receptor%2520Antagonist%2520TIPP%255B%25CE%25A8%255D%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D286%26spage%3D105%26epage%3D108%26doi%3D10.1016%2F0014-2999%2895%2900554-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemori, A. E.</span></span> <span> </span><span class="NLM_article-title">Selective Blockage of Delta Opioid Receptors Prevents the Development of Morphine Tolerance and Dependence in Mice</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>258</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1649297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1Krur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1991&pages=299-303&author=E.+E.+Abdelhamidauthor=M.+Sultanaauthor=P.+S.+Portogheseauthor=A.+E.+Takemori&title=Selective+Blockage+of+Delta+Opioid+Receptors+Prevents+the+Development+of+Morphine+Tolerance+and+Dependence+in+Mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice</span></div><div class="casAuthors">Abdelhamid, Essam E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">299-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The authors have demonstrated that delta opioid binding sites are involved in the development or morphine tolerance and dependence.  Here, the effect of the potent and selective delta antagonist, naltrindole (NTI), and its nonequil. analog, naltrindole 5'-isothiocyanate (5'-NTII), on the development of morphine tolerance and dependence was studied in mice.  The development of acute tolerance and dependence was suppressed markedly in mice pretreated with NTI before induction of tolerance and dependence with 100 mg/kg of morphine sulfate.  Multiple administration of either NTI or 5'-NTII before and during implantation with morphine base pellets also inhibited substantially the development of morphine tolerance and dependence.  The effects of NTI and 5'-NTI on these two adaptive phenomena were thought to occur solely by blockage of delta opioid receptors because the activity of the selective mu opioid receptor agonist, [D-Ala2,MePhe4,Gly-ol5] enkephalin was unaffected by the two antagonists.  It was concluded that delta, as well as mu, opioid receptors play key roles in the development of opiate tolerance and phys. dependence.  Also the use of these delta opioid receptor antagonists allows a way to prevent opiate tolerance and phys. dependence without compromising the antinociceptive activity of mu opioid receptor agonists such as morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-Im8RmjOzL7Vg90H21EOLACvtfcHk0li7hi-Wq9iqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1Krur4%253D&md5=409e1d8fb5cefb48af6cc3a76c0be471</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelhamid%26aufirst%3DE.%2BE.%26aulast%3DSultana%26aufirst%3DM.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DTakemori%26aufirst%3DA.%2BE.%26atitle%3DSelective%2520Blockage%2520of%2520Delta%2520Opioid%2520Receptors%2520Prevents%2520the%2520Development%2520of%2520Morphine%2520Tolerance%2520and%2520Dependence%2520in%2520Mice%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1991%26volume%3D258%26spage%3D299%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hepburn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, C. M.</span></span> <span> </span><span class="NLM_article-title">Differential Effects of Naltrindole on Morphine-Induced Tolerance and Physical Dependence in Rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=9190871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK2sXktVOjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1997&pages=1350-1356&author=M.+J.+Hepburnauthor=P.+J.+Littleauthor=J.+Gingrasauthor=C.+M.+Kuhn&title=Differential+Effects+of+Naltrindole+on+Morphine-Induced+Tolerance+and+Physical+Dependence+in+Rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats</span></div><div class="casAuthors">Hepburn, Matthew J.; Little, Patrick J.; Gingras, Jeanine; Kuhn, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1350-1356</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">This study investigated the effect of delta opioid receptor blockade by naltrindole on the development of phys. dependence and tolerance to the antinociceptive and respiratory depressive effects of morphine in rats.  Chronic morphine was delivered either by s.c. injection of increasing amts. of morphine over 5 days or by s.c. implantation of morphine pellets.  Animals were cotreated with saline or naltrindole.  Antinociception and respiratory depression were assessed after administration of a challenge dose or morphine, and withdrawal signs were detd. after naloxone challenge.  Naltrindole significantly attenuated the development of antinociceptive tolerance after all three chronic treatment regimens.  In addn., rats pretreated with naltrindole displayed significantly fewer withdrawal symptoms and less wt. loss after a naloxone challenge.  In contrast, naltrindole did not prevent the development of tolerance to morphine-induced respiratory depression.  These results imply that tolerance to antinociception and phys. dependence involves adaptations at interacting mu and delta receptor populations, whereas tolerance to respiratory depression reflects actions of independent mu and delta receptor populations.  These findings suggest that delta antagonists may have potential clin. application for decreasing the rapid development of tolerance to opiate-induced analgesia, while allowing for the development of protective tolerance to respiratory depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrymhDNZsyuLrVg90H21EOLACvtfcHk0li7hi-Wq9iqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktVOjtbw%253D&md5=c715220a88c223a89599ca52167fca85</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHepburn%26aufirst%3DM.%2BJ.%26aulast%3DLittle%26aufirst%3DP.%2BJ.%26aulast%3DGingras%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DC.%2BM.%26atitle%3DDifferential%2520Effects%2520of%2520Naltrindole%2520on%2520Morphine-Induced%2520Tolerance%2520and%2520Physical%2520Dependence%2520in%2520Rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D281%26spage%3D1350%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsche, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reidl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elde, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unterwald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pintar, J. E.</span></span> <span> </span><span class="NLM_article-title">Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(00)80836-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2FS0896-6273%2800%2980836-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10677041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVOrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1999&pages=243-252&author=Y.+Zhuauthor=M.+A.+Kingauthor=A.+G.+P.+Schullerauthor=J.+F.+Nitscheauthor=M.+Reidlauthor=R.+P.+Eldeauthor=E.+Unterwaldauthor=G.+W.+Pasternakauthor=J.+E.+Pintar&title=Retention+of+Supraspinal+Delta-like+Analgesia+and+Loss+of+Morphine+Tolerance+in+%CE%B4+Opioid+Receptor+Knockout+Mice&doi=10.1016%2FS0896-6273%2800%2980836-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice</span></div><div class="casAuthors">Zhu, Yanxin; King, Michael A.; Schuller, Alwin G. P.; Nitsche, Joshua F.; Reidl, Maureen; Elde, Robert P.; Unterwald, Ellen; Pasternak, Gavril W.; Pintar, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">243-252</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Gene targeting was used to delete exon 2 of mouse DOR-1, which encodes the δ opioid receptor.  Essentially all 3H-[D-Pen2,D-Pen5]enkephalin (3H-DPDPE) and 3H-[D-Ala2,D-Glu4]deltorphin (3H-deltorphin-2) binding is absent from mutant mice, demonstrating that DOR-1 encodes both δ1 and δ2 receptor subtypes.  Homozygous mutant mice display markedly reduced spinal δ analgesia, but peptide δ agonists retain supraspinal analgesic potency that is only partially antagonized by naltrindole.  Retained DPDPE analgesia is also demonstrated upon formalin testing, while the nonpeptide δ agonist BW373U69 exhibits enhanced activity in DOR-1 mutant mice.  Together, these findings suggest the existence of a second delta-like analgesic system.  Finally, DOR-1 mutant mice do not develop analgesic tolerance to morphine, genetically demonstrating a central role for DOR-1 in this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg3m-zg3QH0LVg90H21EOLACvtfcHk0li7hi-Wq9iqQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVOrs7g%253D&md5=a5035feaf6e63a8abeb8c18df0a32933</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2800%2980836-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252800%252980836-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DKing%26aufirst%3DM.%2BA.%26aulast%3DSchuller%26aufirst%3DA.%2BG.%2BP.%26aulast%3DNitsche%26aufirst%3DJ.%2BF.%26aulast%3DReidl%26aufirst%3DM.%26aulast%3DElde%26aufirst%3DR.%2BP.%26aulast%3DUnterwald%26aufirst%3DE.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DPintar%26aufirst%3DJ.%2BE.%26atitle%3DRetention%2520of%2520Supraspinal%2520Delta-like%2520Analgesia%2520and%2520Loss%2520of%2520Morphine%2520Tolerance%2520in%2520%25CE%25B4%2520Opioid%2520Receptor%2520Knockout%2520Mice%26jtitle%3DNeuron%26date%3D1999%26volume%3D24%26spage%3D243%26epage%3D252%26doi%3D10.1016%2FS0896-6273%2800%2980836-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLemore, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inturrisi, C. E.</span></span> <span> </span><span class="NLM_article-title">An Antisense Oligodeoxynucleotide to the Delta Opioid Receptor (DOR-1) Inhibits Morphine Tolerance and Acute Dependence in Mice</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/0361-9230(95)02092-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2F0361-9230%2895%2902092-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=8866695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK28Xhslantbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=185-188&author=B.+Kestauthor=C.+E.+Leeauthor=G.+L.+McLemoreauthor=C.+E.+Inturrisi&title=An+Antisense+Oligodeoxynucleotide+to+the+Delta+Opioid+Receptor+%28DOR-1%29+Inhibits+Morphine+Tolerance+and+Acute+Dependence+in+Mice&doi=10.1016%2F0361-9230%2895%2902092-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice</span></div><div class="casAuthors">Kest, Benjamin; Lee, Cynthia E.; McLemore, Gabrielle L.; Inturrisi, Charles E.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-8</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pharmacol. data from several labs. support a modulatory role for the delta opioid receptor in morphine analgesia, tolerance, and phys. dependence.  We examd. the role of the delta opioid receptor in these processes using an in vivo antisense strategy in mice.  Intracerebroventricular administration of a 20mer antisense or a mismatch control oligodeoxynucleotide (ODN) targeting the mRNA of the cloned delta opioid receptor (DOR-1) for 3 days did not affect baseline nociceptive thresholds or morphine analgesia compared to untreated or saline-treated mice.  However, dose-response studies indicate that the induction of morphine tolerance following 3 days of chronic morphine administration was blocked in antisense but not mismatch ODN or saline-treated mice.  Antisense ODN treatment also blocked the development of acute morphine dependence, whereas similar protection was not afforded to mice treated with saline or mismatch ODN.  This study demonstrates the relevance of the cloned DOR-1 in morphine tolerance and dependence and provides new evidence for a modulatory role of the delta opioid receptor using this novel approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplCmyzeBkmtrVg90H21EOLACvtfcHk0lhlcXE6mqkNRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhslantbg%253D&md5=4f4518ac59f478bb6605bdb2911d0996</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0361-9230%2895%2902092-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0361-9230%252895%252902092-6%26sid%3Dliteratum%253Aachs%26aulast%3DKest%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DC.%2BE.%26aulast%3DMcLemore%26aufirst%3DG.%2BL.%26aulast%3DInturrisi%26aufirst%3DC.%2BE.%26atitle%3DAn%2520Antisense%2520Oligodeoxynucleotide%2520to%2520the%2520Delta%2520Opioid%2520Receptor%2520%2528DOR-1%2529%2520Inhibits%2520Morphine%2520Tolerance%2520and%2520Acute%2520Dependence%2520in%2520Mice%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D1996%26volume%3D39%26spage%3D185%26epage%3D188%26doi%3D10.1016%2F0361-9230%2895%2902092-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turnaturi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aricò, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsisvalle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquinucci, L.</span></span> <span> </span><span class="NLM_article-title">Multitarget Opioid Ligands in Pain Relief: New Players in an Old Game</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.ejmech.2015.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=26656913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=211-228&author=R.+Turnaturiauthor=G.+Aric%C3%B2author=G.+Ronsisvalleauthor=C.+Parentiauthor=L.+Pasquinucci&title=Multitarget+Opioid+Ligands+in+Pain+Relief%3A+New+Players+in+an+Old+Game&doi=10.1016%2Fj.ejmech.2015.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget opioid ligands in pain relief: New players in an old game</span></div><div class="casAuthors">Turnaturi, Rita; Arico, Giuseppina; Ronsisvalle, Giuseppe; Parenti, Carmela; Pasquinucci, Lorella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-228</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Still nowadays pain is one of the most common disabling conditions and yet it remains too often unsolved.  Analgesic opioid drugs, and mainly MOR agonists such as morphine, are broadly employed for pain management.  MOR activation, however, has been seen to cause not only analgesia but also undesired side effects.  A potential pain treatment option is represented by the simultaneous targeting of different opioid receptors.  In fact, ligands possessing multitarget capabilities led to an improved pharmacol. fingerprint.  This review focuses on the examn. of multitarget opioid ligands which have been distinguished in peptide and non-peptide and further listed as bivalent and bifunctional ligands.  Moreover, the potential of these compds., both as analgesic drugs and pharmacol. tools to explore heteromer receptors, has been stressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp1KgfVHTj67Vg90H21EOLACvtfcHk0lhlcXE6mqkNRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmsrrN&md5=49fa91877cdaa733f7ec58d5e80a3869</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DTurnaturi%26aufirst%3DR.%26aulast%3DAric%25C3%25B2%26aufirst%3DG.%26aulast%3DRonsisvalle%26aufirst%3DG.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DPasquinucci%26aufirst%3DL.%26atitle%3DMultitarget%2520Opioid%2520Ligands%2520in%2520Pain%2520Relief%253A%2520New%2520Players%2520in%2520an%2520Old%2520Game%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D211%26epage%3D228%26doi%3D10.1016%2Fj.ejmech.2015.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span> <span> </span><span class="NLM_article-title">Opioid Ligands with Mixed Mu/Delta Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">E118</span>– <span class="NLM_lpage">E125</span>, <span class="refDoi"> DOI: 10.1208/aapsj080114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1208%2Faapsj080114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=16584118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Kks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=E118-E125&author=S.+Ananthan&title=Opioid+Ligands+with+Mixed+Mu%2FDelta+Opioid+Receptor+Interactions%3A+An+Emerging+Approach+to+Novel+Analgesics&doi=10.1208%2Faapsj080114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid ligands with mixed μ/δ opioid receptor interactions: an emerging approach to novel analgesics</span></div><div class="casAuthors">Ananthan, Subramaniam</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">E118-E125</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">American Association of Pharmaceutical Scientists</span>)
        </div><div class="casAbstract">A review.  Opioids are widely used in the treatment of severe pain.  The clin. use of the opioids is limited by serious side effects such as respiratory depression, constipation, development of tolerance, and phys. dependence and addiction liabilities.  Most of the currently available opioid analgesics exert their analgesic and adverse effects primarily through the opioid μ receptors.  A large no. of biochem. and pharmacol. studies and studies using genetically modified animals have provided convincing evidence regarding the existence of modulatory interactions between opioid μ and δ receptors.  Several studies indicate that δ receptor agonists as well as δ receptor antagonists can provide beneficial modulation to the pharmacol. effects of μ agonists.  For example, δ agonists can enhance the analgesic potency and efficacy of μ agonists, and δ antagonists can prevent or diminish the development of tolerance and phys. dependence by μ agonists.  On the basis of these observations, the development of new opioid ligands possessing mixed μ agonist/δ agonist profile and mixed μ agonist/δ antagonist profile has emerged as a promising new approach to analgesic drug development.  A brief overview of μ-δ interactions and recent developments in identification of ligands possessing mixed μ agonist/δ agonist and μ agonist/δ antagonist activities is provided in this report.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpflBGd3S9H8LVg90H21EOLACvtfcHk0lhlcXE6mqkNRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Kks7s%253D&md5=442aca3a525b3775cc0d1d62d196f482</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1208%2Faapsj080114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Faapsj080114%26sid%3Dliteratum%253Aachs%26aulast%3DAnanthan%26aufirst%3DS.%26atitle%3DOpioid%2520Ligands%2520with%2520Mixed%2520Mu%252FDelta%2520Opioid%2520Receptor%2520Interactions%253A%2520An%2520Emerging%2520Approach%2520to%2520Novel%2520Analgesics%26jtitle%3DAAPS%2520J.%26date%3D2006%26volume%3D8%26spage%3DE118%26epage%3DE125%26doi%3D10.1208%2Faapsj080114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsky, E. J.</span></span> <span> </span><span class="NLM_article-title">In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid Mu-Agonist/Delta-Antagonist That Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">605</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=11303048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1WlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2001&pages=597-605&author=J.+L.+Wellsauthor=J.+L.+Bartlettauthor=S.+Ananthanauthor=E.+J.+Bilsky&title=In+Vivo+Pharmacological+Characterization+of+SoRI+9409%2C+a+Nonpeptidic+Opioid+Mu-Agonist%2FDelta-Antagonist+That+Produces+Limited+Antinociceptive+Tolerance+and+Attenuates+Morphine+Physical+Dependence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid μ-agonist/δ-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence</span></div><div class="casAuthors">Wells, Jennifer L.; Bartlett, Jeffrey L.; Ananthan, Subramaniam; Bilsky, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">597-605</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Repeated exposure to μ-opioid analgesics produces unwanted side effects, including tolerance and phys. dependence.  δ-Opioid antagonists attenuate development of morphine tolerance and phys. dependence.  We recently reported that SoRI 9409, a mixed μ-agonist/δ-antagonist, produces antinociception with limited development of tolerance after repeated i.c.v. injections.  The current studies report on a more complete characterization of the compd. in male ICR mice.  SoRI 9409 produced limited antinociceptive effects in the 55 tail-flick test and full agonist effects in the acetic acid writhing assay after i.c.v. or i.p. administration.  Repeated i.p. administration of A90 doses of SoRI 9409 did not produce tolerance.  The agonist effects of the compd. were preferentially blocked by the μ-selective antagonist β-funaltrexamine.  The κ-antagonist norbinaltorphimine produced partial antagonism, whereas the δ-antagonist naltrindole had no effect on SoRI 9409 antinociception.  I.p. administration of SoRI 9409 preferentially antagonized the antinociceptive actions of the δ-2 agonist [D-Ala2,Glu4]deltorphin over the δ-1 agonist cyclic[D-Pen2,D-Pen5]-enkephalin and the μ-agonist [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin.  SoRI 9409 did not antagonize the antinociceptive effects of the κ-agonist U69,593 (doses up to 60 mg/kg).  SoRI 9409 (10 mg/kg i.p.) elicited much less vertical jumping than naloxone (10 mg/kg i.p.) in acute and chronic morphine dependence models.  SoRI 9409 also suppressed withdrawal jumping when coadministered with naloxone.  These studies indicate that SoRI 9409 acts primarily as a partial μ-agonist/δ-antagonist and supports the hypothesis that this type of compd. may have a better therapeutic profile than currently available μ-agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3w8nDeq53rVg90H21EOLACvtfcHk0lhlcXE6mqkNRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1WlsLk%253D&md5=0f816d8d7d2973e143c74c2dab4cf9e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DJ.%2BL.%26aulast%3DBartlett%26aufirst%3DJ.%2BL.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DBilsky%26aufirst%3DE.%2BJ.%26atitle%3DIn%2520Vivo%2520Pharmacological%2520Characterization%2520of%2520SoRI%25209409%252C%2520a%2520Nonpeptidic%2520Opioid%2520Mu-Agonist%252FDelta-Antagonist%2520That%2520Produces%2520Limited%2520Antinociceptive%2520Tolerance%2520and%2520Attenuates%2520Morphine%2520Physical%2520Dependence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D297%26spage%3D597%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Healy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezawada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1266</span>, <span class="refDoi"> DOI: 10.1021/cn4000428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn4000428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1256-1266&author=J.+R.+Healyauthor=P.+Bezawadaauthor=J.+Shimauthor=J.+W.+Jonesauthor=M.+A.+Kaneauthor=A.+D.+MacKerellauthor=A.+Coopauthor=R.+R.+Matsumoto&title=Synthesis%2C+Modeling%2C+and+Pharmacological+Evaluation+of+UMB+425%2C+a+Mixed+%CE%BC+Agonist%2F%CE%B4+Antagonist+Opioid+Analgesic+with+Reduced+Tolerance+Liabilities&doi=10.1021%2Fcn4000428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span></div><div class="casAuthors">Healy, Jason R.; Bezawada, Padmavani; Shim, Jihyun; Jones, Jace W.; Kane, Maureen A.; MacKerell, Alexander D.; Coop, Andrew; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1256-1266</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid narcotics are used for the treatment of moderate-to-severe pain and primarily exert their analgesic effects through μ receptors.  Although traditional μ agonists can cause undesired side effects, including tolerance, addn. of δ antagonists can attenuate said side effects.  Herein, the authors report 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor synthesized from thebaine.  Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compd. sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols.  As predicted, UMB 425 exhibits a mixed μ agonist/δ antagonist profile as detd. in receptor binding and [35S]GTPγS functional assays in CHO cells.  In vivo studies in mice show that UMB 425 displays potent antinociception in the hot plate and tail-flick assays.  The antinociceptive effects of UMB 425 are blocked by naloxone, but not by the κ-selective antagonist norbinaltorphimine.  During a 6-day tolerance paradigm, UMB 425 maintains significantly greater antinociception compared to morphine.  These studies thus indicate that, even in the absence of δ-specific motifs fused to the C-ring, UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6OgV4pm0lbVg90H21EOLACvtfcHk0lhrM_6_owvcSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D&md5=6949bbfec033537662cfa64b7d281df5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcn4000428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn4000428%26sid%3Dliteratum%253Aachs%26aulast%3DHealy%26aufirst%3DJ.%2BR.%26aulast%3DBezawada%26aufirst%3DP.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%2BW.%26aulast%3DKane%26aufirst%3DM.%2BA.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DCoop%26aufirst%3DA.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSynthesis%252C%2520Modeling%252C%2520and%2520Pharmacological%2520Evaluation%2520of%2520UMB%2520425%252C%2520a%2520Mixed%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520Opioid%2520Analgesic%2520with%2520Reduced%2520Tolerance%2520Liabilities%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D1256%26epage%3D1266%26doi%3D10.1021%2Fcn4000428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dersch, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuvelis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsky, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span> <span> </span><span class="NLM_article-title">14-Alkoxy-and 14-Acyloxypyridomorphinans: μ Agonist/δ Antagonist Opioid Analgesics with Diminished Tolerance and Dependence Side Effects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8350</span>– <span class="NLM_lpage">8363</span>, <span class="refDoi"> DOI: 10.1021/jm300686p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300686p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8350-8363&author=S.+Ananthanauthor=S.+K.+Sainiauthor=C.+M.+Derschauthor=H.+Xuauthor=N.+McGlincheyauthor=D.+Giuvelisauthor=E.+J.+Bilskyauthor=R.+B.+Rothman&title=14-Alkoxy-and+14-Acyloxypyridomorphinans%3A+%CE%BC+Agonist%2F%CE%B4+Antagonist+Opioid+Analgesics+with+Diminished+Tolerance+and+Dependence+Side+Effects&doi=10.1021%2Fjm300686p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm300686p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300686p%26sid%3Dliteratum%253Aachs%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DSaini%26aufirst%3DS.%2BK.%26aulast%3DDersch%26aufirst%3DC.%2BM.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DMcGlinchey%26aufirst%3DN.%26aulast%3DGiuvelis%26aufirst%3DD.%26aulast%3DBilsky%26aufirst%3DE.%2BJ.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26atitle%3D14-Alkoxy-and%252014-Acyloxypyridomorphinans%253A%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520Opioid%2520Analgesics%2520with%2520Diminished%2520Tolerance%2520and%2520Dependence%2520Side%2520Effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8350%26epage%3D8363%26doi%3D10.1021%2Fjm300686p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Váradi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabó, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rouzic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrath, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunkele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagirsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eans, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span> <span> </span><span class="NLM_article-title">Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8381</span>– <span class="NLM_lpage">8397</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00748</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00748" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSkur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8381-8397&author=A.+V%C3%A1radiauthor=G.+F.+Marroneauthor=T.+C.+Palmerauthor=A.+Narayanauthor=M.+R.+Szab%C3%B3author=V.+Le+Rouzicauthor=S.+G.+Grinnellauthor=J.+J.+Subrathauthor=E.+Warnerauthor=S.+Kalraauthor=A.+Hunkeleauthor=J.+Pagirskyauthor=S.+O.+Eansauthor=J.+M.+Medinaauthor=J.+Xuauthor=Y.+Panauthor=A.+Boricsauthor=G.+W.+Pasternakauthor=J.+P.+McLaughlinauthor=S.+Majumdar&title=Mitragynine%2FCorynantheidine+Pseudoindoxyls+As+Opioid+Analgesics+with+Mu+Agonism+and+Delta+Antagonism%2C+Which+Do+Not+Recruit+%CE%B2-Arrestin-2&doi=10.1021%2Facs.jmedchem.6b00748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2</span></div><div class="casAuthors">Varadi, Andras; Marrone, Gina F.; Palmer, Travis C.; Narayan, Ankita; Szabo, Marton R.; Le Rouzic, Valerie; Grinnell, Steven G.; Subrath, Joan J.; Warner, Evelyn; Kalra, Sanjay; Hunkele, Amanda; Pagirsky, Jeremy; Eans, Shainnel O.; Medina, Jessica M.; Xu, Jin; Pan, Ying-Xian; Borics, Attila; Pasternak, Gavril W.; McLaughlin, Jay P.; Majumdar, Susruta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8381-8397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Natural products found in Mitragyna speciosa, commonly known as kratom, represent diverse scaffolds (indole, indolenine, and spiro pseudoindoxyl) with opioid activity, providing opportunities to better understand opioid pharmacol.  Herein, we report the pharmacol. and SAR studies both in vitro and in vivo of mitragynine pseudoindoxyl (3), an oxidative rearrangement product of the corynanthe alkaloid mitragynine. 3 and its corresponding corynantheidine analogs show promise as potent analgesics with a mechanism of action that includes mu opioid receptor agonism/delta opioid receptor antagonism.  In vitro, 3 and its analogs were potent agonists in [35S]GTPγS assays at the mu opioid receptor but failed to recruit β-arrestin-2, which is assocd. with opioid side effects.  Addnl., 3 developed analgesic tolerance more slowly than morphine, showed limited phys. dependence, respiratory depression, constipation, and displayed no reward or aversion in CPP/CPA assays, suggesting that analogs might represent a promising new generation of novel pain relievers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhDBpzV7DBrVg90H21EOLACvtfcHk0lger25z30JdlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSkur3F&md5=92a429837190c339e26e8c55852a0b40</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00748%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25A1radi%26aufirst%3DA.%26aulast%3DMarrone%26aufirst%3DG.%2BF.%26aulast%3DPalmer%26aufirst%3DT.%2BC.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DSzab%25C3%25B3%26aufirst%3DM.%2BR.%26aulast%3DLe%2BRouzic%26aufirst%3DV.%26aulast%3DGrinnell%26aufirst%3DS.%2BG.%26aulast%3DSubrath%26aufirst%3DJ.%2BJ.%26aulast%3DWarner%26aufirst%3DE.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DHunkele%26aufirst%3DA.%26aulast%3DPagirsky%26aufirst%3DJ.%26aulast%3DEans%26aufirst%3DS.%2BO.%26aulast%3DMedina%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DBorics%26aufirst%3DA.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DMajumdar%26aufirst%3DS.%26atitle%3DMitragynine%252FCorynantheidine%2520Pseudoindoxyls%2520As%2520Opioid%2520Analgesics%2520with%2520Mu%2520Agonism%2520and%2520Delta%2520Antagonism%252C%2520Which%2520Do%2520Not%2520Recruit%2520%25CE%25B2-Arrestin-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8381%26epage%3D8397%26doi%3D10.1021%2Facs.jmedchem.6b00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fundytus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merovitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weltrowska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, T. J.</span></span> <span> </span><span class="NLM_article-title">The Opioid μ Agonist/δ Antagonist DIPP-NH<sub>2</sub>[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3520</span>– <span class="NLM_lpage">3526</span>, <span class="refDoi"> DOI: 10.1021/jm980724+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980724%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK1MXkvVCrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3520-3526&author=P.+W.+Schillerauthor=M.+E.+Fundytusauthor=L.+Merovitzauthor=G.+Weltrowskaauthor=T.+M.+Nguyenauthor=C.+Lemieuxauthor=N.+N.+Chungauthor=T.+J.+Coderre&title=The+Opioid+%CE%BC+Agonist%2F%CE%B4+Antagonist+DIPP-NH2%5B%CE%A8%5D+Produces+a+Potent+Analgesic+Effect%2C+No+Physical+Dependence%2C+and+Less+Tolerance+than+Morphine+in+Rats&doi=10.1021%2Fjm980724%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Opioid μ Agonist/δ Antagonist DIPP-NH2[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats</span></div><div class="casAuthors">Schiller, Peter W.; Fundytus, Marian E.; Merovitz, Lisa; Weltrowska, Grazyna; Nguyen, Thi M.-D.; Lemieux, Carole; Chung, Nga N.; Coderre, Terence J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3520-3526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid compds. with mixed μ agonist/δ antagonist properties are expected to be analgesics with low propensity to produce tolerance and dependence.  In an effort to strengthen the μ agonist component of the mixed μ agonist/δ antagonist H-Tyr-Tic-Phe-Phe-NH2 (TIPP-NH2), analogs contg. structurally modified tyrosine residues in place of Tyr1 were synthesized.  Among the prepd. compds., H-Dmt-Tic-Phe-Phe-NH2 (DIPP-NH2; Dmt = 2',6'-dimethyltyrosine) and H-Dmt-TicΨ[CH2NH]Phe-Phe-NH2 (DIPP-NH2[Ψ]) retained a mixed μ agonist/δ antagonist profile, as detd. in the guinea pig ileum and mouse vas deferens assays, whereas H-Tmt-Tic-Phe-Phe-NH2 (Tmt = N,2',6'-trimethyltyrosine) was a partial μ agonist/δ antagonist and H-Tmt-TicΨ[CH2NH]Phe-Phe-NH2 was a μ antagonist/δ antagonist.  DIPP-NH2[Ψ] showed binding affinities in the subnanomolar range for both μ and δ receptors in the rat brain membrane binding assays, thus representing the first example of a balanced μ agonist/δ antagonist with high potency.  In the rat tail flick test, DIPP-NH2[Ψ] given icv produced a potent analgesic effect (ED50 = 0.04 μg), being about 3 times more potent than morphine (ED50 = 0.11 μg).  It produced less acute tolerance than morphine but still a certain level of chronic tolerance.  Unlike morphine, DIPP-NH2[Ψ] produced no phys. dependence whatsoever upon chronic administration at high doses (≤4.5 μg/h) over a 7-day period.  In conclusion, DIPP-NH2[Ψ] fulfills to a large extent the expectations based on the mixed μ agonist/δ antagonist concept with regard to analgesic activity and the development of tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqNgWnqwZWJrVg90H21EOLACvtfcHk0lger25z30JdlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvVCrtL0%253D&md5=91c55724c7bc3530fe8eb00eed86855f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm980724%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980724%252B%26sid%3Dliteratum%253Aachs%26aulast%3DSchiller%26aufirst%3DP.%2BW.%26aulast%3DFundytus%26aufirst%3DM.%2BE.%26aulast%3DMerovitz%26aufirst%3DL.%26aulast%3DWeltrowska%26aufirst%3DG.%26aulast%3DNguyen%26aufirst%3DT.%2BM.%26aulast%3DLemieux%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DN.%2BN.%26aulast%3DCoderre%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520Opioid%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520DIPP-NH2%255B%25CE%25A8%255D%2520Produces%2520a%2520Potent%2520Analgesic%2520Effect%252C%2520No%2520Physical%2520Dependence%252C%2520and%2520Less%2520Tolerance%2520than%2520Morphine%2520in%2520Rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3520%26epage%3D3526%26doi%3D10.1021%2Fjm980724%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochan, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nastase, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span> <span> </span><span class="NLM_article-title">In Vivo Effects of μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Peptidomimetics Following Acute and Repeated Administration</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.1111/bph.14148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1111%2Fbph.14148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=29352503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1Cru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2013-2027&author=J.+P.+Anandauthor=K.+E.+Kochanauthor=A.+F.+Nastaseauthor=D.+Montgomeryauthor=N.+W.+Griggsauthor=J.+R.+Traynorauthor=H.+I.+Mosbergauthor=E.+M.+Jutkiewicz&title=In+Vivo+Effects+of+%CE%BC+Opioid+Receptor+Agonist%2F%CE%B4+Opioid+Receptor+Antagonist+Peptidomimetics+Following+Acute+and+Repeated+Administration&doi=10.1111%2Fbph.14148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration</span></div><div class="casAuthors">Anand, Jessica P.; Kochan, Kelsey E.; Nastase, Anthony F.; Montgomery, Deanna; Griggs, Nicholas W.; Traynor, John R.; Mosberg, Henry I.; Jutkiewicz, Emily M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2013-2027</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Agonists at μ-opioid receptors (μ-receptors) are used for pain management but produce adverse effects including tolerance, dependence and euphoria.  The co-administration of a μ-receptor agonist with a δ-opioid receptor (δ-receptor) antagonist has been shown to produce antinociception with reduced development of some side effects.  We characterized the effects of three μ-receptor agonist/δ-receptor antagonist peptidomimetics in vivo after acute and repeated administration to det. if this profile provides a viable alternative to traditional opioid analgesics.  Three μ-receptor agonist / δ-receptor antagonist peptidomimetics, AAH8, AMB46 and AMB47, and morphine were evaluated for the development of tolerance and dependence after 5 days of twice daily treatment with escalating doses of drug (10-50 mg·kg-1).  Antinociceptive effects were measured in the warm water tail withdrawal assay before and after repeated drug treatment.  Phys. dependence was evaluated by naltrexone-pptd. withdrawal jumping.  The rewarding effects of AAH8 were evaluated using a conditioned place preference (CPP) assay with twice daily conditioning sessions performed for 5 days.  Morphine, AAH8, AMB47 and AMB46 all demonstrated acute antinociceptive effects, but repeated administration only produced tolerance in animals treated with morphine and AMB46.  Injection of naltrexone pptd. fewer jumps in mice treated repeatedly with AAH8 as compared with morphine, AMB47 or AMB46.  Conditioning with morphine, but not AAH8, produced significant CPP.  AAH8 may be a better alternative than traditional opioid analgesics, producing antinociception with less development of tolerance and dependence and may be less rewarding than morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruammciHxwYLVg90H21EOLACvtfcHk0lger25z30JdlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1Cru70%253D&md5=6ad59ce996adbd8e4e76019e851e1ce5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fbph.14148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14148%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DKochan%26aufirst%3DK.%2BE.%26aulast%3DNastase%26aufirst%3DA.%2BF.%26aulast%3DMontgomery%26aufirst%3DD.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26atitle%3DIn%2520Vivo%2520Effects%2520of%2520%25CE%25BC%2520Opioid%2520Receptor%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520Antagonist%2520Peptidomimetics%2520Following%2520Acute%2520and%2520Repeated%2520Administration%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2013%26epage%3D2027%26doi%3D10.1111%2Fbph.14148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2549</span>– <span class="NLM_lpage">2557</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00284</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00284" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2549-2557&author=A.%0AA.+Harlandauthor=I.+D.+Pogozhevaauthor=N.+W.+Griggsauthor=T.+J.+Traskauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Placement+of+Hydroxy+Moiety+on+Pendant+of+Peptidomimetic+Scaffold+Modulates+Mu+and+Kappa+Opioid+Receptor+Efficacy&doi=10.1021%2Facschemneuro.7b00284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy</span></div><div class="casAuthors">Harland, Aubrie A.; Pogozheva, Irina D.; Griggs, Nicholas W.; Trask, Tyler J.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2549-2557</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In an effort to expand the structure-activity relationship (SAR) studies of a series of mixed-efficacy opioid ligands, peptidomimetics that incorporate methoxy and hydroxy groups around a benzyl or 2-methylindanyl pendant on a tetrahydroquinoline (THQ) core of the peptidomimetics were evaluated.  Compds. contg. a methoxy or hydroxy moiety in the o- or m-positions increased binding affinity to the kappa opioid receptor (KOR), whereas compds. contg. methoxy or hydroxy groups in the p-position decreased KOR affinity and reduced or eliminated efficacy at the mu opioid receptor (MOR).  The results from a substituted 2-methylindanyl series aligned with the findings from the substituted benzyl series.  Our studies culminated in the development of 8c, a mixed-efficacy MOR agonist/KOR agonist with subnanomolar binding affinity for both MOR and KOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3CcuOIk8jB7Vg90H21EOLACvtfcHk0lhImG9SdXxUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLvK&md5=58cba30862161dedd803cb284ec90c22</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00284%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DTrask%26aufirst%3DT.%2BJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DPlacement%2520of%2520Hydroxy%2520Moiety%2520on%2520Pendant%2520of%2520Peptidomimetic%2520Scaffold%2520Modulates%2520Mu%2520and%2520Kappa%2520Opioid%2520Receptor%2520Efficacy%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D2549%26epage%3D2557%26doi%3D10.1021%2Facschemneuro.7b00284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeomans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8952</span>– <span class="NLM_lpage">8969</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8952-8969&author=A.+A.+Harlandauthor=L.+Yeomansauthor=N.+W.+Griggsauthor=J.+P.+Anandauthor=I.+D.+Pogozhevaauthor=E.+M.+Jutkiewiczauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Further+Optimization+and+Evaluation+of+Bioavailable%2C+Mixed-Efficacy+%CE%BC-Opioid+Receptor+%28MOR%29+Agonists%2F%CE%B4-Opioid+Receptor+%28DOR%29+Antagonists%3A+Balancing+MOR+and+DOR+Affinities&doi=10.1021%2Facs.jmedchem.5b01270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities</span></div><div class="casAuthors">Harland, Aubrie A.; Yeomans, Larisa; Griggs, Nicholas W.; Anand, Jessica P.; Pogozheva, Irina D.; Jutkiewicz, Emily M.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8952-8969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previously described peptidomimetic series, the authors reported the development of bifunctional μ-opioid receptor (MOR) agonist and δ-opioid receptor (DOR) antagonist ligands with a lead compd. that produced antinociception for 1 h after i.p. administration in mice.  In this paper, the authors expand on the original series by presenting two modifications, both of which were designed with the following objectives: (1) probing bioavailability and improving metabolic stability, (2) balancing affinities between MOR and DOR while reducing affinity and efficacy at the κ-opioid receptor (KOR), and (3) improving in vivo efficacy.  Here, the authors establish that, through N-acetylation of the original peptidomimetic series, the authors are able to improve DOR affinity and increase selectivity relative to KOR while maintaining the desired MOR agonist/DOR antagonist profile.  From initial in vivo studies, one compd. I was found to produce dose-dependent antinociception after peripheral administration with an improved duration of action of longer than 3 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1bP5LC-AXLVg90H21EOLACvtfcHk0lhImG9SdXxUtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmsr%252FP&md5=97e397deac10c2d435dfe465aed6779f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01270%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DYeomans%26aufirst%3DL.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DFurther%2520Optimization%2520and%2520Evaluation%2520of%2520Bioavailable%252C%2520Mixed-Efficacy%2520%25CE%25BC-Opioid%2520Receptor%2520%2528MOR%2529%2520Agonists%252F%25CE%25B4-Opioid%2520Receptor%2520%2528DOR%2529%2520Antagonists%253A%2520Balancing%2520MOR%2520and%2520DOR%2520Affinities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8952%26epage%3D8969%26doi%3D10.1021%2Facs.jmedchem.5b01270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Effects of <i>N</i>-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4985</span>– <span class="NLM_lpage">4998</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4985-4998&author=A.+A.+Harlandauthor=A.+M.+Benderauthor=N.+W.+Griggsauthor=C.+Gaoauthor=J.+P.+Anandauthor=I.+D.+Pogozhevaauthor=J.+R.+Traynorauthor=E.+M.+Jutkiewiczauthor=H.+I.+Mosberg&title=Effects+of+N-Substitutions+on+the+Tetrahydroquinoline+%28THQ%29+Core+of+Mixed-Efficacy+%CE%BC-Opioid+Receptor+%28MOR%29%2F%CE%B4-Opioid+Receptor+%28DOR%29+Ligands&doi=10.1021%2Facs.jmedchem.6b00308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands</span></div><div class="casAuthors">Harland, Aubrie A.; Bender, Aaron M.; Griggs, Nicholas W.; Gao, Chao; Anand, Jessica P.; Pogozheva, Irina D.; Traynor, John R.; Jutkiewicz, Emily M.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4985-4998</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Acetylation of the tetrahydroquinoline (THQ) core of a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands increases DOR affinity, resulting in ligands with balanced MOR and DOR affinities.  We report a series of N-substituted THQ analogs that incorporate various carbonyl-contg. moieties to maintain DOR affinity and define the steric and electronic requirements of the binding pocket across the opioid receptors. 4h produced in vivo antinociception (i.p.) for 1 h at 10 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6PABTi0KVLVg90H21EOLACvtfcHk0ljTthgydndB4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCnt7Y%253D&md5=472c744ca5f66c7de99898aab59a717b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00308%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DEffects%2520of%2520N-Substitutions%2520on%2520the%2520Tetrahydroquinoline%2520%2528THQ%2529%2520Core%2520of%2520Mixed-Efficacy%2520%25CE%25BC-Opioid%2520Receptor%2520%2528MOR%2529%252F%25CE%25B4-Opioid%2520Receptor%2520%2528DOR%2529%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4985%26epage%3D4998%26doi%3D10.1021%2Facs.jmedchem.6b00308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Rapid Synthesis of Boc-2′,6′-Dimethyl-<span class="smallcaps smallerCapital">l</span>-Tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OrsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1199-1203&author=A.+M.+Benderauthor=N.+W.+Griggsauthor=C.+Gaoauthor=T.+J.+Traskauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Rapid+Synthesis+of+Boc-2%E2%80%B2%2C6%E2%80%B2-Dimethyl-l-Tyrosine+and+Derivatives+and+Incorporation+into+Opioid+Peptidomimetics&doi=10.1021%2Facsmedchemlett.5b00344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Synthesis of Boc-2',6'-dimethyl-L-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics</span></div><div class="casAuthors">Bender, Aaron M.; Griggs, Nicholas W.; Gao, Chao; Trask, Tyler J.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unnatural amino acid 2',6'-dimethyl-L-tyrosine has found widespread use in the development of synthetic opioid ligands.  Opioids featuring this residue at the N-terminus often display superior potency at one or more of the opioid receptor types, but the availability of the compd. is hampered by its cost and difficult synthesis.  Here, the authors report a short, three-step synthesis of Boc-2',6'-dimethyl-L-tyrosine (3a) utilizing a microwave-assisted Negishi coupling for the key carbon-carbon bond forming step, and employ this chem. for the expedient synthesis of other unnatural tyrosine derivs.  Three of these derivs. (3c, 3d, 3f) have not previously been examd. as Tyr1 replacements in opioid ligands.  The authors describe the incorporation of these tyrosine derivs. in a series of opioid peptidomimetics employing their previously reported tetrahydroquinoline (THQ) scaffold, and the binding and relative efficacy of each of the analogs at the three opioid receptor subtypes: mu (MOR), delta (DOR), and kappa (KOR).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9wy_i_ifxubVg90H21EOLACvtfcHk0ljTthgydndB4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OrsL%252FE&md5=fa8173b4541991cd10f0cd537a6d97cc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00344%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DTrask%26aufirst%3DT.%2BJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DRapid%2520Synthesis%2520of%2520Boc-2%25E2%2580%25B2%252C6%25E2%2580%25B2-Dimethyl-l-Tyrosine%2520and%2520Derivatives%2520and%2520Incorporation%2520into%2520Opioid%2520Peptidomimetics%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1199%26epage%3D1203%26doi%3D10.1021%2Facsmedchemlett.5b00344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy μ Opioid Receptor/δ Opioid Receptor Ligands</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00100</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00100" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1428-1435&author=A.+M.+Benderauthor=N.+W.+Griggsauthor=J.+P.+Anandauthor=J.+R.+Traynorauthor=E.+M.+Jutkiewiczauthor=H.+I.+Mosberg&title=Asymmetric+Synthesis+and+in+Vitro+and+in+Vivo+Activity+of+Tetrahydroquinolines+Featuring+a+Diverse+Set+of+Polar+Substitutions+at+the+6+Position+as+Mixed-Efficacy+%CE%BC+Opioid+Receptor%2F%CE%B4+Opioid+Receptor+Ligands&doi=10.1021%2Facschemneuro.5b00100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy μ Opioid Receptor/δ Opioid Receptor Ligands</span></div><div class="casAuthors">Bender, Aaron M.; Griggs, Nicholas W.; Anand, Jessica P.; Traynor, John R.; Jutkiewicz, Emily M.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1428-1435</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors previously reported a small series of mixed-efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist peptidomimetics featuring a tetrahydroquinoline scaffold and showed the promise of this series as effective analgesics after i.p. administration in mice.  The authors report here an expanded structure-activity relationship study of the pendant region of these compds. and focus in particular on the incorporation of heteroatoms into this side chain.  These analogs provide new insight into the binding requirements for this scaffold at MOR, DOR, and the κ opioid receptor (KOR), and several of them significantly improve upon the overall MOR agonist/DOR antagonist profile of the previous compds.  In vivo data for these compds. are also reported and show the antinociceptive potency and duration of action of compds. I and II to be comparable to those of morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2zgiTSGa4bVg90H21EOLACvtfcHk0ljdBFBNDoyMwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFOnsr0%253D&md5=a817978f94160be2c0e7077c4a238997</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00100%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DAsymmetric%2520Synthesis%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Activity%2520of%2520Tetrahydroquinolines%2520Featuring%2520a%2520Diverse%2520Set%2520of%2520Polar%2520Substitutions%2520at%2520the%25206%2520Position%2520as%2520Mixed-Efficacy%2520%25CE%25BC%2520Opioid%2520Receptor%252F%25CE%25B4%2520Opioid%2520Receptor%2520Ligands%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1428%26epage%3D1435%26doi%3D10.1021%2Facschemneuro.5b00100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeomans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobczyk-Kojiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span> <span> </span><span class="NLM_article-title">Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2149</span>, <span class="refDoi"> DOI: 10.1021/jm400050y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400050y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2139-2149&author=H.+I.+Mosbergauthor=L.+Yeomansauthor=A.+A.+Harlandauthor=A.+M.+Benderauthor=K.+Sobczyk-Kojiroauthor=J.+P.+Anandauthor=M.+J.+Clarkauthor=E.+M.+Jutkiewiczauthor=J.+R.+Traynor&title=Opioid+Peptidomimetics%3A+Leads+for+the+Design+of+Bioavailable+Mixed+Efficacy+%CE%BC+Opioid+Receptor+%28MOR%29+Agonist%2F%CE%B4+Opioid+Receptor+%28DOR%29+Antagonist+Ligands&doi=10.1021%2Fjm400050y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands</span></div><div class="casAuthors">Mosberg, Henry I.; Yeomans, Larisa; Harland, Aubrie A.; Bender, Aaron M.; Sobczyk-Kojiro, Katarzyna; Anand, Jessica P.; Clark, Mary J.; Jutkiewicz, Emily M.; Traynor, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2139-2149</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaffold and modeled on a series of cyclic tetrapeptide opioid agonists.  We have recently described modifications to these peptides that confer a μ opioid receptor (MOR) agonist, δ opioid receptor (DOR) antagonist profile, which has been shown to reduce the development of tolerance to the analgesic actions of MOR agonists.  Several such bifunctional ligands have been reported, but none has been demonstrated to cross the blood-brain barrier.  Here we describe the transfer of structural features that evoked MOR agonist/DOR antagonist behavior in the cyclic peptides to the tetrahydroquinoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacol. profile.  Further, the 4R diastereomer of 1 was fully efficacious and approx. equipotent to morphine in the mouse warm water tail withdrawal assay following i.p. administration and thus a promising lead for the development of opioid analgesics with reduced tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo03SkkUK9VmrVg90H21EOLACvtfcHk0lh_Z1iW5WGE-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyhtrg%253D&md5=f150f1b184718fd4d73fcac969e93c12</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm400050y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400050y%26sid%3Dliteratum%253Aachs%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DYeomans%26aufirst%3DL.%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DSobczyk-Kojiro%26aufirst%3DK.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26atitle%3DOpioid%2520Peptidomimetics%253A%2520Leads%2520for%2520the%2520Design%2520of%2520Bioavailable%2520Mixed%2520Efficacy%2520%25CE%25BC%2520Opioid%2520Receptor%2520%2528MOR%2529%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520%2528DOR%2529%2520Antagonist%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2139%26epage%3D2149%26doi%3D10.1021%2Fjm400050y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nastase, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1840</span>– <span class="NLM_lpage">1848</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00139</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00139" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1840-1848&author=A.+F.+Nastaseauthor=N.+W.+Griggsauthor=J.+P.+Anandauthor=T.+J.+Fernandezauthor=A.+A.+Harlandauthor=T.+J.+Traskauthor=E.+M.+Jutkiewiczauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Synthesis+and+Pharmacological+Evaluation+of+Novel+C-8+Substituted+Tetrahydroquinolines+as+Balanced-Affinity+Mu%2FDelta+Opioid+Ligands+for+the+Treatment+of+Pain&doi=10.1021%2Facschemneuro.8b00139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain</span></div><div class="casAuthors">Nastase, Anthony F.; Griggs, Nicholas W.; Anand, Jessica P.; Fernandez, Thomas J.; Harland, Aubrie A.; Trask, Tyler J.; Jutkiewicz, Emily M.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1840-1848</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of opioids for the treatment of pain, while largely effective, is limited by detrimental side effects including analgesic tolerance, phys. dependence, and euphoria, which may lead to opioid abuse.  Studies have shown that compds. with a μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist profile reduce or eliminate some of these side effects including the development of tolerance and dependence.  Herein we report the synthesis and pharmacol. evaluation of a series of tetrahydroquinoline-based peptidomimetics with substitutions at the C-8 position.  Relative to our lead peptidomimetic with no C-8 substitution, this series affords an increase in DOR affinity and provides greater balance in MOR and DOR binding affinities.  Moreover, compds. with carbonyl moieties at C-8 display the desired MOR agonist/DOR antagonist profile whereas alkyl substitutions elicit modest DOR agonism.  Several compds. in this series produce a robust antinociceptive effect in vivo and show antinociceptive activity for greater than 2 h after i.p. administration in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpACJdb3aPloLVg90H21EOLACvtfcHk0lgrk2YGBs9QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahtLc%253D&md5=72922fc10ccee02570aeca884b485da1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00139%26sid%3Dliteratum%253Aachs%26aulast%3DNastase%26aufirst%3DA.%2BF.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DFernandez%26aufirst%3DT.%2BJ.%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DTrask%26aufirst%3DT.%2BJ.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Novel%2520C-8%2520Substituted%2520Tetrahydroquinolines%2520as%2520Balanced-Affinity%2520Mu%252FDelta%2520Opioid%2520Ligands%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D9%26spage%3D1840%26epage%3D1848%26doi%3D10.1021%2Facschemneuro.8b00139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Design of a High Affinity Peptidomimetic Opioid Agonist from Peptide Pharmacophore Models</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2688</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00472-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2FS0960-894X%2898%2900472-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=9873603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK1cXntV2rur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=2685-2688&author=C.+Wangauthor=I.+J.+McFadyenauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Design+of+a+High+Affinity+Peptidomimetic+Opioid+Agonist+from+Peptide+Pharmacophore+Models&doi=10.1016%2FS0960-894X%2898%2900472-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models</span></div><div class="casAuthors">Wang, Chenguang; McFadyen, Iain J.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2685-2688</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Based upon opioid receptor-binding pharmacophore models derived from a series of opioid tetrapeptides, a pair of diastereomeric peptidomimetics R- and S-I was synthesized.  Both analogs displayed high opioid receptor affinity, moderate selectivity for the μ opioid receptor, and were potent, full agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrogtCdsiu-4rVg90H21EOLACvtfcHk0lgXxD0A5-phUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntV2rur0%253D&md5=534830af45e44b03bb09c8d1de985f30</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900472-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900472-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMcFadyen%26aufirst%3DI.%2BJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DDesign%2520of%2520a%2520High%2520Affinity%2520Peptidomimetic%2520Opioid%2520Agonist%2520from%2520Peptide%2520Pharmacophore%2520Models%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D2685%26epage%3D2688%26doi%3D10.1016%2FS0960-894X%2898%2900472-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holsworth, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span> <span> </span><span class="NLM_article-title">Metabolic Aromatization of N-Alkyl-1,2,3,4-Tetrahydroquinoline Substructures to Quinolinium by Human Liver Microsomes and Horseradish Peroxidase</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2044</span>– <span class="NLM_lpage">2055</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.012286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1124%2Fdmd.106.012286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=16985099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=2044-2055&author=C.+Guauthor=R.+Collinsauthor=D.+D.+Holsworthauthor=G.+S.+Walkerauthor=R.+L.+Voorman&title=Metabolic+Aromatization+of+N-Alkyl-1%2C2%2C3%2C4-Tetrahydroquinoline+Substructures+to+Quinolinium+by+Human+Liver+Microsomes+and+Horseradish+Peroxidase&doi=10.1124%2Fdmd.106.012286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic aromatization of N-alkyl-1,2,3,4-tetrahydroquinoline substructures to quinolinium by human liver microsomes and horseradish peroxidase</span></div><div class="casAuthors">Gu, Chungang; Collins, Roxane; Holsworth, Daniel D.; Walker, Gregory S.; Voorman, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2044-2055</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Metabolic aromatization of xenobiotics is an unusual reaction with some documented examples.  For instance, the oxidn. of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the neurotoxic pyridinium ion metabolite 1-methyl-4-phenylpyridinium by monoamine oxidase (MAO) B in the brain has been of interest to a no. of investigators.  It has also been reported that although the aromatization of N-methyl-tetrahydroisoquinoline occurs with MAO B, the metab. does not proceed for its isomer, N-methyl-tetrahydroquinoline, by the same enzyme.  The aromatization of an N-alkyl-tetrahydroquinoline substructure was identified during in vitro metabolite profiling of compd. A, which was designed as a potent renin inhibitor for the treatment of hypertension.  The N-alkylquinolinium metabolite of compd. A was identified by liq. chromatog.-tandem mass spectrometry of human liver microsomal incubates and proton NMR of the isolated metabolite.  Further in vitro metab. studies with a com. available chem. (compd. B), contg. the same substructure, also generated an N-alkylquinolinium metabolite.  In vitro cytochrome P 450 reaction phenotyping of compd. A revealed that the metab. was catalyzed exclusively by CYP3A4.  Although compd. B was a substrate for several P 450 isoforms, its quinolinium metabolite was also generated predominantly by CYP3A4.  Neither compd. A nor compd. B was a substrate of MAOs.  The quinolinium metabolites were readily produced by horseradish peroxidase, suggesting that aromatization of the N-alkyltetrahydroquinoline could occur via a mechanism involving single electron transfer from nitrogen.  Although dihydro intermediates from the tetrahydroquinoline substrates were not obsd. in the formation of quinolinium metabolites, cyanide trapping results indicated the occurrence of iminium intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq-tn_67v3MLVg90H21EOLACvtfcHk0liLe3YG0-zThQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltLnM&md5=7dc3c968b0dcccb09eb8350bf0843a77</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.012286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.012286%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DC.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DHolsworth%26aufirst%3DD.%2BD.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26atitle%3DMetabolic%2520Aromatization%2520of%2520N-Alkyl-1%252C2%252C3%252C4-Tetrahydroquinoline%2520Substructures%2520to%2520Quinolinium%2520by%2520Human%2520Liver%2520Microsomes%2520and%2520Horseradish%2520Peroxidase%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D2044%26epage%3D2055%26doi%3D10.1124%2Fdmd.106.012286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aryal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi-Ping, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Discovery of Opioid Analgesics with Reduced Side Effects</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=H.+Xi-Pingauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Duanauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Schoichet&title=Structure-Based+Discovery+of+Opioid+Analgesics+with+Reduced+Side+Effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0lgFabmuETHLYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DXi-Ping%26aufirst%3DH.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSchoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-Based%2520Discovery%2520of%2520Opioid%2520Analgesics%2520with%2520Reduced%2520Side%2520Effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agius, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 4-Substituted Piperidines and Piperazines as Balanced Affinity μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2013.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=24365161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=548-551&author=A.+M.+Benderauthor=M.+J.+Clarkauthor=M.+P.+Agiusauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Synthesis+and+Evaluation+of+4-Substituted+Piperidines+and+Piperazines+as+Balanced+Affinity+%CE%BC+Opioid+Receptor+%28MOR%29+Agonist%2F%CE%B4+Opioid+Receptor+%28DOR%29+Antagonist+Ligands&doi=10.1016%2Fj.bmcl.2013.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands</span></div><div class="casAuthors">Bender, Aaron M.; Clark, Mary J.; Agius, Michael P.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this letter, the authors describe a series of 4-substituted piperidine and piperazine compds., e.g. I [X = CH, N; R = Ph2CHCH2CH2, Ph(CH2)n; n = 1-5]; based on known tetrahydroquinoline II, a compd. that shows balanced, low nanomolar binding affinity for the mu opioid receptor (MOR) and the delta opioid receptor (DOR).  The authors have shown that by changing the length and flexibility profile of the side chain in this position, binding affinity is improved at both receptors by a significant degree.  Furthermore, several of the compds. described herein display good efficacy at MOR, while simultaneously displaying DOR antagonism.  The MOR agonist/DOR antagonist has shown promise in the redn. of neg. side effects displayed by selective MOR agonists, namely the development of dependence and tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa-35Rin5RGbVg90H21EOLACvtfcHk0lgFabmuETHLYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFOr&md5=6a6529893822af4c0e53a2b2766dc693</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DAgius%26aufirst%3DM.%2BP.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25204-Substituted%2520Piperidines%2520and%2520Piperazines%2520as%2520Balanced%2520Affinity%2520%25CE%25BC%2520Opioid%2520Receptor%2520%2528MOR%2529%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520%2528DOR%2529%2520Antagonist%2520Ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D548%26epage%3D551%26doi%3D10.1016%2Fj.bmcl.2013.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Opioidmimetics Containing 2′,6′-Dimethyl-<span class="smallcaps smallerCapital">l</span>-Tyrosine and a Pyrazinone-Ring Platform</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5768</span>– <span class="NLM_lpage">5771</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.08.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2007.08.058" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5768-5771&author=K.+Shiotaniauthor=T.+Liauthor=A.+Miyazakiauthor=Y.+Tsudaauthor=T.+Yokoiauthor=A.+Amboauthor=Y.+Sasakiauthor=S.+D.+Bryantauthor=L.+H.+Lazarusauthor=Y.+Okada&title=Design+and+Synthesis+of+Opioidmimetics+Containing+2%E2%80%B2%2C6%E2%80%B2-Dimethyl-l-Tyrosine+and+a+Pyrazinone-Ring+Platform&doi=10.1016%2Fj.bmcl.2007.08.058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.08.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.08.058%26sid%3Dliteratum%253Aachs%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Opioidmimetics%2520Containing%25202%25E2%2580%25B2%252C6%25E2%2580%25B2-Dimethyl-l-Tyrosine%2520and%2520a%2520Pyrazinone-Ring%2520Platform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5768%26epage%3D5771%26doi%3D10.1016%2Fj.bmcl.2007.08.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 3,6-Bis[H-Tyr/H-Dmt-NH(CH<sub>2</sub>)<sub>m,n</sub>]-2(1H)Pyrazinone Derivatives: Function of Alkyl Chain Length on Opioid Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5793</span>– <span class="NLM_lpage">5796</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.08.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2006.08.079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5793-5796&author=K.+Shiotaniauthor=T.+Liauthor=A.+Miyazakiauthor=Y.+Tsudaauthor=S.+D.+Bryantauthor=A.+Amboauthor=Y.+Sasakiauthor=L.+H.+Lazarusauthor=Y.+Okada&title=Synthesis+of+3%2C6-Bis%5BH-Tyr%2FH-Dmt-NH%28CH2%29m%2Cn%5D-2%281H%29Pyrazinone+Derivatives%3A+Function+of+Alkyl+Chain+Length+on+Opioid+Activity&doi=10.1016%2Fj.bmcl.2006.08.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.08.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.08.079%26sid%3Dliteratum%253Aachs%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DSynthesis%2520of%25203%252C6-Bis%255BH-Tyr%252FH-Dmt-NH%2528CH2%2529m%252Cn%255D-2%25281H%2529Pyrazinone%2520Derivatives%253A%2520Function%2520of%2520Alkyl%2520Chain%2520Length%2520on%2520Opioid%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5793%26epage%3D5796%26doi%3D10.1016%2Fj.bmcl.2006.08.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span> <span> </span><span class="NLM_article-title">Novel 2′,6′-Dimethyl-L-Tyrosine-Containing Pyrazinone Opioid Mimetic μ-Agonists with Potent Antinociceptive Activity in Mice</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.060061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1124%2Fjpet.103.060061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=14718580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFamurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=432-438&author=Y.+Jinsmaaauthor=Y.+Okadaauthor=Y.+Tsudaauthor=K.+Shiotaniauthor=Y.+Sasakiauthor=A.+Amboauthor=S.+D.+Bryantauthor=L.+H.+Lazarus&title=Novel+2%E2%80%B2%2C6%E2%80%B2-Dimethyl-L-Tyrosine-Containing+Pyrazinone+Opioid+Mimetic+%CE%BC-Agonists+with+Potent+Antinociceptive+Activity+in+Mice&doi=10.1124%2Fjpet.103.060061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2',6'-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic μ-agonists with potent antinociceptive activity in mice</span></div><div class="casAuthors">Jinsmaa, Yunden; Okada, Yoshio; Tsuda, Yuko; Shiotani, Kimitaka; Sasaki, Yusuke; Ambo, Akihiro; Bryant, Sharon D.; Lazarus, Lawrence H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">432-438</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Novel bioactive opioid mimetic agonists contg. 2',6'-dimethyl-L-tyrosine (Dmt) and a pyrazinone ring interact with μ-and δ-opioid receptors.  Compd. 1 [3-(4'-Dmt-aminobutyl)-6-(3'-Dmt-aminopropyl)-5-methyl-2(1H)pyrazinone] exhibited high μ-opioid receptor affinity and selectivity (Kiμ = 0.021 nM and Kiδ/Kiμ = 1,519, resp.), and agonist activity on guinea pig ileum (IC50 = 1.7 nM) with weaker δ-bioactivity on mouse vas deferens (IC50 = 25.8 nM).  Other compds. (2-4) had μ-opioid receptor affinities and selectivities 2- to 5-fold and 4- to 7-fold less than 1, resp.  Intracerebroventricular administration of 1 in mice exhibited potent naloxone reversible antinociception (65 to 71 times greater than morphine) in both tail-flick (TF) and hot-plate (HP) tests.  Distinct opioid antagonists had differential effects on antinociception: naltrindole (δ-antagonist) partially blocked antinociception in the TF, but it was ineffective in the HP test, whereas β-funaltrexamine (irreversible antagonist, μ1/μ2-subtypes) but not naloxonazine (μ1-subtype) inhibited TF test antinociception, yet both blocked antinociception in the HP test.  Our data indicated that 1 acted through μ- and δ-opioid receptors to produce spinal antinociception, although primarily through the μ2-receptor subtype; however, the μ1-receptor subtype dominates supraspinally.  S.c. and oral administration indicated that 1 crossed gastrointestinal and blood-brain barriers to produce central nervous system-mediated antinociception.  Furthermore, daily s.c. dosing of mice with 1 for 1 wk developed tolerance in a similar manner to that of morphine in TF and HP tests, implicating that 1 also acts through a similar mechanism analogous to morphine at μ-opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbGSjFwVrCZ7Vg90H21EOLACvtfcHk0lig1HDZJ8eK5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFamurc%253D&md5=390c94999d9ca73767af4c558b1955b8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.060061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.060061%26sid%3Dliteratum%253Aachs%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26atitle%3DNovel%25202%25E2%2580%25B2%252C6%25E2%2580%25B2-Dimethyl-L-Tyrosine-Containing%2520Pyrazinone%2520Opioid%2520Mimetic%2520%25CE%25BC-Agonists%2520with%2520Potent%2520Antinociceptive%2520Activity%2520in%2520Mice%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D432%26epage%3D438%26doi%3D10.1124%2Fjpet.103.060061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">Oral Bioavailability of a New Class of μ-Opioid Receptor Agonists Containing 3,6-Bis[Dmt-NH(CH<sub>2</sub>)<sub>n</sub>]-2(1H)-Pyrazinone with Central-Mediated Analgesia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2599</span>– <span class="NLM_lpage">2610</span>, <span class="refDoi"> DOI: 10.1021/jm0304616</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0304616" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2599-2610&author=Y.+Jinsmaaauthor=A.+Miyazakiauthor=Y.+Fujitaauthor=T.+Liauthor=Y.+Fujisawaauthor=K.+Shiotaniauthor=Y.+Tsudaauthor=T.+Yokoiauthor=A.+Amboauthor=Y.+Sasakiauthor=S.+D.+Bryantauthor=L.+H.+Lazarusauthor=Y.+Okada&title=Oral+Bioavailability+of+a+New+Class+of+%CE%BC-Opioid+Receptor+Agonists+Containing+3%2C6-Bis%5BDmt-NH%28CH2%29n%5D-2%281H%29-Pyrazinone+with+Central-Mediated+Analgesia&doi=10.1021%2Fjm0304616"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0304616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0304616%26sid%3Dliteratum%253Aachs%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DOral%2520Bioavailability%2520of%2520a%2520New%2520Class%2520of%2520%25CE%25BC-Opioid%2520Receptor%2520Agonists%2520Containing%25203%252C6-Bis%255BDmt-NH%2528CH2%2529n%255D-2%25281H%2529-Pyrazinone%2520with%2520Central-Mediated%2520Analgesia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2599%26epage%3D2610%26doi%3D10.1021%2Fjm0304616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">New Series of Potent δ-Opioid Antagonists Containing the H-Dmt-Tic-NH-Hexyl-NH-R Motif</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5517</span>– <span class="NLM_lpage">5520</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.08.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2005.08.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=5517-5520&author=T.+Liauthor=K.+Shiotaniauthor=A.+Miyazakiauthor=Y.+Fujitaauthor=Y.+Tsudaauthor=A.+Amboauthor=Y.+Sasakiauthor=Y.+Jinsmaaauthor=E.+Marczakauthor=S.+D.+Bryantauthor=L.+H.+Lazarusauthor=Y.+Okada&title=New+Series+of+Potent+%CE%B4-Opioid+Antagonists+Containing+the+H-Dmt-Tic-NH-Hexyl-NH-R+Motif&doi=10.1016%2Fj.bmcl.2005.08.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.08.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.08.073%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DMarczak%26aufirst%3DE.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DNew%2520Series%2520of%2520Potent%2520%25CE%25B4-Opioid%2520Antagonists%2520Containing%2520the%2520H-Dmt-Tic-NH-Hexyl-NH-R%2520Motif%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D5517%26epage%3D5520%26doi%3D10.1016%2Fj.bmcl.2005.08.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span> <span> </span><span class="NLM_article-title">Unique High-Affinity Synthetic μ-Opioid Receptor Agonists with Central- and Systemic-Mediated Analgesia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3201</span>– <span class="NLM_lpage">3209</span>, <span class="refDoi"> DOI: 10.1021/jm020459z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020459z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3201-3209&author=Y.+Okadaauthor=Y.+Tsudaauthor=Y.+Fujitaauthor=T.+Yokoiauthor=Y.+Sasakiauthor=A.+Amboauthor=R.+Konishiauthor=M.+Nagataauthor=S.+Salvadoriauthor=Y.+Jinsmaaauthor=S.+D.+Bryantauthor=L.+H.+Lazarus&title=Unique+High-Affinity+Synthetic+%CE%BC-Opioid+Receptor+Agonists+with+Central-+and+Systemic-Mediated+Analgesia&doi=10.1021%2Fjm020459z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm020459z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020459z%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DKonishi%26aufirst%3DR.%26aulast%3DNagata%26aufirst%3DM.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26atitle%3DUnique%2520High-Affinity%2520Synthetic%2520%25CE%25BC-Opioid%2520Receptor%2520Agonists%2520with%2520Central-%2520and%2520Systemic-Mediated%2520Analgesia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3201%26epage%3D3209%26doi%3D10.1021%2Fjm020459z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrakumar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stapelfeld, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorbacher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, D.</span></span> <span> </span><span class="NLM_article-title">Preparation and Opioid Activity of Analogs of the Analgesic Dipeptide 2,6-Dimethyl-l-Tyrosyl-N-(3-Phenylpropyl)-D-Alaninamide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1021/jm00080a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00080a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=223-233&author=N.+S.+Chandrakumarauthor=P.+K.+Yonanauthor=A.+Stapelfeldauthor=M.+Savageauthor=E.+Rorbacherauthor=P.+C.+Contrerasauthor=D.+Hammond&title=Preparation+and+Opioid+Activity+of+Analogs+of+the+Analgesic+Dipeptide+2%2C6-Dimethyl-l-Tyrosyl-N-%283-Phenylpropyl%29-D-Alaninamide&doi=10.1021%2Fjm00080a005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm00080a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00080a005%26sid%3Dliteratum%253Aachs%26aulast%3DChandrakumar%26aufirst%3DN.%2BS.%26aulast%3DYonan%26aufirst%3DP.%2BK.%26aulast%3DStapelfeld%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DM.%26aulast%3DRorbacher%26aufirst%3DE.%26aulast%3DContreras%26aufirst%3DP.%2BC.%26aulast%3DHammond%26aufirst%3DD.%26atitle%3DPreparation%2520and%2520Opioid%2520Activity%2520of%2520Analogs%2520of%2520the%2520Analgesic%2520Dipeptide%25202%252C6-Dimethyl-l-Tyrosyl-N-%25283-Phenylpropyl%2529-D-Alaninamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D223%26epage%3D233%26doi%3D10.1021%2Fjm00080a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neilan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Complex Morphinan Derivative BU72 as a High Efficacy, Long-Lasting Mu-Opioid Receptor Agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>499</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2004.07.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.ejphar.2004.07.097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=15363957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFSqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=499&publication_year=2004&pages=107-116&author=C.+L.+Neilanauthor=S.+M.+Husbandsauthor=S.+Breedenauthor=M.+C.+Koauthor=M.+D.+Acetoauthor=J.+W.+Lewisauthor=J.+H.+Woodsauthor=J.+R.+Traynor&title=Characterization+of+the+Complex+Morphinan+Derivative+BU72+as+a+High+Efficacy%2C+Long-Lasting+Mu-Opioid+Receptor+Agonist&doi=10.1016%2Fj.ejphar.2004.07.097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist</span></div><div class="casAuthors">Neilan, Claire L.; Husbands, Stephen M.; Breeden, Simon; Ko, M. C.; Aceto, Mario D.; Lewis, John W.; Woods, James H.; Traynor, John R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">499</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of buprenorphine as a treatment for opiate abuse and dependence has drawn attention to opioid ligands that have agonist actions followed by long-lasting antagonist actions.  In a search for alternatives to buprenorphine, we discovered a bridged pyrrolidinomorphinan (BU72).  In vitro, BU72 displayed high affinity and efficacy for mu-opioid receptors, but was also a partial delta-opioid receptor agonist and a full kappa-opioid receptor agonist.  BU72 was a highly potent and long-lasting antinociceptive agent against both thermal and chem. nociception in the mouse and against thermal nociception in the monkey.  These effects were prevented by mu-, but not kappa- or delta-, opioid receptor antagonists.  Once the agonist effects of BU72 had subsided, the compd. acted to attenuate the antinociceptive action of morphine.  BU72 is too efficacious for human use but manipulation to reduce efficacy could provide a lead to the development of a treatment for opioid dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgyTfkcE_IbLVg90H21EOLACvtfcHk0li49nwnaCBBIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFSqurY%253D&md5=d0c31c6288c887c4ca24ae8b12545973</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.07.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.07.097%26sid%3Dliteratum%253Aachs%26aulast%3DNeilan%26aufirst%3DC.%2BL.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DBreeden%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DM.%2BC.%26aulast%3DAceto%26aufirst%3DM.%2BD.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DWoods%26aufirst%3DJ.%2BH.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Complex%2520Morphinan%2520Derivative%2520BU72%2520as%2520a%2520High%2520Efficacy%252C%2520Long-Lasting%2520Mu-Opioid%2520Receptor%2520Agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D499%26spage%3D107%26epage%3D116%26doi%3D10.1016%2Fj.ejphar.2004.07.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purington, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobczyk-Kojiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Development and in Vitro Characterization of a Novel Bifunctional μ-Agonist/δ-Antagonist Opioid Tetrapeptide</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1021/cb200263q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb200263q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1375-1381&author=L.+C.+Puringtonauthor=K.+Sobczyk-Kojiroauthor=I.+D.+Pogozhevaauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Development+and+in+Vitro+Characterization+of+a+Novel+Bifunctional+%CE%BC-Agonist%2F%CE%B4-Antagonist+Opioid+Tetrapeptide&doi=10.1021%2Fcb200263q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcb200263q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb200263q%26sid%3Dliteratum%253Aachs%26aulast%3DPurington%26aufirst%3DL.%2BC.%26aulast%3DSobczyk-Kojiro%26aufirst%3DK.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DDevelopment%2520and%2520in%2520Vitro%2520Characterization%2520of%2520a%2520Novel%2520Bifunctional%2520%25CE%25BC-Agonist%252F%25CE%25B4-Antagonist%2520Opioid%2520Tetrapeptide%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D1375%26epage%3D1381%26doi%3D10.1021%2Fcb200263q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Metabolism-Guided Drug Design</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1039/c2md20317k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1039%2Fc2md20317k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslWmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=631-652&author=A.+F.+Stepanauthor=V.+Mascittiauthor=K.+Beaumontauthor=A.+S.+Kalgutkar&title=Metabolism-Guided+Drug+Design&doi=10.1039%2Fc2md20317k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-guided drug design</span></div><div class="casAuthors">Stepan, Antonia F.; Mascitti, Vincent; Beaumont, Kevin; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">631-652</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Preclin. drug metab. studies play a key role in the lead identification and optimization process in drug discovery.  Characterization of the metabolic pathways of new chem. entities is an integral part of drug discovery not only in optimizing clearance properties but also in eliminating potential safety concerns assocd. with the formation of protein and/or DNA-reactive metabolites.  Metab. studies in early discovery have been used to identify metabolic soft spots leading to high metabolic instability, and also in the characterization of active metabolites.  Availability of such information has aided in the rational design of compds. with increased resistance to metab. and overall improvements in oral pharmacokinetics and dose size.  Mechanistic drug metab. studies have proven particularly invaluable in mitigating reactive metabolite risks, which can lead to mutagenicity, time-dependent inactivation of cytochrome P 450 enzymes and/or idiosyncratic adverse drug reactions.  Characterization of stable conjugates derived from bioactivation of small mol. drug candidates provides indirect information on the structure of the reactive metabolite species, thereby providing insight into the bioactivation mechanism and hence a rationale on which to base subsequent chem. intervention strategies.  This review will showcase case studies of metab.-guided drug design using literature and inhouse examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcMOKNkXIUL7Vg90H21EOLACvtfcHk0li6HHoG8CbL7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslWmur0%253D&md5=61c667aa6f5c24de3fe110f384f323bd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc2md20317k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20317k%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMetabolism-Guided%2520Drug%2520Design%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D631%26epage%3D652%26doi%3D10.1039%2Fc2md20317k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahorski, S. R.</span></span> <span> </span><span class="NLM_article-title">Modulation by μ-Opioid Agonists of Guanosine-5′-O-(3-[35S]Thio)Triphosphate Binding to Membranes from Human Neuroblastoma SH-SY5Y Cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">848</span>– <span class="NLM_lpage">854</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=7723747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK2MXltFSlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1995&pages=848-854&author=J.+R.+Traynorauthor=S.+R.+Nahorski&title=Modulation+by+%CE%BC-Opioid+Agonists+of+Guanosine-5%E2%80%B2-O-%283-%5B35S%5DThio%29Triphosphate+Binding+to+Membranes+from+Human+Neuroblastoma+SH-SY5Y+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation by μ-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells</span></div><div class="casAuthors">Traynor, John R.; Nahorski, Stefan R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">848-54</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The ability of μ-opioid agonists to activate G proteins has been demonstrated by studying the binding of the GTP analog guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) to membranes from the human neuroblastoma SH-SY5Y cell line.  The potent opioid agonist fentanyl caused an approx. doubling of basal [35S]GTPγS binding in a naloxone-sensitive manner, confirming this to be an opioid receptor-mediated process.  The presence of GDP was necessary to observe this effect.  Pretreatment of the cells with pertussis toxin (100 ng/mL, for 24 h) completely prevented the fentanyl-stimulated increase in [35S]GTPγS binding and lowered the basal binding of [35S]GTPγS.  These latter data suggest an involvement of Gi and/or Go proteins and their activation by added membrane-bound receptors even in the absence of agonist.  The order of potency of a series of opioid agonists in stimulating the binding of [35S]GTPγS was buprenorphine > cyclazocine = levallorphan > nalorphine > [D-Alan2,MePhe4,Gly-ol5]enkephalin (DAMGO) > fentanyl > morphine > pentazocine.  DAMGO, fentanyl, and morphine were full agonists but the remaining compds. showed decreasing levels of intrinsic activity in the order buprenorphine > pentazocine > cyclazocine = nalorphine > levallorphan.  The opioid antagonist naloxone was without effect.  Under the conditions of the [35S]GTPγS assay, binding of agonists was to a high affinity site, indicating that a high agonist affinity state of the μ-opioid receptor is responsible for the obsd. stimulation of [35S]GTPγS binding.  The level of [35S]GTPγS binding (597 fmol/mg of protein) stimulated by DAMGO was 2-fold greater than the maximal no. of μ-opioid agonist binding sites (Bmax) detd. using [3H]DAMGO (254 fmol/mg of protein).  The opioid agonist-mediated stimulation of [35S]GTPγS binding in SH-SY5Y cell membranes thus provides a "functional" measure of agonist occupation of μ-opioid receptors and offers a simple method for the detn. of efficacy and intrinsic activity of μ-opioid agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFfWit9khK9LVg90H21EOLACvtfcHk0li6HHoG8CbL7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltFSlurw%253D&md5=b9bf6e344ab72e114c58ed47919af065</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DNahorski%26aufirst%3DS.%2BR.%26atitle%3DModulation%2520by%2520%25CE%25BC-Opioid%2520Agonists%2520of%2520Guanosine-5%25E2%2580%25B2-O-%25283-%255B35S%255DThio%2529Triphosphate%2520Binding%2520to%2520Membranes%2520from%2520Human%2520Neuroblastoma%2520SH-SY5Y%2520Cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D47%26spage%3D848%26epage%3D854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sean Henry, Jessica P. Anand, Ashley C. Brinkel, Douglas M. McMillan, Jack. J. Twarozynski, Christian E. Loo, John R. Traynor, <span class="NLM_string-name hlFld-ContribAuthor">Henry I. Mosberg</span>. </span><span class="cited-content_cbyCitation_article-title">SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 216-233. <a href="https://doi.org/10.1021/acschemneuro.0c00693" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00693%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DSAR%252BMatrices%252BEnable%252BDiscovery%252Bof%252BMixed%252BEfficacy%252B%2525CE%2525BC-Opioid%252BReceptor%252BAgonist%252BPeptidomimetics%252Bwith%252BSimplified%252BStructures%252Bthrough%252Ban%252BAromatic-Amine%252BPharmacophore%26aulast%3DHenry%26aufirst%3DSean%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26102020%26date%3D03122020%26date%3D21122020%26volume%3D12%26issue%3D1%26spage%3D216%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean Henry, Jessica P. Anand, Jack J. Twarozynski, Ashley C. Brinkel, Irina D. Pogozheva, Bryan F. Sears, Emily M. Jutkiewicz, John R. Traynor, <span class="NLM_string-name hlFld-ContribAuthor">Henry I. Mosberg</span>. </span><span class="cited-content_cbyCitation_article-title">Aromatic–Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (4)
                                     , 1671-1683. <a href="https://doi.org/10.1021/acs.jmedchem.9b01818" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01818</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01818%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAromatic%2525E2%252580%252593Amine%252BPendants%252BProduce%252BHighly%252BPotent%252Band%252BEfficacious%252BMixed%252BEfficacy%252B%2525CE%2525BC-Opioid%252BReceptor%252B%252528MOR%252529%25252F%2525CE%2525B4-Opioid%252BReceptor%252B%252528DOR%252529%252BPeptidomimetics%252Bwith%252BEnhanced%252BMetabolic%252BStability%26aulast%3DHenry%26aufirst%3DSean%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D05112019%26date%3D10022020%26date%3D27012020%26volume%3D63%26issue%3D4%26spage%3D1671%26epage%3D1683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard J.  Bodnar</span>. </span><span class="cited-content_cbyCitation_article-title">Endogenous opiates and behavior: 2019. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2021,</strong> <em>141 </em>, 170547. <a href="https://doi.org/10.1016/j.peptides.2021.170547" title="DOI URL">https://doi.org/10.1016/j.peptides.2021.170547</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2021.170547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2021.170547%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DEndogenous%252Bopiates%252Band%252Bbehavior%25253A%252B2019%26aulast%3DBodnar%26aufirst%3DRichard%2BJ.%26date%3D2021%26volume%3D141%26spage%3D170547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karol  Wtorek</span>, <span class="hlFld-ContribAuthor ">Justyna  Piekielna-Ciesielska</span>, <span class="hlFld-ContribAuthor ">Tomasz  Janecki</span>, <span class="hlFld-ContribAuthor ">Anna  Janecka</span>. </span><span class="cited-content_cbyCitation_article-title">The search for opioid analgesics with limited tolerance liability. </span><span class="cited-content_cbyCitation_journal-name">Peptides</span><span> <strong>2020,</strong> <em>130 </em>, 170331. <a href="https://doi.org/10.1016/j.peptides.2020.170331" title="DOI URL">https://doi.org/10.1016/j.peptides.2020.170331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.peptides.2020.170331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.peptides.2020.170331%26sid%3Dliteratum%253Aachs%26jtitle%3DPeptides%26atitle%3DThe%252Bsearch%252Bfor%252Bopioid%252Banalgesics%252Bwith%252Blimited%252Btolerance%252Bliability%26aulast%3DWtorek%26aufirst%3DKarol%26date%3D2020%26volume%3D130%26spage%3D170331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deanna  Montgomery</span>, <span class="hlFld-ContribAuthor ">Jessica P.  Anand</span>, <span class="hlFld-ContribAuthor ">Mason A.  Baber</span>, <span class="hlFld-ContribAuthor ">Jack J.  Twarozynski</span>, <span class="hlFld-ContribAuthor ">Joshua G.  Hartman</span>, <span class="hlFld-ContribAuthor ">Lennon J.  Delong</span>, <span class="hlFld-ContribAuthor ">John R.  Traynor</span>, <span class="hlFld-ContribAuthor ">Henry I.  Mosberg</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid Peptidomimetics. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (23)
                                     , 4302. <a href="https://doi.org/10.3390/molecules24234302" title="DOI URL">https://doi.org/10.3390/molecules24234302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24234302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24234302%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252B7-Substituted%252BDimethyltyrosine-Tetrahydroisoquinoline%252BOpioid%252BPeptidomimetics%26aulast%3DMontgomery%26aufirst%3DDeanna%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D23%26spage%3D4302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Notable structures that exhibit a MOR-agonist/DOR-antagonist profile. Some of these compounds utilize the morphinan scaffold shared by many opioids (A) or are a derivative of kratom alkaloids (B), whereas others are derived from endomorphins (C) or cyclic opioid peptides (D).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Pharmacophore and linker elements of our peptidomimetic lead.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19,21)</a> The pharmacophore elements include 2′,6′-dimethyltyrosine and benzyl pendants that are sensitive to modification, and the linker consists of a tetrahydroquinoline (THQ) core. (B) New analogues lacking the THQ core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/medium/jm-2019-00219t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Substituted Monocyclic-Core Analogues <b>5a</b>–<b>p</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-8/acs.jmedchem.9b00219/20190418/images/large/jm-2019-00219t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00219&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(A) 1. (<i>R</i>)-(+)-2-methyl-propane-2-sulfinamide, Ti(OEt)<sub>4</sub>, tetrahydrofuran (THF), 75 °C. 2. NaBH<sub>4</sub>. (B) BnBPin, K<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl<sub>2</sub>, 3:1 acetone/water, 80–100 °C. (C) HCl conc., dioxane. (D) 1. <i>N</i>-Boc-<i>O</i>-Boc-2′,6′-dimethyl-<span class="smallcaps smallerCapital">l</span>-tyrosine (DiBocDMT), <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA), PyBOP, 6-chloro-1-hydroxybenzotriazole (6-Cl-HOBt), dimethylformamide (DMF). 2. TFA, dichloromethane (DCM). (E) Neat acyl anhydride, 100 °C. (F) MeI or Alk-Br, K<sub>2</sub>CO<sub>3</sub>, DMF. (G) BBr<sub>3</sub>, DCM. (H) BH<sub>3</sub>*Me<sub>2</sub>S, THF, 75 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i106">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40283" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40283" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fundytus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weltrowska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, T. J.</span></span> <span> </span><span class="NLM_article-title">Attenuation of Morphine Tolerance and Dependence with the Highly Selective δ-Opioid Receptor Antagonist TIPP[Ψ]</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00554-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2F0014-2999%2895%2900554-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=8566146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK2MXpt1alu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1995&pages=105-108&author=M.+E.+Fundytusauthor=P.+W.+Schillerauthor=M.+Shapiroauthor=G.+Weltrowskaauthor=T.+J.+Coderre&title=Attenuation+of+Morphine+Tolerance+and+Dependence+with+the+Highly+Selective+%CE%B4-Opioid+Receptor+Antagonist+TIPP%5B%CE%A8%5D&doi=10.1016%2F0014-2999%2895%2900554-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ]</span></div><div class="casAuthors">Fundytus, Marian E.; Schiller, Peter W.; Shapiro, Michelle; Weltrowska, Grazyna; Coderre, Terence J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-8</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We examd. the effects of i.c.v. treatment with naltrindole, and the two highly selective peptide δ-opioid receptor antagonists H-Tyr-Tic-Phe-Phe-OH (TIPP) and H-Tyr-Ticψ[CH2-NH]-Phe-Phe-OH (TIPP[ψ]), on the development of morphine tolerance and dependence.  Each treatment significantly decreased naloxone-pptd. withdrawal, with TIPP[ψ] reducing the most symptoms.  TIPP[ψ], but neither naltrindole nor TIPP, attenuated the development of analgesic tolerance in the tail-flick test.  These results suggest that δ-opioid receptors are critically involved in the development of morphine tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDvwID-eMcdrVg90H21EOLACvtfcHk0lhzaRxl7kbywA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpt1alu7s%253D&md5=22ac2008dc965f1d08828e737ef4f9fd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900554-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900554-x%26sid%3Dliteratum%253Aachs%26aulast%3DFundytus%26aufirst%3DM.%2BE.%26aulast%3DSchiller%26aufirst%3DP.%2BW.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DWeltrowska%26aufirst%3DG.%26aulast%3DCoderre%26aufirst%3DT.%2BJ.%26atitle%3DAttenuation%2520of%2520Morphine%2520Tolerance%2520and%2520Dependence%2520with%2520the%2520Highly%2520Selective%2520%25CE%25B4-Opioid%2520Receptor%2520Antagonist%2520TIPP%255B%25CE%25A8%255D%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D286%26spage%3D105%26epage%3D108%26doi%3D10.1016%2F0014-2999%2895%2900554-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemori, A. E.</span></span> <span> </span><span class="NLM_article-title">Selective Blockage of Delta Opioid Receptors Prevents the Development of Morphine Tolerance and Dependence in Mice</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>258</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1649297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1Krur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1991&pages=299-303&author=E.+E.+Abdelhamidauthor=M.+Sultanaauthor=P.+S.+Portogheseauthor=A.+E.+Takemori&title=Selective+Blockage+of+Delta+Opioid+Receptors+Prevents+the+Development+of+Morphine+Tolerance+and+Dependence+in+Mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice</span></div><div class="casAuthors">Abdelhamid, Essam E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">299-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The authors have demonstrated that delta opioid binding sites are involved in the development or morphine tolerance and dependence.  Here, the effect of the potent and selective delta antagonist, naltrindole (NTI), and its nonequil. analog, naltrindole 5'-isothiocyanate (5'-NTII), on the development of morphine tolerance and dependence was studied in mice.  The development of acute tolerance and dependence was suppressed markedly in mice pretreated with NTI before induction of tolerance and dependence with 100 mg/kg of morphine sulfate.  Multiple administration of either NTI or 5'-NTII before and during implantation with morphine base pellets also inhibited substantially the development of morphine tolerance and dependence.  The effects of NTI and 5'-NTI on these two adaptive phenomena were thought to occur solely by blockage of delta opioid receptors because the activity of the selective mu opioid receptor agonist, [D-Ala2,MePhe4,Gly-ol5] enkephalin was unaffected by the two antagonists.  It was concluded that delta, as well as mu, opioid receptors play key roles in the development of opiate tolerance and phys. dependence.  Also the use of these delta opioid receptor antagonists allows a way to prevent opiate tolerance and phys. dependence without compromising the antinociceptive activity of mu opioid receptor agonists such as morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-Im8RmjOzL7Vg90H21EOLACvtfcHk0lhzaRxl7kbywA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1Krur4%253D&md5=409e1d8fb5cefb48af6cc3a76c0be471</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelhamid%26aufirst%3DE.%2BE.%26aulast%3DSultana%26aufirst%3DM.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26aulast%3DTakemori%26aufirst%3DA.%2BE.%26atitle%3DSelective%2520Blockage%2520of%2520Delta%2520Opioid%2520Receptors%2520Prevents%2520the%2520Development%2520of%2520Morphine%2520Tolerance%2520and%2520Dependence%2520in%2520Mice%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1991%26volume%3D258%26spage%3D299%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hepburn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, C. M.</span></span> <span> </span><span class="NLM_article-title">Differential Effects of Naltrindole on Morphine-Induced Tolerance and Physical Dependence in Rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=9190871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK2sXktVOjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1997&pages=1350-1356&author=M.+J.+Hepburnauthor=P.+J.+Littleauthor=J.+Gingrasauthor=C.+M.+Kuhn&title=Differential+Effects+of+Naltrindole+on+Morphine-Induced+Tolerance+and+Physical+Dependence+in+Rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats</span></div><div class="casAuthors">Hepburn, Matthew J.; Little, Patrick J.; Gingras, Jeanine; Kuhn, Cynthia M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1350-1356</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">This study investigated the effect of delta opioid receptor blockade by naltrindole on the development of phys. dependence and tolerance to the antinociceptive and respiratory depressive effects of morphine in rats.  Chronic morphine was delivered either by s.c. injection of increasing amts. of morphine over 5 days or by s.c. implantation of morphine pellets.  Animals were cotreated with saline or naltrindole.  Antinociception and respiratory depression were assessed after administration of a challenge dose or morphine, and withdrawal signs were detd. after naloxone challenge.  Naltrindole significantly attenuated the development of antinociceptive tolerance after all three chronic treatment regimens.  In addn., rats pretreated with naltrindole displayed significantly fewer withdrawal symptoms and less wt. loss after a naloxone challenge.  In contrast, naltrindole did not prevent the development of tolerance to morphine-induced respiratory depression.  These results imply that tolerance to antinociception and phys. dependence involves adaptations at interacting mu and delta receptor populations, whereas tolerance to respiratory depression reflects actions of independent mu and delta receptor populations.  These findings suggest that delta antagonists may have potential clin. application for decreasing the rapid development of tolerance to opiate-induced analgesia, while allowing for the development of protective tolerance to respiratory depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrymhDNZsyuLrVg90H21EOLACvtfcHk0lhzaRxl7kbywA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktVOjtbw%253D&md5=c715220a88c223a89599ca52167fca85</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHepburn%26aufirst%3DM.%2BJ.%26aulast%3DLittle%26aufirst%3DP.%2BJ.%26aulast%3DGingras%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DC.%2BM.%26atitle%3DDifferential%2520Effects%2520of%2520Naltrindole%2520on%2520Morphine-Induced%2520Tolerance%2520and%2520Physical%2520Dependence%2520in%2520Rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D281%26spage%3D1350%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuller, A. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsche, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reidl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elde, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unterwald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pintar, J. E.</span></span> <span> </span><span class="NLM_article-title">Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(00)80836-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2FS0896-6273%2800%2980836-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10677041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVOrs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1999&pages=243-252&author=Y.+Zhuauthor=M.+A.+Kingauthor=A.+G.+P.+Schullerauthor=J.+F.+Nitscheauthor=M.+Reidlauthor=R.+P.+Eldeauthor=E.+Unterwaldauthor=G.+W.+Pasternakauthor=J.+E.+Pintar&title=Retention+of+Supraspinal+Delta-like+Analgesia+and+Loss+of+Morphine+Tolerance+in+%CE%B4+Opioid+Receptor+Knockout+Mice&doi=10.1016%2FS0896-6273%2800%2980836-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice</span></div><div class="casAuthors">Zhu, Yanxin; King, Michael A.; Schuller, Alwin G. P.; Nitsche, Joshua F.; Reidl, Maureen; Elde, Robert P.; Unterwald, Ellen; Pasternak, Gavril W.; Pintar, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">243-252</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Gene targeting was used to delete exon 2 of mouse DOR-1, which encodes the δ opioid receptor.  Essentially all 3H-[D-Pen2,D-Pen5]enkephalin (3H-DPDPE) and 3H-[D-Ala2,D-Glu4]deltorphin (3H-deltorphin-2) binding is absent from mutant mice, demonstrating that DOR-1 encodes both δ1 and δ2 receptor subtypes.  Homozygous mutant mice display markedly reduced spinal δ analgesia, but peptide δ agonists retain supraspinal analgesic potency that is only partially antagonized by naltrindole.  Retained DPDPE analgesia is also demonstrated upon formalin testing, while the nonpeptide δ agonist BW373U69 exhibits enhanced activity in DOR-1 mutant mice.  Together, these findings suggest the existence of a second delta-like analgesic system.  Finally, DOR-1 mutant mice do not develop analgesic tolerance to morphine, genetically demonstrating a central role for DOR-1 in this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg3m-zg3QH0LVg90H21EOLACvtfcHk0li55lkXCxWXkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVOrs7g%253D&md5=a5035feaf6e63a8abeb8c18df0a32933</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2800%2980836-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252800%252980836-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DKing%26aufirst%3DM.%2BA.%26aulast%3DSchuller%26aufirst%3DA.%2BG.%2BP.%26aulast%3DNitsche%26aufirst%3DJ.%2BF.%26aulast%3DReidl%26aufirst%3DM.%26aulast%3DElde%26aufirst%3DR.%2BP.%26aulast%3DUnterwald%26aufirst%3DE.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DPintar%26aufirst%3DJ.%2BE.%26atitle%3DRetention%2520of%2520Supraspinal%2520Delta-like%2520Analgesia%2520and%2520Loss%2520of%2520Morphine%2520Tolerance%2520in%2520%25CE%25B4%2520Opioid%2520Receptor%2520Knockout%2520Mice%26jtitle%3DNeuron%26date%3D1999%26volume%3D24%26spage%3D243%26epage%3D252%26doi%3D10.1016%2FS0896-6273%2800%2980836-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLemore, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inturrisi, C. E.</span></span> <span> </span><span class="NLM_article-title">An Antisense Oligodeoxynucleotide to the Delta Opioid Receptor (DOR-1) Inhibits Morphine Tolerance and Acute Dependence in Mice</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1016/0361-9230(95)02092-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2F0361-9230%2895%2902092-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=8866695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK28Xhslantbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=185-188&author=B.+Kestauthor=C.+E.+Leeauthor=G.+L.+McLemoreauthor=C.+E.+Inturrisi&title=An+Antisense+Oligodeoxynucleotide+to+the+Delta+Opioid+Receptor+%28DOR-1%29+Inhibits+Morphine+Tolerance+and+Acute+Dependence+in+Mice&doi=10.1016%2F0361-9230%2895%2902092-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice</span></div><div class="casAuthors">Kest, Benjamin; Lee, Cynthia E.; McLemore, Gabrielle L.; Inturrisi, Charles E.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-8</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pharmacol. data from several labs. support a modulatory role for the delta opioid receptor in morphine analgesia, tolerance, and phys. dependence.  We examd. the role of the delta opioid receptor in these processes using an in vivo antisense strategy in mice.  Intracerebroventricular administration of a 20mer antisense or a mismatch control oligodeoxynucleotide (ODN) targeting the mRNA of the cloned delta opioid receptor (DOR-1) for 3 days did not affect baseline nociceptive thresholds or morphine analgesia compared to untreated or saline-treated mice.  However, dose-response studies indicate that the induction of morphine tolerance following 3 days of chronic morphine administration was blocked in antisense but not mismatch ODN or saline-treated mice.  Antisense ODN treatment also blocked the development of acute morphine dependence, whereas similar protection was not afforded to mice treated with saline or mismatch ODN.  This study demonstrates the relevance of the cloned DOR-1 in morphine tolerance and dependence and provides new evidence for a modulatory role of the delta opioid receptor using this novel approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplCmyzeBkmtrVg90H21EOLACvtfcHk0li55lkXCxWXkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xhslantbg%253D&md5=4f4518ac59f478bb6605bdb2911d0996</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0361-9230%2895%2902092-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0361-9230%252895%252902092-6%26sid%3Dliteratum%253Aachs%26aulast%3DKest%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DC.%2BE.%26aulast%3DMcLemore%26aufirst%3DG.%2BL.%26aulast%3DInturrisi%26aufirst%3DC.%2BE.%26atitle%3DAn%2520Antisense%2520Oligodeoxynucleotide%2520to%2520the%2520Delta%2520Opioid%2520Receptor%2520%2528DOR-1%2529%2520Inhibits%2520Morphine%2520Tolerance%2520and%2520Acute%2520Dependence%2520in%2520Mice%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D1996%26volume%3D39%26spage%3D185%26epage%3D188%26doi%3D10.1016%2F0361-9230%2895%2902092-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turnaturi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aricò, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsisvalle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquinucci, L.</span></span> <span> </span><span class="NLM_article-title">Multitarget Opioid Ligands in Pain Relief: New Players in an Old Game</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.ejmech.2015.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=26656913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=211-228&author=R.+Turnaturiauthor=G.+Aric%C3%B2author=G.+Ronsisvalleauthor=C.+Parentiauthor=L.+Pasquinucci&title=Multitarget+Opioid+Ligands+in+Pain+Relief%3A+New+Players+in+an+Old+Game&doi=10.1016%2Fj.ejmech.2015.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget opioid ligands in pain relief: New players in an old game</span></div><div class="casAuthors">Turnaturi, Rita; Arico, Giuseppina; Ronsisvalle, Giuseppe; Parenti, Carmela; Pasquinucci, Lorella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-228</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Still nowadays pain is one of the most common disabling conditions and yet it remains too often unsolved.  Analgesic opioid drugs, and mainly MOR agonists such as morphine, are broadly employed for pain management.  MOR activation, however, has been seen to cause not only analgesia but also undesired side effects.  A potential pain treatment option is represented by the simultaneous targeting of different opioid receptors.  In fact, ligands possessing multitarget capabilities led to an improved pharmacol. fingerprint.  This review focuses on the examn. of multitarget opioid ligands which have been distinguished in peptide and non-peptide and further listed as bivalent and bifunctional ligands.  Moreover, the potential of these compds., both as analgesic drugs and pharmacol. tools to explore heteromer receptors, has been stressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp1KgfVHTj67Vg90H21EOLACvtfcHk0li55lkXCxWXkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmsrrN&md5=49fa91877cdaa733f7ec58d5e80a3869</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DTurnaturi%26aufirst%3DR.%26aulast%3DAric%25C3%25B2%26aufirst%3DG.%26aulast%3DRonsisvalle%26aufirst%3DG.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DPasquinucci%26aufirst%3DL.%26atitle%3DMultitarget%2520Opioid%2520Ligands%2520in%2520Pain%2520Relief%253A%2520New%2520Players%2520in%2520an%2520Old%2520Game%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D211%26epage%3D228%26doi%3D10.1016%2Fj.ejmech.2015.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span> <span> </span><span class="NLM_article-title">Opioid Ligands with Mixed Mu/Delta Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">E118</span>– <span class="NLM_lpage">E125</span>, <span class="refDoi"> DOI: 10.1208/aapsj080114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1208%2Faapsj080114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=16584118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Kks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=E118-E125&author=S.+Ananthan&title=Opioid+Ligands+with+Mixed+Mu%2FDelta+Opioid+Receptor+Interactions%3A+An+Emerging+Approach+to+Novel+Analgesics&doi=10.1208%2Faapsj080114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid ligands with mixed μ/δ opioid receptor interactions: an emerging approach to novel analgesics</span></div><div class="casAuthors">Ananthan, Subramaniam</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">E118-E125</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">American Association of Pharmaceutical Scientists</span>)
        </div><div class="casAbstract">A review.  Opioids are widely used in the treatment of severe pain.  The clin. use of the opioids is limited by serious side effects such as respiratory depression, constipation, development of tolerance, and phys. dependence and addiction liabilities.  Most of the currently available opioid analgesics exert their analgesic and adverse effects primarily through the opioid μ receptors.  A large no. of biochem. and pharmacol. studies and studies using genetically modified animals have provided convincing evidence regarding the existence of modulatory interactions between opioid μ and δ receptors.  Several studies indicate that δ receptor agonists as well as δ receptor antagonists can provide beneficial modulation to the pharmacol. effects of μ agonists.  For example, δ agonists can enhance the analgesic potency and efficacy of μ agonists, and δ antagonists can prevent or diminish the development of tolerance and phys. dependence by μ agonists.  On the basis of these observations, the development of new opioid ligands possessing mixed μ agonist/δ agonist profile and mixed μ agonist/δ antagonist profile has emerged as a promising new approach to analgesic drug development.  A brief overview of μ-δ interactions and recent developments in identification of ligands possessing mixed μ agonist/δ agonist and μ agonist/δ antagonist activities is provided in this report.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpflBGd3S9H8LVg90H21EOLACvtfcHk0lj3ShlBgjfa_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Kks7s%253D&md5=442aca3a525b3775cc0d1d62d196f482</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1208%2Faapsj080114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Faapsj080114%26sid%3Dliteratum%253Aachs%26aulast%3DAnanthan%26aufirst%3DS.%26atitle%3DOpioid%2520Ligands%2520with%2520Mixed%2520Mu%252FDelta%2520Opioid%2520Receptor%2520Interactions%253A%2520An%2520Emerging%2520Approach%2520to%2520Novel%2520Analgesics%26jtitle%3DAAPS%2520J.%26date%3D2006%26volume%3D8%26spage%3DE118%26epage%3DE125%26doi%3D10.1208%2Faapsj080114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsky, E. J.</span></span> <span> </span><span class="NLM_article-title">In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid Mu-Agonist/Delta-Antagonist That Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">605</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=11303048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1WlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2001&pages=597-605&author=J.+L.+Wellsauthor=J.+L.+Bartlettauthor=S.+Ananthanauthor=E.+J.+Bilsky&title=In+Vivo+Pharmacological+Characterization+of+SoRI+9409%2C+a+Nonpeptidic+Opioid+Mu-Agonist%2FDelta-Antagonist+That+Produces+Limited+Antinociceptive+Tolerance+and+Attenuates+Morphine+Physical+Dependence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid μ-agonist/δ-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence</span></div><div class="casAuthors">Wells, Jennifer L.; Bartlett, Jeffrey L.; Ananthan, Subramaniam; Bilsky, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">597-605</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Repeated exposure to μ-opioid analgesics produces unwanted side effects, including tolerance and phys. dependence.  δ-Opioid antagonists attenuate development of morphine tolerance and phys. dependence.  We recently reported that SoRI 9409, a mixed μ-agonist/δ-antagonist, produces antinociception with limited development of tolerance after repeated i.c.v. injections.  The current studies report on a more complete characterization of the compd. in male ICR mice.  SoRI 9409 produced limited antinociceptive effects in the 55 tail-flick test and full agonist effects in the acetic acid writhing assay after i.c.v. or i.p. administration.  Repeated i.p. administration of A90 doses of SoRI 9409 did not produce tolerance.  The agonist effects of the compd. were preferentially blocked by the μ-selective antagonist β-funaltrexamine.  The κ-antagonist norbinaltorphimine produced partial antagonism, whereas the δ-antagonist naltrindole had no effect on SoRI 9409 antinociception.  I.p. administration of SoRI 9409 preferentially antagonized the antinociceptive actions of the δ-2 agonist [D-Ala2,Glu4]deltorphin over the δ-1 agonist cyclic[D-Pen2,D-Pen5]-enkephalin and the μ-agonist [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin.  SoRI 9409 did not antagonize the antinociceptive effects of the κ-agonist U69,593 (doses up to 60 mg/kg).  SoRI 9409 (10 mg/kg i.p.) elicited much less vertical jumping than naloxone (10 mg/kg i.p.) in acute and chronic morphine dependence models.  SoRI 9409 also suppressed withdrawal jumping when coadministered with naloxone.  These studies indicate that SoRI 9409 acts primarily as a partial μ-agonist/δ-antagonist and supports the hypothesis that this type of compd. may have a better therapeutic profile than currently available μ-agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3w8nDeq53rVg90H21EOLACvtfcHk0lj3ShlBgjfa_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1WlsLk%253D&md5=0f816d8d7d2973e143c74c2dab4cf9e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DJ.%2BL.%26aulast%3DBartlett%26aufirst%3DJ.%2BL.%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DBilsky%26aufirst%3DE.%2BJ.%26atitle%3DIn%2520Vivo%2520Pharmacological%2520Characterization%2520of%2520SoRI%25209409%252C%2520a%2520Nonpeptidic%2520Opioid%2520Mu-Agonist%252FDelta-Antagonist%2520That%2520Produces%2520Limited%2520Antinociceptive%2520Tolerance%2520and%2520Attenuates%2520Morphine%2520Physical%2520Dependence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D297%26spage%3D597%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Healy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezawada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1266</span>, <span class="refDoi"> DOI: 10.1021/cn4000428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn4000428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1256-1266&author=J.+R.+Healyauthor=P.+Bezawadaauthor=J.+Shimauthor=J.+W.+Jonesauthor=M.+A.+Kaneauthor=A.+D.+MacKerellauthor=A.+Coopauthor=R.+R.+Matsumoto&title=Synthesis%2C+Modeling%2C+and+Pharmacological+Evaluation+of+UMB+425%2C+a+Mixed+%CE%BC+Agonist%2F%CE%B4+Antagonist+Opioid+Analgesic+with+Reduced+Tolerance+Liabilities&doi=10.1021%2Fcn4000428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span></div><div class="casAuthors">Healy, Jason R.; Bezawada, Padmavani; Shim, Jihyun; Jones, Jace W.; Kane, Maureen A.; MacKerell, Alexander D.; Coop, Andrew; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1256-1266</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid narcotics are used for the treatment of moderate-to-severe pain and primarily exert their analgesic effects through μ receptors.  Although traditional μ agonists can cause undesired side effects, including tolerance, addn. of δ antagonists can attenuate said side effects.  Herein, the authors report 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor synthesized from thebaine.  Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compd. sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols.  As predicted, UMB 425 exhibits a mixed μ agonist/δ antagonist profile as detd. in receptor binding and [35S]GTPγS functional assays in CHO cells.  In vivo studies in mice show that UMB 425 displays potent antinociception in the hot plate and tail-flick assays.  The antinociceptive effects of UMB 425 are blocked by naloxone, but not by the κ-selective antagonist norbinaltorphimine.  During a 6-day tolerance paradigm, UMB 425 maintains significantly greater antinociception compared to morphine.  These studies thus indicate that, even in the absence of δ-specific motifs fused to the C-ring, UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6OgV4pm0lbVg90H21EOLACvtfcHk0lj3ShlBgjfa_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D&md5=6949bbfec033537662cfa64b7d281df5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fcn4000428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn4000428%26sid%3Dliteratum%253Aachs%26aulast%3DHealy%26aufirst%3DJ.%2BR.%26aulast%3DBezawada%26aufirst%3DP.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%2BW.%26aulast%3DKane%26aufirst%3DM.%2BA.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DCoop%26aufirst%3DA.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSynthesis%252C%2520Modeling%252C%2520and%2520Pharmacological%2520Evaluation%2520of%2520UMB%2520425%252C%2520a%2520Mixed%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520Opioid%2520Analgesic%2520with%2520Reduced%2520Tolerance%2520Liabilities%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D1256%26epage%3D1266%26doi%3D10.1021%2Fcn4000428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dersch, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuvelis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsky, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span> <span> </span><span class="NLM_article-title">14-Alkoxy-and 14-Acyloxypyridomorphinans: μ Agonist/δ Antagonist Opioid Analgesics with Diminished Tolerance and Dependence Side Effects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8350</span>– <span class="NLM_lpage">8363</span>, <span class="refDoi"> DOI: 10.1021/jm300686p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300686p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8350-8363&author=S.+Ananthanauthor=S.+K.+Sainiauthor=C.+M.+Derschauthor=H.+Xuauthor=N.+McGlincheyauthor=D.+Giuvelisauthor=E.+J.+Bilskyauthor=R.+B.+Rothman&title=14-Alkoxy-and+14-Acyloxypyridomorphinans%3A+%CE%BC+Agonist%2F%CE%B4+Antagonist+Opioid+Analgesics+with+Diminished+Tolerance+and+Dependence+Side+Effects&doi=10.1021%2Fjm300686p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm300686p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300686p%26sid%3Dliteratum%253Aachs%26aulast%3DAnanthan%26aufirst%3DS.%26aulast%3DSaini%26aufirst%3DS.%2BK.%26aulast%3DDersch%26aufirst%3DC.%2BM.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DMcGlinchey%26aufirst%3DN.%26aulast%3DGiuvelis%26aufirst%3DD.%26aulast%3DBilsky%26aufirst%3DE.%2BJ.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26atitle%3D14-Alkoxy-and%252014-Acyloxypyridomorphinans%253A%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520Opioid%2520Analgesics%2520with%2520Diminished%2520Tolerance%2520and%2520Dependence%2520Side%2520Effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8350%26epage%3D8363%26doi%3D10.1021%2Fjm300686p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Váradi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabó, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Rouzic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinnell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subrath, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunkele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagirsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eans, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borics, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span> <span> </span><span class="NLM_article-title">Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8381</span>– <span class="NLM_lpage">8397</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00748</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00748" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSkur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8381-8397&author=A.+V%C3%A1radiauthor=G.+F.+Marroneauthor=T.+C.+Palmerauthor=A.+Narayanauthor=M.+R.+Szab%C3%B3author=V.+Le+Rouzicauthor=S.+G.+Grinnellauthor=J.+J.+Subrathauthor=E.+Warnerauthor=S.+Kalraauthor=A.+Hunkeleauthor=J.+Pagirskyauthor=S.+O.+Eansauthor=J.+M.+Medinaauthor=J.+Xuauthor=Y.+Panauthor=A.+Boricsauthor=G.+W.+Pasternakauthor=J.+P.+McLaughlinauthor=S.+Majumdar&title=Mitragynine%2FCorynantheidine+Pseudoindoxyls+As+Opioid+Analgesics+with+Mu+Agonism+and+Delta+Antagonism%2C+Which+Do+Not+Recruit+%CE%B2-Arrestin-2&doi=10.1021%2Facs.jmedchem.6b00748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2</span></div><div class="casAuthors">Varadi, Andras; Marrone, Gina F.; Palmer, Travis C.; Narayan, Ankita; Szabo, Marton R.; Le Rouzic, Valerie; Grinnell, Steven G.; Subrath, Joan J.; Warner, Evelyn; Kalra, Sanjay; Hunkele, Amanda; Pagirsky, Jeremy; Eans, Shainnel O.; Medina, Jessica M.; Xu, Jin; Pan, Ying-Xian; Borics, Attila; Pasternak, Gavril W.; McLaughlin, Jay P.; Majumdar, Susruta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8381-8397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Natural products found in Mitragyna speciosa, commonly known as kratom, represent diverse scaffolds (indole, indolenine, and spiro pseudoindoxyl) with opioid activity, providing opportunities to better understand opioid pharmacol.  Herein, we report the pharmacol. and SAR studies both in vitro and in vivo of mitragynine pseudoindoxyl (3), an oxidative rearrangement product of the corynanthe alkaloid mitragynine. 3 and its corresponding corynantheidine analogs show promise as potent analgesics with a mechanism of action that includes mu opioid receptor agonism/delta opioid receptor antagonism.  In vitro, 3 and its analogs were potent agonists in [35S]GTPγS assays at the mu opioid receptor but failed to recruit β-arrestin-2, which is assocd. with opioid side effects.  Addnl., 3 developed analgesic tolerance more slowly than morphine, showed limited phys. dependence, respiratory depression, constipation, and displayed no reward or aversion in CPP/CPA assays, suggesting that analogs might represent a promising new generation of novel pain relievers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhDBpzV7DBrVg90H21EOLACvtfcHk0lj2rX9CFZ174Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSkur3F&md5=92a429837190c339e26e8c55852a0b40</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00748%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25A1radi%26aufirst%3DA.%26aulast%3DMarrone%26aufirst%3DG.%2BF.%26aulast%3DPalmer%26aufirst%3DT.%2BC.%26aulast%3DNarayan%26aufirst%3DA.%26aulast%3DSzab%25C3%25B3%26aufirst%3DM.%2BR.%26aulast%3DLe%2BRouzic%26aufirst%3DV.%26aulast%3DGrinnell%26aufirst%3DS.%2BG.%26aulast%3DSubrath%26aufirst%3DJ.%2BJ.%26aulast%3DWarner%26aufirst%3DE.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DHunkele%26aufirst%3DA.%26aulast%3DPagirsky%26aufirst%3DJ.%26aulast%3DEans%26aufirst%3DS.%2BO.%26aulast%3DMedina%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DBorics%26aufirst%3DA.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DMajumdar%26aufirst%3DS.%26atitle%3DMitragynine%252FCorynantheidine%2520Pseudoindoxyls%2520As%2520Opioid%2520Analgesics%2520with%2520Mu%2520Agonism%2520and%2520Delta%2520Antagonism%252C%2520Which%2520Do%2520Not%2520Recruit%2520%25CE%25B2-Arrestin-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8381%26epage%3D8397%26doi%3D10.1021%2Facs.jmedchem.6b00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fundytus, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merovitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weltrowska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderre, T. J.</span></span> <span> </span><span class="NLM_article-title">The Opioid μ Agonist/δ Antagonist DIPP-NH<sub>2</sub>[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3520</span>– <span class="NLM_lpage">3526</span>, <span class="refDoi"> DOI: 10.1021/jm980724+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980724%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK1MXkvVCrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=3520-3526&author=P.+W.+Schillerauthor=M.+E.+Fundytusauthor=L.+Merovitzauthor=G.+Weltrowskaauthor=T.+M.+Nguyenauthor=C.+Lemieuxauthor=N.+N.+Chungauthor=T.+J.+Coderre&title=The+Opioid+%CE%BC+Agonist%2F%CE%B4+Antagonist+DIPP-NH2%5B%CE%A8%5D+Produces+a+Potent+Analgesic+Effect%2C+No+Physical+Dependence%2C+and+Less+Tolerance+than+Morphine+in+Rats&doi=10.1021%2Fjm980724%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Opioid μ Agonist/δ Antagonist DIPP-NH2[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats</span></div><div class="casAuthors">Schiller, Peter W.; Fundytus, Marian E.; Merovitz, Lisa; Weltrowska, Grazyna; Nguyen, Thi M.-D.; Lemieux, Carole; Chung, Nga N.; Coderre, Terence J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3520-3526</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid compds. with mixed μ agonist/δ antagonist properties are expected to be analgesics with low propensity to produce tolerance and dependence.  In an effort to strengthen the μ agonist component of the mixed μ agonist/δ antagonist H-Tyr-Tic-Phe-Phe-NH2 (TIPP-NH2), analogs contg. structurally modified tyrosine residues in place of Tyr1 were synthesized.  Among the prepd. compds., H-Dmt-Tic-Phe-Phe-NH2 (DIPP-NH2; Dmt = 2',6'-dimethyltyrosine) and H-Dmt-TicΨ[CH2NH]Phe-Phe-NH2 (DIPP-NH2[Ψ]) retained a mixed μ agonist/δ antagonist profile, as detd. in the guinea pig ileum and mouse vas deferens assays, whereas H-Tmt-Tic-Phe-Phe-NH2 (Tmt = N,2',6'-trimethyltyrosine) was a partial μ agonist/δ antagonist and H-Tmt-TicΨ[CH2NH]Phe-Phe-NH2 was a μ antagonist/δ antagonist.  DIPP-NH2[Ψ] showed binding affinities in the subnanomolar range for both μ and δ receptors in the rat brain membrane binding assays, thus representing the first example of a balanced μ agonist/δ antagonist with high potency.  In the rat tail flick test, DIPP-NH2[Ψ] given icv produced a potent analgesic effect (ED50 = 0.04 μg), being about 3 times more potent than morphine (ED50 = 0.11 μg).  It produced less acute tolerance than morphine but still a certain level of chronic tolerance.  Unlike morphine, DIPP-NH2[Ψ] produced no phys. dependence whatsoever upon chronic administration at high doses (≤4.5 μg/h) over a 7-day period.  In conclusion, DIPP-NH2[Ψ] fulfills to a large extent the expectations based on the mixed μ agonist/δ antagonist concept with regard to analgesic activity and the development of tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqNgWnqwZWJrVg90H21EOLACvtfcHk0lj2rX9CFZ174Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvVCrtL0%253D&md5=91c55724c7bc3530fe8eb00eed86855f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm980724%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980724%252B%26sid%3Dliteratum%253Aachs%26aulast%3DSchiller%26aufirst%3DP.%2BW.%26aulast%3DFundytus%26aufirst%3DM.%2BE.%26aulast%3DMerovitz%26aufirst%3DL.%26aulast%3DWeltrowska%26aufirst%3DG.%26aulast%3DNguyen%26aufirst%3DT.%2BM.%26aulast%3DLemieux%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DN.%2BN.%26aulast%3DCoderre%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520Opioid%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520DIPP-NH2%255B%25CE%25A8%255D%2520Produces%2520a%2520Potent%2520Analgesic%2520Effect%252C%2520No%2520Physical%2520Dependence%252C%2520and%2520Less%2520Tolerance%2520than%2520Morphine%2520in%2520Rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D3520%26epage%3D3526%26doi%3D10.1021%2Fjm980724%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochan, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nastase, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span> <span> </span><span class="NLM_article-title">In Vivo Effects of μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Peptidomimetics Following Acute and Repeated Administration</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.1111/bph.14148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1111%2Fbph.14148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=29352503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1Cru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2013-2027&author=J.+P.+Anandauthor=K.+E.+Kochanauthor=A.+F.+Nastaseauthor=D.+Montgomeryauthor=N.+W.+Griggsauthor=J.+R.+Traynorauthor=H.+I.+Mosbergauthor=E.+M.+Jutkiewicz&title=In+Vivo+Effects+of+%CE%BC+Opioid+Receptor+Agonist%2F%CE%B4+Opioid+Receptor+Antagonist+Peptidomimetics+Following+Acute+and+Repeated+Administration&doi=10.1111%2Fbph.14148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration</span></div><div class="casAuthors">Anand, Jessica P.; Kochan, Kelsey E.; Nastase, Anthony F.; Montgomery, Deanna; Griggs, Nicholas W.; Traynor, John R.; Mosberg, Henry I.; Jutkiewicz, Emily M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2013-2027</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Agonists at μ-opioid receptors (μ-receptors) are used for pain management but produce adverse effects including tolerance, dependence and euphoria.  The co-administration of a μ-receptor agonist with a δ-opioid receptor (δ-receptor) antagonist has been shown to produce antinociception with reduced development of some side effects.  We characterized the effects of three μ-receptor agonist/δ-receptor antagonist peptidomimetics in vivo after acute and repeated administration to det. if this profile provides a viable alternative to traditional opioid analgesics.  Three μ-receptor agonist / δ-receptor antagonist peptidomimetics, AAH8, AMB46 and AMB47, and morphine were evaluated for the development of tolerance and dependence after 5 days of twice daily treatment with escalating doses of drug (10-50 mg·kg-1).  Antinociceptive effects were measured in the warm water tail withdrawal assay before and after repeated drug treatment.  Phys. dependence was evaluated by naltrexone-pptd. withdrawal jumping.  The rewarding effects of AAH8 were evaluated using a conditioned place preference (CPP) assay with twice daily conditioning sessions performed for 5 days.  Morphine, AAH8, AMB47 and AMB46 all demonstrated acute antinociceptive effects, but repeated administration only produced tolerance in animals treated with morphine and AMB46.  Injection of naltrexone pptd. fewer jumps in mice treated repeatedly with AAH8 as compared with morphine, AMB47 or AMB46.  Conditioning with morphine, but not AAH8, produced significant CPP.  AAH8 may be a better alternative than traditional opioid analgesics, producing antinociception with less development of tolerance and dependence and may be less rewarding than morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruammciHxwYLVg90H21EOLACvtfcHk0li-smFsDkTGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1Cru70%253D&md5=6ad59ce996adbd8e4e76019e851e1ce5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fbph.14148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14148%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DKochan%26aufirst%3DK.%2BE.%26aulast%3DNastase%26aufirst%3DA.%2BF.%26aulast%3DMontgomery%26aufirst%3DD.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26atitle%3DIn%2520Vivo%2520Effects%2520of%2520%25CE%25BC%2520Opioid%2520Receptor%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520Antagonist%2520Peptidomimetics%2520Following%2520Acute%2520and%2520Repeated%2520Administration%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2013%26epage%3D2027%26doi%3D10.1111%2Fbph.14148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2549</span>– <span class="NLM_lpage">2557</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00284</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00284" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2549-2557&author=A.%0AA.+Harlandauthor=I.+D.+Pogozhevaauthor=N.+W.+Griggsauthor=T.+J.+Traskauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Placement+of+Hydroxy+Moiety+on+Pendant+of+Peptidomimetic+Scaffold+Modulates+Mu+and+Kappa+Opioid+Receptor+Efficacy&doi=10.1021%2Facschemneuro.7b00284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy</span></div><div class="casAuthors">Harland, Aubrie A.; Pogozheva, Irina D.; Griggs, Nicholas W.; Trask, Tyler J.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2549-2557</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In an effort to expand the structure-activity relationship (SAR) studies of a series of mixed-efficacy opioid ligands, peptidomimetics that incorporate methoxy and hydroxy groups around a benzyl or 2-methylindanyl pendant on a tetrahydroquinoline (THQ) core of the peptidomimetics were evaluated.  Compds. contg. a methoxy or hydroxy moiety in the o- or m-positions increased binding affinity to the kappa opioid receptor (KOR), whereas compds. contg. methoxy or hydroxy groups in the p-position decreased KOR affinity and reduced or eliminated efficacy at the mu opioid receptor (MOR).  The results from a substituted 2-methylindanyl series aligned with the findings from the substituted benzyl series.  Our studies culminated in the development of 8c, a mixed-efficacy MOR agonist/KOR agonist with subnanomolar binding affinity for both MOR and KOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3CcuOIk8jB7Vg90H21EOLACvtfcHk0li-smFsDkTGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitLvK&md5=58cba30862161dedd803cb284ec90c22</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00284%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DTrask%26aufirst%3DT.%2BJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DPlacement%2520of%2520Hydroxy%2520Moiety%2520on%2520Pendant%2520of%2520Peptidomimetic%2520Scaffold%2520Modulates%2520Mu%2520and%2520Kappa%2520Opioid%2520Receptor%2520Efficacy%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D2549%26epage%3D2557%26doi%3D10.1021%2Facschemneuro.7b00284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeomans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8952</span>– <span class="NLM_lpage">8969</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8952-8969&author=A.+A.+Harlandauthor=L.+Yeomansauthor=N.+W.+Griggsauthor=J.+P.+Anandauthor=I.+D.+Pogozhevaauthor=E.+M.+Jutkiewiczauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Further+Optimization+and+Evaluation+of+Bioavailable%2C+Mixed-Efficacy+%CE%BC-Opioid+Receptor+%28MOR%29+Agonists%2F%CE%B4-Opioid+Receptor+%28DOR%29+Antagonists%3A+Balancing+MOR+and+DOR+Affinities&doi=10.1021%2Facs.jmedchem.5b01270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities</span></div><div class="casAuthors">Harland, Aubrie A.; Yeomans, Larisa; Griggs, Nicholas W.; Anand, Jessica P.; Pogozheva, Irina D.; Jutkiewicz, Emily M.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8952-8969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a previously described peptidomimetic series, the authors reported the development of bifunctional μ-opioid receptor (MOR) agonist and δ-opioid receptor (DOR) antagonist ligands with a lead compd. that produced antinociception for 1 h after i.p. administration in mice.  In this paper, the authors expand on the original series by presenting two modifications, both of which were designed with the following objectives: (1) probing bioavailability and improving metabolic stability, (2) balancing affinities between MOR and DOR while reducing affinity and efficacy at the κ-opioid receptor (KOR), and (3) improving in vivo efficacy.  Here, the authors establish that, through N-acetylation of the original peptidomimetic series, the authors are able to improve DOR affinity and increase selectivity relative to KOR while maintaining the desired MOR agonist/DOR antagonist profile.  From initial in vivo studies, one compd. I was found to produce dose-dependent antinociception after peripheral administration with an improved duration of action of longer than 3 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1bP5LC-AXLVg90H21EOLACvtfcHk0li-smFsDkTGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmsr%252FP&md5=97e397deac10c2d435dfe465aed6779f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01270%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DYeomans%26aufirst%3DL.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DFurther%2520Optimization%2520and%2520Evaluation%2520of%2520Bioavailable%252C%2520Mixed-Efficacy%2520%25CE%25BC-Opioid%2520Receptor%2520%2528MOR%2529%2520Agonists%252F%25CE%25B4-Opioid%2520Receptor%2520%2528DOR%2529%2520Antagonists%253A%2520Balancing%2520MOR%2520and%2520DOR%2520Affinities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8952%26epage%3D8969%26doi%3D10.1021%2Facs.jmedchem.5b01270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Effects of <i>N</i>-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4985</span>– <span class="NLM_lpage">4998</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4985-4998&author=A.+A.+Harlandauthor=A.+M.+Benderauthor=N.+W.+Griggsauthor=C.+Gaoauthor=J.+P.+Anandauthor=I.+D.+Pogozhevaauthor=J.+R.+Traynorauthor=E.+M.+Jutkiewiczauthor=H.+I.+Mosberg&title=Effects+of+N-Substitutions+on+the+Tetrahydroquinoline+%28THQ%29+Core+of+Mixed-Efficacy+%CE%BC-Opioid+Receptor+%28MOR%29%2F%CE%B4-Opioid+Receptor+%28DOR%29+Ligands&doi=10.1021%2Facs.jmedchem.6b00308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands</span></div><div class="casAuthors">Harland, Aubrie A.; Bender, Aaron M.; Griggs, Nicholas W.; Gao, Chao; Anand, Jessica P.; Pogozheva, Irina D.; Traynor, John R.; Jutkiewicz, Emily M.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4985-4998</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Acetylation of the tetrahydroquinoline (THQ) core of a series of μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist ligands increases DOR affinity, resulting in ligands with balanced MOR and DOR affinities.  We report a series of N-substituted THQ analogs that incorporate various carbonyl-contg. moieties to maintain DOR affinity and define the steric and electronic requirements of the binding pocket across the opioid receptors. 4h produced in vivo antinociception (i.p.) for 1 h at 10 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6PABTi0KVLVg90H21EOLACvtfcHk0ljQGTSdlhbtlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCnt7Y%253D&md5=472c744ca5f66c7de99898aab59a717b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00308%26sid%3Dliteratum%253Aachs%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DEffects%2520of%2520N-Substitutions%2520on%2520the%2520Tetrahydroquinoline%2520%2528THQ%2529%2520Core%2520of%2520Mixed-Efficacy%2520%25CE%25BC-Opioid%2520Receptor%2520%2528MOR%2529%252F%25CE%25B4-Opioid%2520Receptor%2520%2528DOR%2529%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4985%26epage%3D4998%26doi%3D10.1021%2Facs.jmedchem.6b00308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Rapid Synthesis of Boc-2′,6′-Dimethyl-<span class="smallcaps smallerCapital">l</span>-Tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OrsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1199-1203&author=A.+M.+Benderauthor=N.+W.+Griggsauthor=C.+Gaoauthor=T.+J.+Traskauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Rapid+Synthesis+of+Boc-2%E2%80%B2%2C6%E2%80%B2-Dimethyl-l-Tyrosine+and+Derivatives+and+Incorporation+into+Opioid+Peptidomimetics&doi=10.1021%2Facsmedchemlett.5b00344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Synthesis of Boc-2',6'-dimethyl-L-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics</span></div><div class="casAuthors">Bender, Aaron M.; Griggs, Nicholas W.; Gao, Chao; Trask, Tyler J.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unnatural amino acid 2',6'-dimethyl-L-tyrosine has found widespread use in the development of synthetic opioid ligands.  Opioids featuring this residue at the N-terminus often display superior potency at one or more of the opioid receptor types, but the availability of the compd. is hampered by its cost and difficult synthesis.  Here, the authors report a short, three-step synthesis of Boc-2',6'-dimethyl-L-tyrosine (3a) utilizing a microwave-assisted Negishi coupling for the key carbon-carbon bond forming step, and employ this chem. for the expedient synthesis of other unnatural tyrosine derivs.  Three of these derivs. (3c, 3d, 3f) have not previously been examd. as Tyr1 replacements in opioid ligands.  The authors describe the incorporation of these tyrosine derivs. in a series of opioid peptidomimetics employing their previously reported tetrahydroquinoline (THQ) scaffold, and the binding and relative efficacy of each of the analogs at the three opioid receptor subtypes: mu (MOR), delta (DOR), and kappa (KOR).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9wy_i_ifxubVg90H21EOLACvtfcHk0ljQGTSdlhbtlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OrsL%252FE&md5=fa8173b4541991cd10f0cd537a6d97cc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00344%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DTrask%26aufirst%3DT.%2BJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DRapid%2520Synthesis%2520of%2520Boc-2%25E2%2580%25B2%252C6%25E2%2580%25B2-Dimethyl-l-Tyrosine%2520and%2520Derivatives%2520and%2520Incorporation%2520into%2520Opioid%2520Peptidomimetics%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1199%26epage%3D1203%26doi%3D10.1021%2Facsmedchemlett.5b00344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy μ Opioid Receptor/δ Opioid Receptor Ligands</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1428</span>– <span class="NLM_lpage">1435</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00100</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00100" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1428-1435&author=A.+M.+Benderauthor=N.+W.+Griggsauthor=J.+P.+Anandauthor=J.+R.+Traynorauthor=E.+M.+Jutkiewiczauthor=H.+I.+Mosberg&title=Asymmetric+Synthesis+and+in+Vitro+and+in+Vivo+Activity+of+Tetrahydroquinolines+Featuring+a+Diverse+Set+of+Polar+Substitutions+at+the+6+Position+as+Mixed-Efficacy+%CE%BC+Opioid+Receptor%2F%CE%B4+Opioid+Receptor+Ligands&doi=10.1021%2Facschemneuro.5b00100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy μ Opioid Receptor/δ Opioid Receptor Ligands</span></div><div class="casAuthors">Bender, Aaron M.; Griggs, Nicholas W.; Anand, Jessica P.; Traynor, John R.; Jutkiewicz, Emily M.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1428-1435</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors previously reported a small series of mixed-efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist peptidomimetics featuring a tetrahydroquinoline scaffold and showed the promise of this series as effective analgesics after i.p. administration in mice.  The authors report here an expanded structure-activity relationship study of the pendant region of these compds. and focus in particular on the incorporation of heteroatoms into this side chain.  These analogs provide new insight into the binding requirements for this scaffold at MOR, DOR, and the κ opioid receptor (KOR), and several of them significantly improve upon the overall MOR agonist/DOR antagonist profile of the previous compds.  In vivo data for these compds. are also reported and show the antinociceptive potency and duration of action of compds. I and II to be comparable to those of morphine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2zgiTSGa4bVg90H21EOLACvtfcHk0ljQGTSdlhbtlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFOnsr0%253D&md5=a817978f94160be2c0e7077c4a238997</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00100%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DAsymmetric%2520Synthesis%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Activity%2520of%2520Tetrahydroquinolines%2520Featuring%2520a%2520Diverse%2520Set%2520of%2520Polar%2520Substitutions%2520at%2520the%25206%2520Position%2520as%2520Mixed-Efficacy%2520%25CE%25BC%2520Opioid%2520Receptor%252F%25CE%25B4%2520Opioid%2520Receptor%2520Ligands%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1428%26epage%3D1435%26doi%3D10.1021%2Facschemneuro.5b00100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeomans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobczyk-Kojiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span> <span> </span><span class="NLM_article-title">Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2149</span>, <span class="refDoi"> DOI: 10.1021/jm400050y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400050y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyhtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2139-2149&author=H.+I.+Mosbergauthor=L.+Yeomansauthor=A.+A.+Harlandauthor=A.+M.+Benderauthor=K.+Sobczyk-Kojiroauthor=J.+P.+Anandauthor=M.+J.+Clarkauthor=E.+M.+Jutkiewiczauthor=J.+R.+Traynor&title=Opioid+Peptidomimetics%3A+Leads+for+the+Design+of+Bioavailable+Mixed+Efficacy+%CE%BC+Opioid+Receptor+%28MOR%29+Agonist%2F%CE%B4+Opioid+Receptor+%28DOR%29+Antagonist+Ligands&doi=10.1021%2Fjm400050y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands</span></div><div class="casAuthors">Mosberg, Henry I.; Yeomans, Larisa; Harland, Aubrie A.; Bender, Aaron M.; Sobczyk-Kojiro, Katarzyna; Anand, Jessica P.; Clark, Mary J.; Jutkiewicz, Emily M.; Traynor, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2139-2149</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaffold and modeled on a series of cyclic tetrapeptide opioid agonists.  We have recently described modifications to these peptides that confer a μ opioid receptor (MOR) agonist, δ opioid receptor (DOR) antagonist profile, which has been shown to reduce the development of tolerance to the analgesic actions of MOR agonists.  Several such bifunctional ligands have been reported, but none has been demonstrated to cross the blood-brain barrier.  Here we describe the transfer of structural features that evoked MOR agonist/DOR antagonist behavior in the cyclic peptides to the tetrahydroquinoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacol. profile.  Further, the 4R diastereomer of 1 was fully efficacious and approx. equipotent to morphine in the mouse warm water tail withdrawal assay following i.p. administration and thus a promising lead for the development of opioid analgesics with reduced tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo03SkkUK9VmrVg90H21EOLACvtfcHk0lgnpeseuDuF8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyhtrg%253D&md5=f150f1b184718fd4d73fcac969e93c12</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm400050y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400050y%26sid%3Dliteratum%253Aachs%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DYeomans%26aufirst%3DL.%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DSobczyk-Kojiro%26aufirst%3DK.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26atitle%3DOpioid%2520Peptidomimetics%253A%2520Leads%2520for%2520the%2520Design%2520of%2520Bioavailable%2520Mixed%2520Efficacy%2520%25CE%25BC%2520Opioid%2520Receptor%2520%2528MOR%2529%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520%2528DOR%2529%2520Antagonist%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2139%26epage%3D2149%26doi%3D10.1021%2Fjm400050y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nastase, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trask, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutkiewicz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1840</span>– <span class="NLM_lpage">1848</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00139</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00139" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVahtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1840-1848&author=A.+F.+Nastaseauthor=N.+W.+Griggsauthor=J.+P.+Anandauthor=T.+J.+Fernandezauthor=A.+A.+Harlandauthor=T.+J.+Traskauthor=E.+M.+Jutkiewiczauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Synthesis+and+Pharmacological+Evaluation+of+Novel+C-8+Substituted+Tetrahydroquinolines+as+Balanced-Affinity+Mu%2FDelta+Opioid+Ligands+for+the+Treatment+of+Pain&doi=10.1021%2Facschemneuro.8b00139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain</span></div><div class="casAuthors">Nastase, Anthony F.; Griggs, Nicholas W.; Anand, Jessica P.; Fernandez, Thomas J.; Harland, Aubrie A.; Trask, Tyler J.; Jutkiewicz, Emily M.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1840-1848</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of opioids for the treatment of pain, while largely effective, is limited by detrimental side effects including analgesic tolerance, phys. dependence, and euphoria, which may lead to opioid abuse.  Studies have shown that compds. with a μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist profile reduce or eliminate some of these side effects including the development of tolerance and dependence.  Herein we report the synthesis and pharmacol. evaluation of a series of tetrahydroquinoline-based peptidomimetics with substitutions at the C-8 position.  Relative to our lead peptidomimetic with no C-8 substitution, this series affords an increase in DOR affinity and provides greater balance in MOR and DOR binding affinities.  Moreover, compds. with carbonyl moieties at C-8 display the desired MOR agonist/DOR antagonist profile whereas alkyl substitutions elicit modest DOR agonism.  Several compds. in this series produce a robust antinociceptive effect in vivo and show antinociceptive activity for greater than 2 h after i.p. administration in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpACJdb3aPloLVg90H21EOLACvtfcHk0lgnpeseuDuF8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVahtLc%253D&md5=72922fc10ccee02570aeca884b485da1</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00139%26sid%3Dliteratum%253Aachs%26aulast%3DNastase%26aufirst%3DA.%2BF.%26aulast%3DGriggs%26aufirst%3DN.%2BW.%26aulast%3DAnand%26aufirst%3DJ.%2BP.%26aulast%3DFernandez%26aufirst%3DT.%2BJ.%26aulast%3DHarland%26aufirst%3DA.%2BA.%26aulast%3DTrask%26aufirst%3DT.%2BJ.%26aulast%3DJutkiewicz%26aufirst%3DE.%2BM.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Novel%2520C-8%2520Substituted%2520Tetrahydroquinolines%2520as%2520Balanced-Affinity%2520Mu%252FDelta%2520Opioid%2520Ligands%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D9%26spage%3D1840%26epage%3D1848%26doi%3D10.1021%2Facschemneuro.8b00139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Design of a High Affinity Peptidomimetic Opioid Agonist from Peptide Pharmacophore Models</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2688</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(98)00472-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2FS0960-894X%2898%2900472-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=9873603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK1cXntV2rur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=2685-2688&author=C.+Wangauthor=I.+J.+McFadyenauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Design+of+a+High+Affinity+Peptidomimetic+Opioid+Agonist+from+Peptide+Pharmacophore+Models&doi=10.1016%2FS0960-894X%2898%2900472-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models</span></div><div class="casAuthors">Wang, Chenguang; McFadyen, Iain J.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2685-2688</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Based upon opioid receptor-binding pharmacophore models derived from a series of opioid tetrapeptides, a pair of diastereomeric peptidomimetics R- and S-I was synthesized.  Both analogs displayed high opioid receptor affinity, moderate selectivity for the μ opioid receptor, and were potent, full agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrogtCdsiu-4rVg90H21EOLACvtfcHk0lgnpeseuDuF8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntV2rur0%253D&md5=534830af45e44b03bb09c8d1de985f30</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900472-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900472-7%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMcFadyen%26aufirst%3DI.%2BJ.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DDesign%2520of%2520a%2520High%2520Affinity%2520Peptidomimetic%2520Opioid%2520Agonist%2520from%2520Peptide%2520Pharmacophore%2520Models%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D2685%26epage%3D2688%26doi%3D10.1016%2FS0960-894X%2898%2900472-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holsworth, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span> <span> </span><span class="NLM_article-title">Metabolic Aromatization of N-Alkyl-1,2,3,4-Tetrahydroquinoline Substructures to Quinolinium by Human Liver Microsomes and Horseradish Peroxidase</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2044</span>– <span class="NLM_lpage">2055</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.012286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1124%2Fdmd.106.012286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=16985099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yltLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=2044-2055&author=C.+Guauthor=R.+Collinsauthor=D.+D.+Holsworthauthor=G.+S.+Walkerauthor=R.+L.+Voorman&title=Metabolic+Aromatization+of+N-Alkyl-1%2C2%2C3%2C4-Tetrahydroquinoline+Substructures+to+Quinolinium+by+Human+Liver+Microsomes+and+Horseradish+Peroxidase&doi=10.1124%2Fdmd.106.012286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic aromatization of N-alkyl-1,2,3,4-tetrahydroquinoline substructures to quinolinium by human liver microsomes and horseradish peroxidase</span></div><div class="casAuthors">Gu, Chungang; Collins, Roxane; Holsworth, Daniel D.; Walker, Gregory S.; Voorman, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2044-2055</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Metabolic aromatization of xenobiotics is an unusual reaction with some documented examples.  For instance, the oxidn. of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the neurotoxic pyridinium ion metabolite 1-methyl-4-phenylpyridinium by monoamine oxidase (MAO) B in the brain has been of interest to a no. of investigators.  It has also been reported that although the aromatization of N-methyl-tetrahydroisoquinoline occurs with MAO B, the metab. does not proceed for its isomer, N-methyl-tetrahydroquinoline, by the same enzyme.  The aromatization of an N-alkyl-tetrahydroquinoline substructure was identified during in vitro metabolite profiling of compd. A, which was designed as a potent renin inhibitor for the treatment of hypertension.  The N-alkylquinolinium metabolite of compd. A was identified by liq. chromatog.-tandem mass spectrometry of human liver microsomal incubates and proton NMR of the isolated metabolite.  Further in vitro metab. studies with a com. available chem. (compd. B), contg. the same substructure, also generated an N-alkylquinolinium metabolite.  In vitro cytochrome P 450 reaction phenotyping of compd. A revealed that the metab. was catalyzed exclusively by CYP3A4.  Although compd. B was a substrate for several P 450 isoforms, its quinolinium metabolite was also generated predominantly by CYP3A4.  Neither compd. A nor compd. B was a substrate of MAOs.  The quinolinium metabolites were readily produced by horseradish peroxidase, suggesting that aromatization of the N-alkyltetrahydroquinoline could occur via a mechanism involving single electron transfer from nitrogen.  Although dihydro intermediates from the tetrahydroquinoline substrates were not obsd. in the formation of quinolinium metabolites, cyanide trapping results indicated the occurrence of iminium intermediates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq-tn_67v3MLVg90H21EOLACvtfcHk0lgnpeseuDuF8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yltLnM&md5=7dc3c968b0dcccb09eb8350bf0843a77</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.012286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.012286%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DC.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DHolsworth%26aufirst%3DD.%2BD.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26atitle%3DMetabolic%2520Aromatization%2520of%2520N-Alkyl-1%252C2%252C3%252C4-Tetrahydroquinoline%2520Substructures%2520to%2520Quinolinium%2520by%2520Human%2520Liver%2520Microsomes%2520and%2520Horseradish%2520Peroxidase%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D2044%26epage%3D2055%26doi%3D10.1124%2Fdmd.106.012286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aryal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi-Ping, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Discovery of Opioid Analgesics with Reduced Side Effects</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=H.+Xi-Pingauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Duanauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Schoichet&title=Structure-Based+Discovery+of+Opioid+Analgesics+with+Reduced+Side+Effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0lgavwcyjSlkoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DXi-Ping%26aufirst%3DH.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSchoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-Based%2520Discovery%2520of%2520Opioid%2520Analgesics%2520with%2520Reduced%2520Side%2520Effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agius, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 4-Substituted Piperidines and Piperazines as Balanced Affinity μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2013.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=24365161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=548-551&author=A.+M.+Benderauthor=M.+J.+Clarkauthor=M.+P.+Agiusauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Synthesis+and+Evaluation+of+4-Substituted+Piperidines+and+Piperazines+as+Balanced+Affinity+%CE%BC+Opioid+Receptor+%28MOR%29+Agonist%2F%CE%B4+Opioid+Receptor+%28DOR%29+Antagonist+Ligands&doi=10.1016%2Fj.bmcl.2013.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands</span></div><div class="casAuthors">Bender, Aaron M.; Clark, Mary J.; Agius, Michael P.; Traynor, John R.; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this letter, the authors describe a series of 4-substituted piperidine and piperazine compds., e.g. I [X = CH, N; R = Ph2CHCH2CH2, Ph(CH2)n; n = 1-5]; based on known tetrahydroquinoline II, a compd. that shows balanced, low nanomolar binding affinity for the mu opioid receptor (MOR) and the delta opioid receptor (DOR).  The authors have shown that by changing the length and flexibility profile of the side chain in this position, binding affinity is improved at both receptors by a significant degree.  Furthermore, several of the compds. described herein display good efficacy at MOR, while simultaneously displaying DOR antagonism.  The MOR agonist/DOR antagonist has shown promise in the redn. of neg. side effects displayed by selective MOR agonists, namely the development of dependence and tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa-35Rin5RGbVg90H21EOLACvtfcHk0lgavwcyjSlkoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFOr&md5=6a6529893822af4c0e53a2b2766dc693</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BM.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DAgius%26aufirst%3DM.%2BP.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25204-Substituted%2520Piperidines%2520and%2520Piperazines%2520as%2520Balanced%2520Affinity%2520%25CE%25BC%2520Opioid%2520Receptor%2520%2528MOR%2529%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520%2528DOR%2529%2520Antagonist%2520Ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D548%26epage%3D551%26doi%3D10.1016%2Fj.bmcl.2013.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Opioidmimetics Containing 2′,6′-Dimethyl-<span class="smallcaps smallerCapital">l</span>-Tyrosine and a Pyrazinone-Ring Platform</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">5768</span>– <span class="NLM_lpage">5771</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.08.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2007.08.058" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5768-5771&author=K.+Shiotaniauthor=T.+Liauthor=A.+Miyazakiauthor=Y.+Tsudaauthor=T.+Yokoiauthor=A.+Amboauthor=Y.+Sasakiauthor=S.+D.+Bryantauthor=L.+H.+Lazarusauthor=Y.+Okada&title=Design+and+Synthesis+of+Opioidmimetics+Containing+2%E2%80%B2%2C6%E2%80%B2-Dimethyl-l-Tyrosine+and+a+Pyrazinone-Ring+Platform&doi=10.1016%2Fj.bmcl.2007.08.058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.08.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.08.058%26sid%3Dliteratum%253Aachs%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Opioidmimetics%2520Containing%25202%25E2%2580%25B2%252C6%25E2%2580%25B2-Dimethyl-l-Tyrosine%2520and%2520a%2520Pyrazinone-Ring%2520Platform%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5768%26epage%3D5771%26doi%3D10.1016%2Fj.bmcl.2007.08.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 3,6-Bis[H-Tyr/H-Dmt-NH(CH<sub>2</sub>)<sub>m,n</sub>]-2(1H)Pyrazinone Derivatives: Function of Alkyl Chain Length on Opioid Activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5793</span>– <span class="NLM_lpage">5796</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.08.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2006.08.079" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5793-5796&author=K.+Shiotaniauthor=T.+Liauthor=A.+Miyazakiauthor=Y.+Tsudaauthor=S.+D.+Bryantauthor=A.+Amboauthor=Y.+Sasakiauthor=L.+H.+Lazarusauthor=Y.+Okada&title=Synthesis+of+3%2C6-Bis%5BH-Tyr%2FH-Dmt-NH%28CH2%29m%2Cn%5D-2%281H%29Pyrazinone+Derivatives%3A+Function+of+Alkyl+Chain+Length+on+Opioid+Activity&doi=10.1016%2Fj.bmcl.2006.08.079"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.08.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.08.079%26sid%3Dliteratum%253Aachs%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DSynthesis%2520of%25203%252C6-Bis%255BH-Tyr%252FH-Dmt-NH%2528CH2%2529m%252Cn%255D-2%25281H%2529Pyrazinone%2520Derivatives%253A%2520Function%2520of%2520Alkyl%2520Chain%2520Length%2520on%2520Opioid%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5793%26epage%3D5796%26doi%3D10.1016%2Fj.bmcl.2006.08.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span> <span> </span><span class="NLM_article-title">Novel 2′,6′-Dimethyl-L-Tyrosine-Containing Pyrazinone Opioid Mimetic μ-Agonists with Potent Antinociceptive Activity in Mice</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.060061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1124%2Fjpet.103.060061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=14718580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFamurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=432-438&author=Y.+Jinsmaaauthor=Y.+Okadaauthor=Y.+Tsudaauthor=K.+Shiotaniauthor=Y.+Sasakiauthor=A.+Amboauthor=S.+D.+Bryantauthor=L.+H.+Lazarus&title=Novel+2%E2%80%B2%2C6%E2%80%B2-Dimethyl-L-Tyrosine-Containing+Pyrazinone+Opioid+Mimetic+%CE%BC-Agonists+with+Potent+Antinociceptive+Activity+in+Mice&doi=10.1124%2Fjpet.103.060061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2',6'-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic μ-agonists with potent antinociceptive activity in mice</span></div><div class="casAuthors">Jinsmaa, Yunden; Okada, Yoshio; Tsuda, Yuko; Shiotani, Kimitaka; Sasaki, Yusuke; Ambo, Akihiro; Bryant, Sharon D.; Lazarus, Lawrence H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">432-438</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Novel bioactive opioid mimetic agonists contg. 2',6'-dimethyl-L-tyrosine (Dmt) and a pyrazinone ring interact with μ-and δ-opioid receptors.  Compd. 1 [3-(4'-Dmt-aminobutyl)-6-(3'-Dmt-aminopropyl)-5-methyl-2(1H)pyrazinone] exhibited high μ-opioid receptor affinity and selectivity (Kiμ = 0.021 nM and Kiδ/Kiμ = 1,519, resp.), and agonist activity on guinea pig ileum (IC50 = 1.7 nM) with weaker δ-bioactivity on mouse vas deferens (IC50 = 25.8 nM).  Other compds. (2-4) had μ-opioid receptor affinities and selectivities 2- to 5-fold and 4- to 7-fold less than 1, resp.  Intracerebroventricular administration of 1 in mice exhibited potent naloxone reversible antinociception (65 to 71 times greater than morphine) in both tail-flick (TF) and hot-plate (HP) tests.  Distinct opioid antagonists had differential effects on antinociception: naltrindole (δ-antagonist) partially blocked antinociception in the TF, but it was ineffective in the HP test, whereas β-funaltrexamine (irreversible antagonist, μ1/μ2-subtypes) but not naloxonazine (μ1-subtype) inhibited TF test antinociception, yet both blocked antinociception in the HP test.  Our data indicated that 1 acted through μ- and δ-opioid receptors to produce spinal antinociception, although primarily through the μ2-receptor subtype; however, the μ1-receptor subtype dominates supraspinally.  S.c. and oral administration indicated that 1 crossed gastrointestinal and blood-brain barriers to produce central nervous system-mediated antinociception.  Furthermore, daily s.c. dosing of mice with 1 for 1 wk developed tolerance in a similar manner to that of morphine in TF and HP tests, implicating that 1 also acts through a similar mechanism analogous to morphine at μ-opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbGSjFwVrCZ7Vg90H21EOLACvtfcHk0lgNfffA2hmxBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFamurc%253D&md5=390c94999d9ca73767af4c558b1955b8</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.060061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.060061%26sid%3Dliteratum%253Aachs%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26atitle%3DNovel%25202%25E2%2580%25B2%252C6%25E2%2580%25B2-Dimethyl-L-Tyrosine-Containing%2520Pyrazinone%2520Opioid%2520Mimetic%2520%25CE%25BC-Agonists%2520with%2520Potent%2520Antinociceptive%2520Activity%2520in%2520Mice%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D432%26epage%3D438%26doi%3D10.1124%2Fjpet.103.060061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">Oral Bioavailability of a New Class of μ-Opioid Receptor Agonists Containing 3,6-Bis[Dmt-NH(CH<sub>2</sub>)<sub>n</sub>]-2(1H)-Pyrazinone with Central-Mediated Analgesia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2599</span>– <span class="NLM_lpage">2610</span>, <span class="refDoi"> DOI: 10.1021/jm0304616</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0304616" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2599-2610&author=Y.+Jinsmaaauthor=A.+Miyazakiauthor=Y.+Fujitaauthor=T.+Liauthor=Y.+Fujisawaauthor=K.+Shiotaniauthor=Y.+Tsudaauthor=T.+Yokoiauthor=A.+Amboauthor=Y.+Sasakiauthor=S.+D.+Bryantauthor=L.+H.+Lazarusauthor=Y.+Okada&title=Oral+Bioavailability+of+a+New+Class+of+%CE%BC-Opioid+Receptor+Agonists+Containing+3%2C6-Bis%5BDmt-NH%28CH2%29n%5D-2%281H%29-Pyrazinone+with+Central-Mediated+Analgesia&doi=10.1021%2Fjm0304616"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0304616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0304616%26sid%3Dliteratum%253Aachs%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DOral%2520Bioavailability%2520of%2520a%2520New%2520Class%2520of%2520%25CE%25BC-Opioid%2520Receptor%2520Agonists%2520Containing%25203%252C6-Bis%255BDmt-NH%2528CH2%2529n%255D-2%25281H%2529-Pyrazinone%2520with%2520Central-Mediated%2520Analgesia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2599%26epage%3D2610%26doi%3D10.1021%2Fjm0304616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span> <span> </span><span class="NLM_article-title">New Series of Potent δ-Opioid Antagonists Containing the H-Dmt-Tic-NH-Hexyl-NH-R Motif</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5517</span>– <span class="NLM_lpage">5520</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.08.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.bmcl.2005.08.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=5517-5520&author=T.+Liauthor=K.+Shiotaniauthor=A.+Miyazakiauthor=Y.+Fujitaauthor=Y.+Tsudaauthor=A.+Amboauthor=Y.+Sasakiauthor=Y.+Jinsmaaauthor=E.+Marczakauthor=S.+D.+Bryantauthor=L.+H.+Lazarusauthor=Y.+Okada&title=New+Series+of+Potent+%CE%B4-Opioid+Antagonists+Containing+the+H-Dmt-Tic-NH-Hexyl-NH-R+Motif&doi=10.1016%2Fj.bmcl.2005.08.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.08.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.08.073%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DShiotani%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DA.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DMarczak%26aufirst%3DE.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26aulast%3DOkada%26aufirst%3DY.%26atitle%3DNew%2520Series%2520of%2520Potent%2520%25CE%25B4-Opioid%2520Antagonists%2520Containing%2520the%2520H-Dmt-Tic-NH-Hexyl-NH-R%2520Motif%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D5517%26epage%3D5520%26doi%3D10.1016%2Fj.bmcl.2005.08.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinsmaa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, L. H.</span></span> <span> </span><span class="NLM_article-title">Unique High-Affinity Synthetic μ-Opioid Receptor Agonists with Central- and Systemic-Mediated Analgesia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3201</span>– <span class="NLM_lpage">3209</span>, <span class="refDoi"> DOI: 10.1021/jm020459z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020459z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3201-3209&author=Y.+Okadaauthor=Y.+Tsudaauthor=Y.+Fujitaauthor=T.+Yokoiauthor=Y.+Sasakiauthor=A.+Amboauthor=R.+Konishiauthor=M.+Nagataauthor=S.+Salvadoriauthor=Y.+Jinsmaaauthor=S.+D.+Bryantauthor=L.+H.+Lazarus&title=Unique+High-Affinity+Synthetic+%CE%BC-Opioid+Receptor+Agonists+with+Central-+and+Systemic-Mediated+Analgesia&doi=10.1021%2Fjm020459z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm020459z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020459z%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DAmbo%26aufirst%3DA.%26aulast%3DKonishi%26aufirst%3DR.%26aulast%3DNagata%26aufirst%3DM.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DJinsmaa%26aufirst%3DY.%26aulast%3DBryant%26aufirst%3DS.%2BD.%26aulast%3DLazarus%26aufirst%3DL.%2BH.%26atitle%3DUnique%2520High-Affinity%2520Synthetic%2520%25CE%25BC-Opioid%2520Receptor%2520Agonists%2520with%2520Central-%2520and%2520Systemic-Mediated%2520Analgesia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3201%26epage%3D3209%26doi%3D10.1021%2Fjm020459z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrakumar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stapelfeld, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorbacher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, D.</span></span> <span> </span><span class="NLM_article-title">Preparation and Opioid Activity of Analogs of the Analgesic Dipeptide 2,6-Dimethyl-l-Tyrosyl-N-(3-Phenylpropyl)-D-Alaninamide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1021/jm00080a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00080a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=223-233&author=N.+S.+Chandrakumarauthor=P.+K.+Yonanauthor=A.+Stapelfeldauthor=M.+Savageauthor=E.+Rorbacherauthor=P.+C.+Contrerasauthor=D.+Hammond&title=Preparation+and+Opioid+Activity+of+Analogs+of+the+Analgesic+Dipeptide+2%2C6-Dimethyl-l-Tyrosyl-N-%283-Phenylpropyl%29-D-Alaninamide&doi=10.1021%2Fjm00080a005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm00080a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00080a005%26sid%3Dliteratum%253Aachs%26aulast%3DChandrakumar%26aufirst%3DN.%2BS.%26aulast%3DYonan%26aufirst%3DP.%2BK.%26aulast%3DStapelfeld%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DM.%26aulast%3DRorbacher%26aufirst%3DE.%26aulast%3DContreras%26aufirst%3DP.%2BC.%26aulast%3DHammond%26aufirst%3DD.%26atitle%3DPreparation%2520and%2520Opioid%2520Activity%2520of%2520Analogs%2520of%2520the%2520Analgesic%2520Dipeptide%25202%252C6-Dimethyl-l-Tyrosyl-N-%25283-Phenylpropyl%2529-D-Alaninamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D223%26epage%3D233%26doi%3D10.1021%2Fjm00080a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neilan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breeden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Complex Morphinan Derivative BU72 as a High Efficacy, Long-Lasting Mu-Opioid Receptor Agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>499</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2004.07.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1016%2Fj.ejphar.2004.07.097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=15363957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFSqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=499&publication_year=2004&pages=107-116&author=C.+L.+Neilanauthor=S.+M.+Husbandsauthor=S.+Breedenauthor=M.+C.+Koauthor=M.+D.+Acetoauthor=J.+W.+Lewisauthor=J.+H.+Woodsauthor=J.+R.+Traynor&title=Characterization+of+the+Complex+Morphinan+Derivative+BU72+as+a+High+Efficacy%2C+Long-Lasting+Mu-Opioid+Receptor+Agonist&doi=10.1016%2Fj.ejphar.2004.07.097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist</span></div><div class="casAuthors">Neilan, Claire L.; Husbands, Stephen M.; Breeden, Simon; Ko, M. C.; Aceto, Mario D.; Lewis, John W.; Woods, James H.; Traynor, John R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">499</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development of buprenorphine as a treatment for opiate abuse and dependence has drawn attention to opioid ligands that have agonist actions followed by long-lasting antagonist actions.  In a search for alternatives to buprenorphine, we discovered a bridged pyrrolidinomorphinan (BU72).  In vitro, BU72 displayed high affinity and efficacy for mu-opioid receptors, but was also a partial delta-opioid receptor agonist and a full kappa-opioid receptor agonist.  BU72 was a highly potent and long-lasting antinociceptive agent against both thermal and chem. nociception in the mouse and against thermal nociception in the monkey.  These effects were prevented by mu-, but not kappa- or delta-, opioid receptor antagonists.  Once the agonist effects of BU72 had subsided, the compd. acted to attenuate the antinociceptive action of morphine.  BU72 is too efficacious for human use but manipulation to reduce efficacy could provide a lead to the development of a treatment for opioid dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgyTfkcE_IbLVg90H21EOLACvtfcHk0lggzxglEpxguw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFSqurY%253D&md5=d0c31c6288c887c4ca24ae8b12545973</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.07.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.07.097%26sid%3Dliteratum%253Aachs%26aulast%3DNeilan%26aufirst%3DC.%2BL.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DBreeden%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DM.%2BC.%26aulast%3DAceto%26aufirst%3DM.%2BD.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DWoods%26aufirst%3DJ.%2BH.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Complex%2520Morphinan%2520Derivative%2520BU72%2520as%2520a%2520High%2520Efficacy%252C%2520Long-Lasting%2520Mu-Opioid%2520Receptor%2520Agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D499%26spage%3D107%26epage%3D116%26doi%3D10.1016%2Fj.ejphar.2004.07.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purington, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobczyk-Kojiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Development and in Vitro Characterization of a Novel Bifunctional μ-Agonist/δ-Antagonist Opioid Tetrapeptide</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1021/cb200263q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb200263q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1375-1381&author=L.+C.+Puringtonauthor=K.+Sobczyk-Kojiroauthor=I.+D.+Pogozhevaauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Development+and+in+Vitro+Characterization+of+a+Novel+Bifunctional+%CE%BC-Agonist%2F%CE%B4-Antagonist+Opioid+Tetrapeptide&doi=10.1021%2Fcb200263q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fcb200263q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb200263q%26sid%3Dliteratum%253Aachs%26aulast%3DPurington%26aufirst%3DL.%2BC.%26aulast%3DSobczyk-Kojiro%26aufirst%3DK.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DDevelopment%2520and%2520in%2520Vitro%2520Characterization%2520of%2520a%2520Novel%2520Bifunctional%2520%25CE%25BC-Agonist%252F%25CE%25B4-Antagonist%2520Opioid%2520Tetrapeptide%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2011%26volume%3D6%26spage%3D1375%26epage%3D1381%26doi%3D10.1021%2Fcb200263q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Metabolism-Guided Drug Design</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1039/c2md20317k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=10.1039%2Fc2md20317k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslWmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=631-652&author=A.+F.+Stepanauthor=V.+Mascittiauthor=K.+Beaumontauthor=A.+S.+Kalgutkar&title=Metabolism-Guided+Drug+Design&doi=10.1039%2Fc2md20317k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-guided drug design</span></div><div class="casAuthors">Stepan, Antonia F.; Mascitti, Vincent; Beaumont, Kevin; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">631-652</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Preclin. drug metab. studies play a key role in the lead identification and optimization process in drug discovery.  Characterization of the metabolic pathways of new chem. entities is an integral part of drug discovery not only in optimizing clearance properties but also in eliminating potential safety concerns assocd. with the formation of protein and/or DNA-reactive metabolites.  Metab. studies in early discovery have been used to identify metabolic soft spots leading to high metabolic instability, and also in the characterization of active metabolites.  Availability of such information has aided in the rational design of compds. with increased resistance to metab. and overall improvements in oral pharmacokinetics and dose size.  Mechanistic drug metab. studies have proven particularly invaluable in mitigating reactive metabolite risks, which can lead to mutagenicity, time-dependent inactivation of cytochrome P 450 enzymes and/or idiosyncratic adverse drug reactions.  Characterization of stable conjugates derived from bioactivation of small mol. drug candidates provides indirect information on the structure of the reactive metabolite species, thereby providing insight into the bioactivation mechanism and hence a rationale on which to base subsequent chem. intervention strategies.  This review will showcase case studies of metab.-guided drug design using literature and inhouse examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcMOKNkXIUL7Vg90H21EOLACvtfcHk0lggzxglEpxguw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslWmur0%253D&md5=61c667aa6f5c24de3fe110f384f323bd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fc2md20317k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20317k%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DMetabolism-Guided%2520Drug%2520Design%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D631%26epage%3D652%26doi%3D10.1039%2Fc2md20317k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahorski, S. R.</span></span> <span> </span><span class="NLM_article-title">Modulation by μ-Opioid Agonists of Guanosine-5′-O-(3-[35S]Thio)Triphosphate Binding to Membranes from Human Neuroblastoma SH-SY5Y Cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">848</span>– <span class="NLM_lpage">854</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=7723747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;key=1%3ACAS%3A528%3ADyaK2MXltFSlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1995&pages=848-854&author=J.+R.+Traynorauthor=S.+R.+Nahorski&title=Modulation+by+%CE%BC-Opioid+Agonists+of+Guanosine-5%E2%80%B2-O-%283-%5B35S%5DThio%29Triphosphate+Binding+to+Membranes+from+Human+Neuroblastoma+SH-SY5Y+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation by μ-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells</span></div><div class="casAuthors">Traynor, John R.; Nahorski, Stefan R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">848-54</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The ability of μ-opioid agonists to activate G proteins has been demonstrated by studying the binding of the GTP analog guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) to membranes from the human neuroblastoma SH-SY5Y cell line.  The potent opioid agonist fentanyl caused an approx. doubling of basal [35S]GTPγS binding in a naloxone-sensitive manner, confirming this to be an opioid receptor-mediated process.  The presence of GDP was necessary to observe this effect.  Pretreatment of the cells with pertussis toxin (100 ng/mL, for 24 h) completely prevented the fentanyl-stimulated increase in [35S]GTPγS binding and lowered the basal binding of [35S]GTPγS.  These latter data suggest an involvement of Gi and/or Go proteins and their activation by added membrane-bound receptors even in the absence of agonist.  The order of potency of a series of opioid agonists in stimulating the binding of [35S]GTPγS was buprenorphine > cyclazocine = levallorphan > nalorphine > [D-Alan2,MePhe4,Gly-ol5]enkephalin (DAMGO) > fentanyl > morphine > pentazocine.  DAMGO, fentanyl, and morphine were full agonists but the remaining compds. showed decreasing levels of intrinsic activity in the order buprenorphine > pentazocine > cyclazocine = nalorphine > levallorphan.  The opioid antagonist naloxone was without effect.  Under the conditions of the [35S]GTPγS assay, binding of agonists was to a high affinity site, indicating that a high agonist affinity state of the μ-opioid receptor is responsible for the obsd. stimulation of [35S]GTPγS binding.  The level of [35S]GTPγS binding (597 fmol/mg of protein) stimulated by DAMGO was 2-fold greater than the maximal no. of μ-opioid agonist binding sites (Bmax) detd. using [3H]DAMGO (254 fmol/mg of protein).  The opioid agonist-mediated stimulation of [35S]GTPγS binding in SH-SY5Y cell membranes thus provides a "functional" measure of agonist occupation of μ-opioid receptors and offers a simple method for the detn. of efficacy and intrinsic activity of μ-opioid agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFfWit9khK9LVg90H21EOLACvtfcHk0ljCeYQPOFcufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltFSlurw%253D&md5=b9bf6e344ab72e114c58ed47919af065</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DNahorski%26aufirst%3DS.%2BR.%26atitle%3DModulation%2520by%2520%25CE%25BC-Opioid%2520Agonists%2520of%2520Guanosine-5%25E2%2580%25B2-O-%25283-%255B35S%255DThio%2529Triphosphate%2520Binding%2520to%2520Membranes%2520from%2520Human%2520Neuroblastoma%2520SH-SY5Y%2520Cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D47%26spage%3D848%26epage%3D854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i102"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00219">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62244"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00219">10.1021/acs.jmedchem.9b00219</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00219/suppl_file/jm9b00219_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00219/suppl_file/jm9b00219_si_001.csv">jm9b00219_si_001.csv (3.34 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00219&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-8%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00219" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00219" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                990KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679935896d783ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
